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ABSTRACT 
The prevalence and prognostic significance of depression and anxiety in patients with 
atrial fibrillation 
Objective: The purpose of the current study was to examine the persistence of 
depression and anxiety in atrial fibrillation (AF) patients, and their implications for 
future quality of life (QoL) and major adverse cardiovascular events (MACE). 
Methods: The Beck Depression Inventory (BDI), State-Trait Anxiety Inventory 
(STAI), and Dartmouth Care Cooperative Information Project (COOP) charts were 
complete by 101 patients with AF and 97 patients with hypertension.  Six-month 
survival status and presentation for MACE were ascertained; QoL was re-assessed at 
six-months using the Dartmouth COOP charts. 
Results: Symptoms of depression prevailed in 38% of patients with AF, with elevated 
state and trait anxiety being reported in 28% and 38% of patients, respectively.  No 
significant differences in depression, state anxiety, and QoL were observed between 
patients with AF and hypertension, although AF patients displayed higher levels of trait 
anxiety.  Analysis of survival status and MACE was not conducted due to an 
insufficient number of events.  Symptoms of depression and anxiety at baseline, female 
gender, ethnicity, and employment status were significantly correlated with QoL at six-
months in patients with AF.  In a multiple regression model in which all of these 
variables were entered, baseline depression scores provided the best independent 
prediction of six-month QoL, although gender and employment status also entered the 
model.    
Conclusions: The prevalence of depression and anxiety in patients with AF is 
comparable to patients following a myocardial infarction.  Baseline symptoms of 
depression were the strongest independent predictor of QoL at six-months in patients 
with AF. 
i. 
ABSTRACT 
Effects of acute mental and postural stress on haemorheology, endothelial, and platelet 
reactivity in patients with atrial fibrillation 
 
Background: The purpose of the study was to examine the effects of acute mental 
stress, acute postural stress, and hydration status on haemorhelogy, endothelial function, 
and platelet reactivity in patients with atrial fibrillation (AF). 
Methods: Fourteen male patients with AF (6 paroxysmal AF and 8 permanent AF), 10 
patients with hypertension, and 10 healthy controls underwent four testing sessions; 
completing two mental stress tasks (mental arithmetic) and two postural stress tasks 
(640 head-up tilt).  Cardiovascular and rheological reactivity, in addition to plasma von 
Willebrand Factor (vWF), E-selectin (sE-sel), P-selectin (sP-sel), intra-platelet levels of 
P-selectin (pP-sel) and measures of platelet morphology were obtained after 20 minute 
of supine rest, immediately following the stress task, and at 30 and 60 minutes recovery. 
Results: Acute mental stress yielded a significant increase in all cardiovascular 
variables, haematocrit, and mean platelet volume (MPV).  Postural stress evoked 
significant increases in haematocrit, sE-sel, platelet count, MPV, sP-sel, and a 
significant decrease in intra-platelet P-selectin.  Hyperhydration caused a significant 
reduction in blood pressure in hypertensive patients, as well decreasing markers of 
endothelial perturbation and platelet morphology both at rest and in response to the 
stress tasks. 
Conclusions: Anecdotal and epidemiological evidence has linked behavioural activities 
to the trigger of acute coronary syndromes (ACS).  The current study adds some insight 
into the potential pathophysiological mechanisms through which acute mental stress and 
postural change may trigger the onset of ACS.   
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 CHAPTER 1 
 
Introduction 
 
 
1.1 General Introduction  
 
1.1.1 Atrial Fibrillation 
Atrial fibrillation (AF) is the most commonly encountered cardiac arrhythmia in clinical 
practice, and is defined as a supraventricular tachyarrhythmia characterised by 
uncoordinated atrial activation [1].  AF can be observed on an electrocardiogram (ECG) 
by the absence of a P-wave, which is replaced with rapid oscillations or fibrillatory 
waves.  These fibrillatory waves can vary in size, shape and timing, and are generally 
associated with an irregular ventricular response when the atrioventricular (AV) node is 
intact [2].  The ventricular response in AF is dependent on three major factors; AV 
nodal properties, the levels of sympathetic and parasympathetic tone acting on the 
sinoatrial (SA) node, and the effect that anti-arrhythmic drugs (i.e. beta-blockers, non-
dihydropyridine calcium channel blockers, digitalis glycosides) have on AV nodal 
conduction [3].  The exact aetiology of AF is complex, but is thought to involve several 
coexisting re-entrant wavefronts continuously sweeping around the atria in an irregular 
motion, repeatedly encountering excitable myocardium [4]. 
 
1.1.2 Epidemiology  
Current estimates suggest that AF afflicts approximately 2.2 million Americans [5].  In 
the United Kingdom (UK) approximately 740,000 individuals are thought to have AF 
[6], with more than 46,000 new cases being diagnosed each year [7].  The majority of 
epidemiological studies have been population-based, predominantly looking at the 
prevalence of AF in Western countries, comprised mainly of Caucasians.  The 
Cardiovascular Health and Framingham studies reported prevalence figures between 2.3 
- 1 - 
 and 6.2% in individuals aged over 30 years [8,9].   In the Renfrew-Paisley cohort, the 
prevalence of AF was 8 per 1000 in males and 4.2 per 1000 in females [10], increasing 
to 19.2 persons per 1000 when the study population excluded those aged <65 years [11].  
The prevalence of AF has been shown to increase with advancing age.  The 
Framingham Study demonstrated an increase in prevalence from 0.5% in people aged 
50-59 years to almost 9% in people aged 80 years or older [9], a trend borne out in other 
studies [8,10,12].  The prevalence of AF in non-Caucasian populations has received 
relatively little attention. The Cardiovascular Health Study demonstrated that there was 
a lower incidence of AF in Afro-Caribbeans compared to a Caucasians [8].  The 
Northern Manhattan Stroke Study observed that of patients presenting an ischaemic 
stroke, AF was more common in Caucasians (29%) than in either Black (11%) or 
Hispanic (11%) patients [13].  Further, a general practice survey in West Birmingham, 
UK, examining the prevalence of AF in an South-Asian population aged >50 years, 
found that although this ethnic group comprised 65% of the population, the prevalence 
of AF was only 0.6% [14].   
 
Population-based data from the Framingham Study demonstrates that the prevalence of 
AF in persons aged 65-84 years has substantially increased over a 21 year period.  
Between 1968 and 1989, the prevalence rose from 3.2% to 9.1% in men, with a smaller 
and but non-significant increase observed for females [9].  Explanations for the 
increasing prevalence include the aging population, greater awareness and surveillance 
by diagnosing doctors, and an increased myocardial infarction (MI) survival rate [4].   
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 1.1.3        Cost of atrial fibrillation 
The increased prevalence of AF is accompanied with an increased economic burden to 
our national health service (NHS).  Stewart and colleagues (2004) calculated the 
economic cost of AF to the health and social services in the UK in 1995, and based on 
epidemiological trends, projected this estimate to 2000.  The authors estimated that in 
2000 the ‘direct’ cost of health care for AF patients would be £459 million or 0.97% of 
the total NHS expenditure [15].  Analogous figures are not available for the United 
States; however, a recent editorial stated that similar economic costs are probably 
incurred [16], as the cost of acute hospital admissions and total Medicare payments 
were significantly higher in patients with AF [17].   
 
1.1.4  Classification of atrial fibrillation 
AF is an arrhythmia that has a heterogeneous clinical presentation.  Although several 
classification schemes have been proposed, none have fully accounted for all aspects of 
AF [18-21].  In 2003, the Working Group on Arrhythmias of the European Society of 
Cardiology (WGA-ESC) and the North American Society of Pacing and 
Electrophysiology (NASPE) recognised the need for consensus on the terminology and 
classification of AF [22].  Table 1.1 shows the WGA-ESC and NASPE clinical 
classifications of AF.  This proposed scheme has been adopted by the American College 
of Cardiology (ACC)/American Heart Association (AHA)/European Society of 
Cardiology (ESC) [23] and the National Institute of Clinical Excellence (NICE) 
guidelines for the management of AF in the UK [24]. 
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 Table 1.1: Classification of atrial fibrillation 
Terminology Clinical Features Pattern 
Initial event 
(first detected episode) 
Symptomatic 
Asymptomatic (1st detected) 
Onset unknown (1st detected) 
 
 
May or may not occur 
Paroxysmal AF Spontaneous termination <7   
days and most often <48 hours 
 
Recurrent 
Persistent AF Not self-terminating 
Lasting >7 days 
 
Recurrent 
Permanent AF Not terminated 
Terminated but relapsed 
Cardioversion not attemptedt 
Established 
 
1.1.5 Risk factors 
Numerous risk factors have been identified for the development of AF and these can be 
broadly grouped into cardiovascular and non-cardiovascular (Table 1.2).  In some 
individuals with AF, no predisposing factor can be identified and patients are 
subsequently classified as “lone AF”.  The true prevalence of lone AF varies and is 
highly dependent upon the definition and population studied.  Kopecky and colleagues 
demonstrated that over a 30-year follow-up period 97 patients (2.7%) developed lone 
AF (atrial fibrillation in the absence of overt cardiovascular disease or precipitating 
illness) [25].  Other studies examining the presence of lone AF are confounded by the 
inclusion of hypertensive and diabetic patients [26]. 
 
Cardiovascular risk factors are commonly associated with the development of AF.  
Hypertension and/or hypertensive heart disease is the most common underlying disorder 
in patients who have AF, accounting for approximately 50% of cases [11,27-29].  In 
addition to advancing age, the Framingham study demonstrated that the development of 
AF was significantly associated with diabetes (OR, 1.4 for men and 1.6 for women), 
hypertension (OR, 1.5 for men and 1.4 for women), congestive heart failure (OR, 4.5 
for men and 5.9 for women), and valve disease (OR, 1.8 for men and 3.4 for women) 
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 [9].  Psaty and colleagues also demonstrated that age, and coronary and valvular disease 
were important risk factors for the development of AF [11].  However, the authors 
demonstrated that levels of blood pressure and glucose were more important predictors 
than the diagnoses of high blood pressure and diabetes per se [11].  Ischaemic heart 
disease is probably the most common underlying cause of AF in the UK [30].  In the 
Framingham study, MI was significantly associated with the development of AF in 
men.  Krahn and colleagues also demonstrated that the risk of AF was associated with 
MI (relative risk (RR) 3.62), angina (RR 2.84), and S-T wave abnormalities in the 
absence of ischaemic heart disease (RR 2.21) [31].   
 
AF is the most common arrhythmia reported following cardiac surgery.  Among 
patients undergoing coronary artery bypass grafting (CABG), 33% developed AF in the 
post-operative period [31].  Independent predictors of post-operative AF include 
increasing age, male sex, hypertension, need for an intra-operative balloon pump, post 
operative pneumonia, ventilation for >24 hours, and return to the intensive care unit 
[31]. 
 
Hyperthyroidism is the most prominent non-cardiovascular variable associated with the 
development of AF [32], with AF occurring in 9-22% of patients with thyrotoxicosis 
[33].  Signs of hyperthyroidism may be less obvious in the elderly, and indeed sub-
clinical hyperthyroidism (indicated by a low TSH, and normal or high T4 in an 
asymptomatic patient) has been reported in patients with AF [34]. 
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 Table 1.2: Causes of atrial fibrillation 
Cardiovascular causes 
Common Less common 
¾ Ischaemic heart disease 
¾ Hypertension 
¾ Rheumatic heart disease 
¾ Heart failure 
¾ Sick sinus syndrome 
¾ Pre-excitation syndromes (i.e. Wolf-
Parkinson-White 
¾ Cardiac surgery 
¾ Cardiomyopathy or heart muscle disease 
¾ Pericardial disease, including effusion and 
constrictive pericarditis 
¾  Sinus node dysfunction 
¾ Atrial septal defect 
¾ Atrial myxoma 
Non-cardiovascular causes 
Metabolic causes Respiratory Other causes 
¾ Thyrotoxicosis 
¾ Low potassium, 
magnesium, or calcium 
¾ Drugs 
¾ Alcohol 
¾ Postoperative (non-
cardiac surgery) 
¾ Hypothermia  
¾ Pneumonia 
¾ Carcinoma 
¾ Pulmonary 
thromboemolism 
¾ Trauma 
¾ Thoracic  
¾ Vagal AF 
¾ Adrenergic AF 
 
 
1.1.6 Prognosis 
1.1.6.1 Morbidity and mortality  
The majority of the morbidity associated with AF is the result of haemodynamic 
changes, and thromboembolic complications [24].  From the outset, AF patients are 
haemodynamically compromised.  The absence of atrial systole, combined with the 
rapid irregularity of the ventricular response causes a reduction in cardiac output of 
between 10-20% [36].  This disturbance is more important in the elderly and/or those 
with progressive impairment of left ventricular contraction, in whom atrial systole 
contributes increasingly (>30%) towards the overall stroke volume.  It has also been 
speculated that sudden increases in ventricular rate associated with uncontrolled AF 
may lead to the development of critical cardiac ischaemia or even MI in patients with 
significant coronary artery disease (CAD) [37].  The main haemodynamic symptoms 
reported during AF are palpitations, dyspnoea, dizziness, and angina.  Syncope is rare in 
people with AF, unless associated with sick sinus syndrome or pre-excitation 
syndromes, such as Wolf-Parkinson-White syndrome.  As expected, these symptoms are 
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 more pronounced during physical activity, with a rapid ventricular response 
substantially impairing exercise tolerance [30]. 
 
AF is associated with the development of a prothrombotic state [37], with patients at an 
increased risk of thromboembolic complications, such as stroke [38].  The development 
of ischaemic stokes in AF results predominately from cardioemboli, most commonly 
occurring in the left atrial appendage.  Manning and colleagues demonstrated left atrial 
thrombi in more than 40% of patients with acute thromboembolism and newly 
diagnosed AF [40].  The fulfilment of Virchow’s Triad for thrombogensis [41], through 
abnormalities of flow (i.e. stasis of blood within the left atrium), abnormalities of the 
vessel wall (i.e. endothelial/endocardial damage), and abnormalities in blood 
constituents (i.e. platelet hyper-reactivity, coagulation-fibrinolytic imbalance) leads to 
the development of a hypercoagulable or prothrombotic state, and is likely to be of 
significance in intra-atrial thrombogenesis.  
  
Data from the Framingham study revealed that non-valvular AF (NVAF) is an 
independent risk factor for stroke, accounting for approximately 10-15% of all 
ischaemic strokes, and nearly a quarter of strokes for those >80 years.  Among those 
patients with NVAF, the stroke rate is approximately five times higher than for 
individuals in sinus rhythm [38].  AF patients also have a worse outcome following a 
stroke, with an elevated 30-day [42-43] and 12-month mortality [42], and stroke 
recurrence rates [42].  The severity of stroke is also greater in patients with AF [43-44], 
which is coupled with longer hospital stays [44] and lower discharge rates to their own 
homes [44].  
 
- 7 - 
 AF is associated with an increased risk of mortality.  Data from the Framingham study 
demonstrated that following adjustment for age, hypertension, smoking, diabetes, left 
ventricular hypertrophy, myocardial infarction, congestive heart failure, valvular heart 
disease, and stroke or transient ischemic attack, AF was associated with an odd ratio 
(OR) for death of 1.5 (95% CI, 1.2 to 1.8) in men and 1.9 (95% CI, 1.5 to 2.2) in 
women [26].   
 
1.1.6.2 Psychological prognosis 
In addition to established cardiovascular risk factors such as diabetes, hypertension, and 
smoking, psychological variables have been implicated in the aetiology and progression 
of coronary heart disease (CHD).  Numerous studies have examined the prognostic 
significance of depression and anxiety in patients with CHD, although there are no 
published data on whether such psychological variables can predict future 
cardiovascular morbidity and mortality (cardiac and all-cause) in patients with AF.  
Accordingly, the literature examining the impact of depression and anxiety on prognosis 
in patients with CHD will be reviewed. 
 
1.1.6.2.1 Depression 
 
Table 1.3 summarises the main studies examining the impact of depression on future 
cardiovascular morbidity and mortality (cardiac and all-cause) in patients with CHD 
[45-75].  Eight studies examined the impact of depression on all-cause mortality 
[45,53,61,63-64,70,72,75], with positive and negative outcomes findings being reported 
in equal measure.  Kauffman and colleagues [61] demonstrated that although depression 
failed to predict all-cause mortality over six-month follow-up (OR 2.46; CI, 0.86-6.98), 
a positive association was observed at 12-months (OR 2.34; CI, 1.18-4.65).  Carney and 
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 colleagues were the only group to correct for known cardiac risk factors (age, smoking, 
LVEF, diabetes), demonstrating that even following statistical adjustment their positive 
association between depressive disorder and 30-month all-cause mortality persisted (HR 
[adj] 2.4; CI, 1.20-4.70) [72]. 
 
The majority of research examining the prognostic significance of depression has 
centred on its impact on cardiovascular mortality.  Twenty publications reporting on 13 
studies have examined this relationship [46-52,54-60,62,65-69], mainly in patients 
following a MI [46-52,58-60,62,65,67-68].  Frasure-smith and colleagues [49-52] were 
one of the 10 [47-52,54-62,65-66] positive studies to emerge, demonstrating that 
depressive symptoms were predictive of cardiovascular mortality in the initial six 
months following a MI (OR 6.24; CI, 1.88-20.67) even after adjustment for known 
cardiac risk factors (HR [adj] 4.29; CI, 3.14-5.86).  Although Schleifer and colleagues 
demonstrated that depression was not predictive of cardiovascular mortality over a three 
month follow-up period (OR 0.59; CI, 0.20-1.74) [46], other investigators have 
replicated the results of Frasure-Smith and colleagues in follow-up periods up to 10 
years [54-62,65-66].   
 
Lane and colleagues [67-68] were one of only three groups [46,67-68,69] to report no 
impact of depression on cardiovascular mortality following MI, demonstrating that 
depressive symptoms failed to predict cardiovascular mortality at 12-month (OR 1.15; 
CI, 0.49-2.70) [67] and 3-years (OR 0.84; CI, 0.37-1.91) [68].  With the authors 
reporting similar rates of mild to moderate depressive symptoms, socio-economic 
status, and 12-month post-discharge mortality rates to Frasure-Smith and colleagues 
[49-52], the authors speculated about potential reasons for the discrepancies in findings.  
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 Lane et al. suggested that some of the inconsistency may have arisen from the exclusion 
of patients who died prior to discharge from hospital.  However, further analysis by the 
authors revealed that even when they excluded such patients in their analyses, 
symptoms of depression still failed to predict mortality [67].   
 
As many of the questionnaires (e.g. Beck Depression Inventory) assessing depressive 
symptoms have a significant somatic component, a more robust explanation of the 
discrepancy in outcome may be centred around the confounding issue of disease 
severity.  Many studies reporting an association between depression and mortality have 
also reported a positive association between cardiac disease severity and depressive 
symptomatology.  In contrast however, Lane and colleagues [68] failed to find any 
association between depression and medication status at discharge, nor, with exception 
of diabetes, any conventional cardiac risk factors (e.g. blood pressure status, smoking 
hyperlipidaemia), which they suggested may account for their null findings.  Further 
support for this hypothesis has arisen from studies [47-48,61-62] where the significant 
association between depression and mortality following an MI has been abolished when 
disease severity has been statistical adjustment for. 
 
Two recent meta-analyses have examined the relationship between depressive 
symptoms and depressive disorders on cardiac and all-cause mortality in patients with 
CHD.  The first by Barth and colleagues [76], including patients following an initial 
CHD event (MI, coronary artery bypass graft [CABG], percutaneous transluminal 
coronary angiography [PTCA]) or angiographically validated CHD, examined the 
association between depressive symptoms and disorders on cardiac and all-cause 
mortality.  The review, including 29 publications reporting on 20 studies, demonstrated 
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 that in both short and medium term (OR 2.24; CI, 1.37-3.60), and long term (>5 years) 
follow-up (OR 1.78; CI, 1.12-2.83) studies, depressed CHD patients were at an 
increased risk of all-cause mortality.  The authors found that even after adjustment for 
know cardiac risk factors (age, sex, physical illness, smoking, hyperlipidaemia, 
hypertension) patients exhibiting depressive symptoms were still at an increased risk of 
dying from any cause in the first two years after their initial assessment (HR [adj], 1.76; 
CI, 1.27-2.43).  Further analysis also revealed that depressive symptoms were a slightly 
better predictor for cardiac mortality (HR [adj], 2.07; CI, 1.31-3.27) than for all-cause 
mortality (HR [adj], 1.76; CI, 1.27-2.43).   
 
Six of the 20 included studies examined the impact of depressive disorders.  Although 
no impact on mortality was observed within the first 6 months (OR, 2.07; CI, 0.82-
5.26), the risk of depressive disorders was more than two times greater for CHD 
patients with clinical depression (OR, 2.61; CI, 1.53-4.47) in the two years after their 
initial assessment.  The limited number of studies reporting adjusted risk analysis, 
revealed an adjusted HR for all-cause mortality of 4.29 (CI, 3.14-5.86).  However, 
Carney and colleagues were the only group to report follow-up over two years, 
demonstrating an adjusted HR of 2.4 (CI, 1.20-4.70) [72].    
 
The second meta-analysis by van Melle and colleagues [77], examined the impact of 
depression post-MI (<3 months) on cardiac and all-cause mortality and cardiovascular 
events.  The authors included 22 studies, 15 of which were also included in the meta-
analysis by Barth and colleagues.  This review demonstrated that depression post-MI 
was significantly associated with a two-fold increased risk of all-cause mortality (OR, 
2.38; CI, 1.76-3.22), cardiac mortality (OR, 2.59; CI, 1.77-3.77), and cardiovascular 
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 events (OR 1.95; 1.33-2.85).  Secondary analysis revealed that the significant 
association between post-MI depression and all-cause and cardiac mortality was not 
influenced by the way that depression was assessed (questionnaire vs. psychiatric 
interview).  Although non significant (p=0.08), the authors revealed that there was a 
trend for the year of data collection (pre 1992) to influence the effect of depression on 
mortality, with stronger associations found in earlier studies (OR 3.22; CI, 2.14-4.86) 
compared with the later studies (OR 2.01; CI, 1.45-2.78).   
 
 
1.1.6.2.2 Anxiety 
 
In contrast to the plethora of research examining the impact of depression, only eight 
studies have examined whether symptoms of anxiety can predict outcome in patients 
with CHD (see Table 1.4) [63-64,67,74,78-81].  Pfiffner and colleagues [81] were one 
of the four studies [63-64,67,81] examining whether symptoms of anxiety can predict 
all-cause mortality in CHD patients.  In contrast to the other three studies, the authors 
demonstrated a significant association between symptoms of anxiety and death from 
any cause over a seven years follow-up period (OR 1.19; CI, not reported).  Caution is 
warranted when interpreting such findings as the authors limited the analysis to male 
patients less than 60 years and failed to adjust statistically for know cardiac risk factors.   
 
Four studies examined whether anxiety can predict cardiovascular mortality over 
follow-up periods ranging from one to 12 years [67,78-79,81].  The two studies with a 
protracted follow-up period (8 and 12 years) demonstrated a positive association 
between symptoms of anxiety and death from cardiac causes [78-79].  Frasure-Smith 
and colleagues [80] were the only group to undertake and report statistical adjustment, 
demonstrating that when various baseline and treatment variables were accounted for, 
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 the positive association (OR 1.21; CI, 1.01-1.46) between anxiety and cardiac mortality 
was abolished (HR [adj] 1.14; CI, 0.93-1.38). 
 
Two studies have examined the effect of anxiety on future cardiovascular events.  
Denollet and colleagues [79] demonstrated that in patients (left ventricular ejection 
fraction (LVEF) <50%) following an MI, anxiety was predictive of future 
cardiovascular events (e.g. recurrent MI, CABG, PTCA) (OR 3.4; CI, 1.2-9.6).  Strik 
and colleagues [74] replicated such findings over a shorter follow-up period (3.4 years).  
The authors demonstrated that even after adjustment for certain risk factors (e.g. age, 
LVEF, and use of anti-depressants) the impact of anxiety on future cardiovascular 
events persisted (HR [adj] 3.01; CI, 1.20-7.60).   
 
 
1.1.6.2.3 Possible mechanisms linking negative emotions to cardiovascular outcomes 
 
Despite the evidence that negative emotions (particularly depression) increase the risk 
of cardiovascular morbidity and mortality, no commonly accepted theory on the 
underlying mechanisms exists.  Although research on the related mechanisms is sparse, 
current debate centres on “indirect” and “direct” theories.  The “indirect” theory states 
that psychosocial factors may affect health related behaviours (eg, physical inactivity, 
poor diet, pharmacological non-compliance, smoking) which may in turn influence the 
risk of CHD [82].  The “direct” theory hypothesises that psychophysiological factors 
may directly lead to the development/progression of acute coronary syndromes (ACS).  
Currently the main candidate mechanisms linking negative emotions to cardiovascular 
outcome are (1) anti-depressant cardio-toxicity; (2) modification of health related 
behaviours; (3) alterations in the autonomic function; (4) haemostatic abnormalities; 
and (5) immunological dysregulation.   
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 1.1.6.2.3.1 Anti-depressant cardio-toxicity 
It is commonly recognised that certain anti-depressants, such as tricyclics and 
monoamine oxidase inhibitors, have cardio-toxic side effects.  Such findings have 
prompted speculation over whether the excess in cardiac morbidity and mortality may 
be due to the effects of pharmacological therapy and not depression per se [83]. 
Although plausible, the available evidence suggests that antidepressants are unlikely to 
contribute significantly to the morbidity and mortality in depressed CHD patients.  First, 
associations between depression and cardiovascular outcome were observed prior to the 
development of anti-depressant medication. Secondly, only a small proportion of anti-
depressants have severe cardiotoxic side effects, and third, selective serotonin reuptake 
inhibitors (SSRIs) have few cardiotoxic side effects, and they currently are the frontline 
antidepressants for cardiac patients [84].  
 
1.1.6.2.3.2 Modification of health related behaviour 
The “indirect theory” speculates that a modification of health related behaviours 
following a MI may increase an individual’s cardiovascular risk.  A recent study by 
Ziegelstien and colleagues revealed that post-MI patients demonstrating mild to 
moderate levels of depression reported lower levels of adherence to low-fat diets, 
regular exercise and stress reduction programs, and are less likely to socialise [85].  A 
meta-analysis by Dimatteo and colleagues examined the effect of depression and 
anxiety on patient adherence to medical therapy [86].  The review, including 12 articles 
on depression and 13 on anxiety, revealed a substantial and significant relationship 
between depression and non-compliance (OR 3.03; CI, 1.96-4.89).  However, the 
authors failed to find a significant association between anxiety and non-compliance.   
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 Although plausible, evidence suggests that health related behaviours do not contribute 
significantly to the excess in morbidity and mortality in depressed CHD patients.  First, 
in studies were depression has been shown to predict cardiovascular events (morbidity 
and mortality), no significant relationship has been shown between depression and 
cardiac risk factors (e.g. smoking status, social status) [49-52].  Secondly, in studies 
where depression has been shown to have prognostic significance, the statistical 
adjustment for cardiac risk factors (smoking, social support, physical activity) has failed 
to abolish the significant association [47-48,58-60,65,71]. 
 
1.1.6.2.3.3 Alterations in autonomic function 
Neurohormonal dysregulation has emerged as the most plausible explanation for the 
effects of depression and anxiety on cardiac morbidity and mortality.  An activation of 
the hypothalamic-pituitary-adrenocortical (HPA) axis and the sympathetic-adrenal-
medullary (SAM) system has been linked to an elevation of serum levels of cortisol and 
catecholamines.  If such negative emotions and elevated hormone levels persist over 
time, free fatty acid levels, blood pressure, and total peripheral resistance will increase, 
altering the individuals cardiovascular risk profile [87].  In addition, autonomic 
dysregulation may predispose CHD patients to myocardial ischaemia, ventricular 
tachycardia, ventricular fibrillation, and sudden cardiac death [88]. 
 
1.1.6.2.3.4 Haemostatic abnormalities and immunological dysregulation 
Abnormalities in the autonomic nervous system may also promote procoagulant and 
proinflammatory processes which have been implicated in the aetiology of ACS   
Musselman and colleagues demonstrated that healthy depressed individuals exhibited a 
41% increased platelet aggregation in comparison to healthy non-depressed individuals 
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 [89].  Although limited evidence is available for depressed CHD patients, Lagrissi-
Thode and colleagues [90] found higher plasma concentrations of platelet factor-4 and 
β-thromboglobulin (two proteins that are secreted from alpha granules) for depressed 
patients with CHD compared to non-depressed patients with CHD. 
 
As coronary artery disease (CAD) is now commonly regarded as a chronic 
inflammatory process it would appear reasonable to hypothesis that depression may lead 
to immunological dysregulation.  Depression has been shown to enhance the production 
of proinflammatory cytokine, including Interleuken (IL)-6, C-reactive protein (CRP), 
and tumour necrosis factor-α (TNF-α) in medically healthy adults [91-92].  However, 
interpretation of such findings is made difficult by the failure to account for the 
confounding of medication and smoking status, acute infections present at time of 
assessment, and hospitalisation [93].  As with alterations in platelet reactivity, little 
attention has been paid to the link between depression and inflammation in patients with 
existing CHD.  A study by Appels and colleagues, addressing this issue, revealed 
elevated levels of IL-1β and TNF-α in the coronary circulation in patients undergoing 
angioplasty due to severe angina [94].  
 
 
1.1.7 Management  
1.1.7.1       Risk stratification for anti-thrombotic therapy 
Numerous studies have investigated the degree to which anti-thrombotic regimes can 
decrease the risk of ischaemic stroke in AF.  A recent meta-analysis of 13 studies 
(14,435 participants) demonstrated that dose-adjusted warfarin decreased the risk of 
ischaemic stroke by 33% compared to placebo, in combination with a 69% risk 
reduction in all cause mortality [95].  An earlier meta-analysis demonstrated that aspirin 
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 therapy also has the potential to reduce the risk of stroke by 22% in comparison to 
placebo [96].  A comparative analysis of dose-adjusted warfarin and aspirin 
demonstrates the superiority of warfarin in reducing total stroke (RR 0.35, 95% CI 0.14 
to 0.51) [96] and ischaemic stroke and/or systemic embolism (RR 0.59, 95% CI 0.40 to 
0.86) [95].  In light of such findings, it is imperative that physicians are given guidance 
on (1) which patients should be considered for anticoagulation, and (2) how to tailor 
anti-thrombotic regime for an individual, based on variables such as age, co-
morbidities, and contraindications.  Several risk stratification models have been 
proposed (see Table 1.3), and pooled analysis from these findings has led to the 
development of the current UK National Institute of Clinical Excellence (NICE) 
guidelines on risk stratification for antithrombotic therapy (see Figure 1.1).  In brief, the 
guidelines suggest that AF patients at high risk for stroke should be considered for 
warafin therapy (unless contraindicated), moderate risk patients can be considered for 
either aspirin or warfarin, and low risk patients prescribed asprin only.  It is imperative 
that physicians realise that the assessment and reassessment of risk is a continual 
process and patients should be re-stratified based on the development of additional risk 
factors. 
 
1.1.7.2 Current recommendations for non-invasive treatment  
Table 1.4 depicts the current non-invasive management aims and recommendations for 
the treatment of paroxysmal AF (PAF), persistent AF, and permanent AF [24].  In 
addition to the therapeutic strategies outlined, highly symptomatic patients can also be 
considered for invasive procedures such as radiofrequency catheter ablation, 
external/internal pacing, and surgical procedures. 
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 Figure 1.1: Risk Stratification for anti-thrombotic therapy in AF patients [24] 
 
High-risk 
• Previous ischaemic 
stroke/TIA or 
thrombotic events 
• Age >75 with 
hypertension, 
diabetes, or vascular 
disease 
• Evidence of valve 
disease, heart failure, 
or left ventricular 
dysfunction 
Moderate-risk 
• Age >65 with no risk 
factors 
• Age <65 with 
hypertension, 
diabetes, or vascular 
disease. 
Consider 
anticoagulation 
Either anticoagulation 
or aspirin can be 
considered 
Aspirin 300 
mg/day unless 
contraindicated 
Are there any 
contraindications to 
warfarin? 
NO 
YES 
Reassess risk 
stratification whenever 
individual risk factors 
are reviewed 
Anticoagulate with 
warfarin, target INR = 
2.5 (2.0 – 3.0) 
Low-risk 
• Age <65 with no 
moderate risk 
factors 
Paroxysmal, persistent, 
permanent AF 
INR = International Normalised Ratio; TIA = Transient Ischaemic attack; > = equal to 
or greater than; < = equal to or less than 
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 Table 1.3: Summary of the main stroke risk stratification schemes proposed for patients 
with AF [97]  
 
Risk Strata  
Risk Stratification 
scheme 
High Intermediate Low 
AFI (1994) High – intermediate risk: aged >65 years; history of 
hypertension, CAD, or diabetes 
Aged <65 years; no 
high/intermediate risk 
features 
 
SPAF (1995) Women aged >75; SBP >160 
mmHg; LV dysfunction 
 
History of 
hypertension; no high 
risk features 
No history of 
hypertension; no high 
risk features 
Lip (1999) All patients with previous 
TIA or cerebrovascular 
accident; aged >75 with 
diabetes or hypertension; 
clinical evidence of valve 
disease, heart failure, thyroid 
disease, and impaired LV 
function  
 
Aged >65 with clinical 
risk factors: 
hypertension, diabetes, 
peripheral vascular 
disease, ischaemic 
heart disease; all 
patients >65 not in 
high risk 
Aged <65 with no history 
of embolism, 
hypertension, diabetes, or 
other clinical risk factors 
ACC/AHA/ESC 
(2001) 
Aged >60 years with diabetes 
or CAD; aged >75 years 
(especially women); any age 
with risk factors (clinical 
heart failure, LVEF <35%; 
thyrotoxicosis, or 
hypertension); rheumatic 
heart disease, prosthetic heart 
valves; previous 
thromboembolism; persistent 
atrial thrombus on TOE 
 
Aged <60 years with 
CAD but no risk 
factors; aged >60 years 
and risk factors 
Aged <60 years and no 
risk factors 
CHADS2 (2001 & 
2004) 
One point scored for each of the following: recent congestive heart failure, hyp, 
aged >75 years, diabetes. Two points scored if there is a history of stroke or TIA. 
Total score available is six. Scores 3 – 6 = high risk, 1 – 2 = moderate risk, 0 = low 
risk  
 
Framingham 
(2003) 
Weighted point scoring system—points are given for the following risk factors: ↑ 
age (maximum score <10); sex (female = 6, male = 0); hypertension (<4); and 
diabetes (6). Total score (maximum 31 points) corresponds to a predicted 5 year 
stroke risk 
 
ACCP (2004) Prior stroke, TIA, or systemic 
embolic event; aged >75 
years; moderately to severely 
impaired LV function with or 
without CHF; hypertension 
or diabetes 
Aged 65–75 years with 
no other risk factors 
Aged <65 years with no 
risk factors 
 
ACC = American College of Cardiology; ACCP = American College of Chest Physicians; AFI = Atrial 
Fibrillation Investigators; AHA = American Heart Association; CAD = coronary artery disease; CHF = 
congestive heart failure; ESC = European Society of Cardiology; ;LV = left ventricular; LVEF = left 
ventricular ejection fraction; SBP = systolic blood pressure; SPAF = stroke prevention in atrial 
fibrillation; TIA = transient ischaemic attack; TOE = transoesophageal echocardiography 
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 Table 1.4: Non-invasive management strategies for the treatment of atrial fibrillation  
 
 Management Aims Recommendations  
Paroxysmal 
AF 
1. Suppress the 
paroxysmsof AF 
2. Control of heart rate 
during paroxysms of 
AF if they occur  
3. Prevent associated 
thromboembolic 
complications 
 
1. Cardioversion 
 If paroxysms persist (>7days/usually >48hour) 
consider either electrical cardioversion or 
pharmacological cardioversion to return patient to SR 
2. Anti-arrhythmic prophylaxis 
 If future paroxysms are mild and infrequent it may be 
possible to avoid chronic anti-arrhythmic prophylaxis 
or adopt a ‘pill-in-the-pocket’ approach 
 If future paroxysms are symptomatic and frequent 
chronic prophylaxis with pharmacological therapy 
should be implemented 
 Beta-blockers or low-dose sotalol are usually 
considered as a first line drugs 
 If symptomatic episodes persist or the patient has 
intolerable side effects, Class Ic (i.e. flecainide, 
propafenone) and III drugs (sotalol, amiodarone) 
should be considered 
3. Rate control prophylaxis 
 Beta-blocker therapy will assist in reducing heart rate 
during paroxysms of AF 
4. Anti-thrombotic prophylaxis 
 As the annual rate of ischaemic stroke is 3.2% patients 
should be risk stratified for anti-thrombotic therapy 
(see Figure 1.1) 
  
Persistent AF  1. Increase the likelihood 
of maintaining SR 
following an electrical 
or pharmacological 
cardioversion 
2. Prevent associated 
thromboembolic 
complications 
 
1. Cardioversion 
 If AF persists for >7 days electrical cardioversion  
should be considered 
2. Anti-arrhythmic prophylaxis 
 Long term anti-arrhythmic prophylaxis should be 
given to help maintain SR (see PAF) 
3.  Anti-thrombotic prophylaxis 
 Thromboembolic events occur in between 1% and 7% 
of patients who do not receive anticoagulation prior to 
cardioversion.  Therefore patients should maintain 
therapeutic anticoagulation with warfarin (INR 2.5; 2.0 
– 3.0)  for a period of three weeks prior to, and four 
weeks following a successful cardioversion 
 
Permanent AF 1. Control of heart rate  
2. Prevent associated 
thromboembolic 
complications 
 
1. Rate control 
 Ventricular rate should be controlled between 60 and 
80 beats per minute at rest, and between 90 and 115 
beats per minute during moderate exercise 
 Beta-blockers or calcium-antagonists are usually 
considered as first line drugs 
 Adequate rate control is not always achieved through 
monotherapy. Beta-blockers/digoxin combination is 
the preferred first choice to control heart rate during 
normal daily activities, with a calcium-
antagonist/digoxin combination preferred if the patient 
partakes in regular exercise 
2. Anti-thrombotic prophylaxis 
 As the annual rate of ischaemic stroke is 3.3% patients 
should be risk stratified for anti-thrombotic therapy 
(see Figure 1.1) 
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 1.2 Quality of life in patients with atrial fibrillation 
 
1.2.1 Background 
 
Whereas the epidemiology, clinical consequences, and costs of AF have been subject to 
considerable study, less attention has been paid to patient-related issues, such as quality 
of life (QoL).  The concept of QoL emerged in the late 1940s, when the World Health 
Organisation (WHO) extended the definition of health to encompass the presence of 
physical, mental, and social well-being [98].  Since the 1980s, QoL issues have become 
more important in health care practice and clinical research, with a search of the 
Cochrane Controlled Trials Register demonstrating an increase from 0.34% in 1980 to 
3.6% in 1997 in the number of cardiovascular trials reporting QoL as an end point [99]. 
 
Assessment of QoL has been used for a variety of purposes in health-care settings: to 
screen for psychological morbidity; prioritise patients for various treatment regimes; 
determine the choice of treatment; monitor patients’ progress; and as an outcome 
measure in research studies and clinical trials [99-101].  QoL is particularly relevant to 
the treatment of chronic conditions such as AF, a condition that is not immediately life 
threatening but is likely to cause a substantial impairment in QoL [102].  A previous 
review of QoL studies in AF patients revealed various methodological weaknesses 
including small sample sizes, non-validated questionnaires, and highly selective patient 
populations.  However, since this review was undertaken a number of new 
interventions, including pulmonary vein (PV) isolation, implantable defibrillators, and 
the Maze operation, have become more common procedures for symptomatic AF 
patients, and the impact of such interventions on QoL has not been reviewed.  In 
addition, a number of recent randomised controlled trials have examined the impact of 
rate versus rhythm control strategies on QoL [103-106].  With rapid medical advances 
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 and subsequent reductions in mortality, variations in QoL may be the only reliable way 
of differentiating between treatment options. 
 
1.2.2 Non-interventional observational studies examining quality of life in atrial 
fibrillation patients 
Five observational studies [107-111] have examined QoL, using the Short Form (SF) - 
36, in a ‘general’ AF population, comprising of patients with paroxysmal AF and 
chronic AF, in addition to elderly and newly diagnosed AF patients (see Table 1.7).  
Four of these studies [107,109-111], compared AF patients with a control group: other 
CHD patients [107], general population [111], and healthy controls [107,109-110].  
Three of these studies [107,109-110] reported a poorer QoL in AF patients on some 
[109-110] or all of the SF-36 subscales [107].  One study [108] comparing the QoL of 
male and female AF patients, revealed that women reported significantly poorer 
physical and functional health, although, mental health and well-being scores were 
virtually identical for men and women. 
 
1.2.3 The effect of rate control strategies on quality of life in atrial fibrillation 
patients 
Six studies [112-117] have examined the effect of AV node/junction and bundle of HIS 
ablate and pace procedures, in paroxysmal AF, persistent and chronic AF patients.  All 
these studies demonstrated a significant improvement in QoL over the post-intervention 
follow-up periods, which ranged from six weeks to 12-months (see Table 1.8).   
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 Ten studies [118-127] have evaluated the effects of various rate control strategies on 
QoL in AF patients; eight comparing AV node/junction ablation and pacing [118-125] 
to AV modification [119-120], various modalities of pacing [118,124], against [125] or 
with the addition of pharmacological therapy post-intervention [121-123], and two 
[126-127] comparing ventricular rate control with drugs [126] or pacing [127].  Two 
studies [119-120] examining the effect of AV node ablation and pacing versus AV node 
modification report significant improvement in QoL in the ablate and pace group.  The 
benefit of AV node modification on QoL is equivocal, with one study reporting no 
change in QoL for patients who had successful AV node modification [120], wheras the 
other reported significant improvement [119]. 
 
Permanent destruction of the AV node/junction and synchronous dual chamber/single 
chamber ventricular pacing is another rate control strategy in the management of 
refractory AF.  Two studies [118,124] have examined the effect of various pacing 
strategies following ablation on QoL.  Both single chamber pacing in chronic AF and 
dual chamber pacing in paroxysmal AF patients following ablation provided similar 
significant improvements in QoL [118], irrespective of whether rate responsive pacing 
was turned on or off [124].  The remaining four studies [121-123,125] have examined 
the effect of pharmacological rate control therapy, in addition to [121-123], and in 
comparison to [125], ablation and/or pacing procedures.  Two studies demonstrated that 
adjunctive pharmacological therapy confers no additional benefit for QoL over and 
above ablation and pacing procedures alone [122,124].  However, Weerasooriya and 
colleagues [125] suggest that pharmacological rate control alone was as efficacious as 
AV junction ablation and pacing alone in improving QoL.  Two studies comparing the 
effect of pacing and pharmacological therapy, with ablation and pacing with or without 
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 drug therapy have also yielded conflicting results.  One study found similar 
improvements in QoL under both rate-control regimes [122], whereas the other 
demonstrated no improvement in QoL in the group undergoing pacing with the addition 
of drug therapy [121].  The final two studies [126-127] examining the effects of 
ventricular rate control drugs [126] and pacing (without ablation) with or without 
ventricular response pacing [127], both reported no significant differences in QoL 
between groups following treatment. 
 
1.2.4 The effect of rhythm control strategies on quality of life in atrial fibrillation 
patients  
Fifteen studies have examined the effect of rhythm controlling strategies alone on QoL 
in AF patients using a number of different methods, including percutaneous [128-136] 
or surgical interventions [137-139], or internal/external cardioversion [140,142-143] 
and pacing [141] (see Table 1.9).  Of the nine percutaneous intervention studies, four 
have used radio-frequency catheter ablation of atrial foci [128-130,133,136], and four 
[131-132,134-135] have employed pulmonary vein isolation, as rhythm control 
strategies for AF.  All nine studies [128-136], assessing QoL with the SF-36, 
demonstrated significant improvements in QoL among these highly symptomatic 
patients following the intervention.  Even unsuccessful PV isolation lead to increased 
QoL on half of the SF-36 subscales [136]. 
 
Three studies [137-139] have examined the impact of the Maze operation on QoL; one 
following mitral valve surgery [139]. QoL, again assessed by the SF-36, was 
significantly improved following the intervention [137-139], with AF patients reporting 
similar QoL scores to the general population [138]. However, the Maze operation, in 
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 addition to mitral valve surgery, did not afford any additional enhancement in QoL, 
compared to mitral valve surgery alone [139]. 
 
Few studies [140-143] have examined the effect of cardioversion, atrial pacing or 
defibrillation, as rhythm control strategies on the QoL of AF patients.  QoL is 
significantly improved among patients who have undergone DC cardioversion and 
remain in sinus rhythm [140], patients with an implanted atrial defibrillator [142-143], 
irrespective of the number of shocks applied [142], and patients with an implanted atrial 
septal pacemaker [141]. 
 
Only four studies to date [144-147] have compared the effects of two [145-146] or more 
[144,147] different rhythm controlling strategies on QoL.  Two of these studies [145-
146], comparing radio-frequency PV ablation to anti-arrhythmic drug therapy, revealed 
a better QoL in those patients receiving ablation, with little improvement in QoL among 
those treated pharmacologically.  Of the other two studies [144,147], one compared the 
effects of short-term (8 weeks) and long-term (52 weeks) amiodarone therapy following 
successful DC cardioversion, with placebo and demonstrated a similar improvement in 
QoL in all three groups during the first year [147].  The other compared the effects of 
amiodarone, sotalol, or propafenone (with or without DC cardioversion) and found 
significant improvements in QoL in all three groups, but only for the first three months 
of follow-up [144]. 
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 1.2.5 The effect of rate- versus rhythm-control strategies on quality of life in atrial 
fibrillation patients 
 
Eight studies have examined the effect of rate-control versus rhythm-control strategies 
on QoL in AF patients [148-155] (see Table 1.10).  Five studies [148-152], including 
four large randomised trials, STAF [148], PIAF [149], RACE [150], and AFFIRM 
[152], compared pharmacological rate control with or without AV node ablation to 
cardioversion (DC or pharmacological) with or without pharmacological rhythm 
control.  All reported an improvement in QoL following intervention.  Of the four 
randomised trials, three [148-150] demonstrated a greater improvement in QoL, 
assessed using the SF-36, among patients receiving rate-control treatment.  However, 
the AFFIRM trial [152] revealed that the improvement in QoL following intervention 
was similar for both rate- and rhythm-control strategies.  The other study [151] to 
compare rate and rhythm strategies demonstrated that there was a significantly greater 
improvement in QoL among patients in the rhythm-control group.  However, this study 
used a non-validated measure of QoL, in an uncharacteristically young AF population, 
and therefore caution is warranted in interpreting the results. 
 
Three studies [153-155] have compared AV node/junction ablation with or without 
pacing to pharmacological therapy.  All three studies, employing a variety of QoL 
assessments, demonstrated a significant increase in QoL in AF patients undergoing rate-
control intervention compared to rhythm-control treatment [153-155]. 
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 1.3 Triggering of acute cardiovascular events 
1.3.1 Background 
Cardiovascular disease (CVD) remains the major cause of mortality and morbidity in 
the western world, with acute myocardial infarction (MI) accounting for a large 
percentage of the deaths observed [156].  The aetiology of MI is usually a chronic and 
multi-factorial process, with several risk factors, such as elevated serum cholesterol, 
hypertension, and smoking, being well recognised.  In addition to established risk 
factors, it has been suggested that lifestyle and daily activities, such as psychological 
stress, postural adjustments and physical activity, may act as triggers for acute coronary 
syndromes (ACS).   
 
The concept of ‘triggering’ emerged almost a century ago when Obraztsov and 
Strazhesko provided anecdotal evidence stating that ‘direct events’ (such as 
psychological stress or physical activity) could precipitate MI [157].  More robust 
evidence has subsequently emerged from self-report studies, demonstrating that in a 
population of patients who had experienced a MI nearly half (40-50%) reported one or 
more potential trigger, the most common being moderate/heavy physical activity, 
sudden change in position, and acute emotional upset [158-160].   
 
Further support for the postural change triggering acute cardiovascular (CV) events is 
derived from research examining whether there is a morning excess in acute MI and 
sudden cardiac death.  In 1985, a study by Muller and colleagues dispelled the long held 
opinion that acute CV events, such as myocardial infarction (MI), were completely 
random in nature [161]; there was an increased frequency between 6 a.m. and noon 
compared to the remaining 18 hours of the day [162].  Such findings sparked a great 
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 deal of interest in the timing of cardiovascular events, and a number of retrospective and 
prospective studies subsequently demonstrated a morning excess in the onset of MI 
[163-164], sudden cardiac death [165-166], and transient myocardial ischaemia [167-
168].  A resultant meta-analysis confirmed these findings, demonstrating a morning 
excess in acute MI and sudden cardiac death of 40% and 29%, respectively [169].  
Indeed, further analysis revealed that the morning peak in acute CV events was more 
abrupt when time of awakening was taken into account.  After adjusting for wake time, 
the incidence of sudden cardiac death in the 3 hours after awakening increased from 1.7 
(95% CI, 1.0 – 2.8) to 2.6 (95% CI, 1.6 – 4.2) [170], observations that have also been 
replicated in MI patients [171-172].  Accordingly, it would be reasonable to hypothesize 
that the morning excess in acute CV events may result from the act of getting out of bed 
and commencing daily activities, and not be an intrinsic consequence of the morning 
period itself [173].  Although difficulty would arise in attempting attribute a specific 
external trigger (i.e. dehydration, physical exertion, mental stress) to the excess CV 
events in this period, it is possible that the assumption of an upright posture may be of 
significance.   
 
Coronary plaque disruption and subsequent thrombosis is recognized as the underlying 
pathophysiological process marking the transition from stable coronary artery disease to 
ACS [174].  The exact mechanism of how psychological stress, assumption of an 
upright posture, and physical activity trigger this transition is still unknown.  From 
current knowledge on thrombogenesis it is reasonable to postulate the increases in 
haemodynamic and mechanical sheer stress, reflected in increases in blood pressure, 
pulse rate, and cardiac contractility, in combination with increases in blood viscosity, 
could trigger plaque disruption, if circumstances were favourable.  The next stage in the 
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 transformation of a disrupted plaque to a ‘clinically’ active plaque involves the process 
of ‘overlying’ thrombosis.   A number of studies have demonstrated an increase in 
platelet reactivity (aggregation and soluble markers) during implicated behavioural 
activities, which may play a significant role in the triggering of arterial thrombogenesis 
and eventual vessel occlusion.   
 
1.3.2 Effects of acute psychological stress on haemorheology, coagulation, 
fibrinolysis and platelet reactivity 
Laboratory studies examining the effect of acute psychological stress on haemorheology 
have focused on changes in blood viscosity and haemoconcentration.  Findings from 
these studies demonstrate that the administration of a laboratory stress task of between 5 
and 28 minutes duration can decrease plasma volume by up to 7 % [175-183], as well as 
increase in whole blood and plasma viscosity [178-180].  Only one study to date has 
reported no change in haematocrit following stress exposure [184].   
 
A series of studies on healthy individuals by Veldhuijzen van Zanten and colleagues 
[177] demonstrated, in accordance with Ross et al. [178], that males exhibit an 
exaggerated stress-induced heamorheological stress response compared to age-matched 
females.  Based on these findings, it has been speculated that this difference may, in 
part, contribute to the lower cardiovascular risk associated with pre-menopausal women.   
 
Table 1.11 summarises the studies that have examined the effect of acute laboratory 
psychological stress tasks on haemostasis and platelet reactivity.  Studies examining the 
effect of acute psychological stress on coagulation have in general yielded positive 
findings, demonstrating increases in clotting factors such as FVII:C, FVIII:C and 
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 FXII:C [185-186], thrombin-antithrombin (TAT) complex [187,189-190], fibrinogen 
[186,188,196] and fibrin D-dimer levels [187,189-190].  Such results suggest that acute 
psychological stress affects biological processes at the beginning of both the intrinsic 
(FXII:C) and extrinsic (FVII:C) coagulation pathways, as well as in the final stages of 
the common pathway (fibrinogen and D-dimer).  A study by von Kanel and colleagues 
demonstrated that prothrombin time (PT) and activated partial thromboplastin time 
(aPTT), more functional screening measures of coagulation, were unaffected by an 
acute stress task, suggesting that such measures may be too ‘crude’ to detect subtle 
changes in the cascade [186].  Research on fibrinolysis is far less conclusive, primarily 
due to the limited number of studies and the inconsistency of the findings.  Work 
examining tissue-type plasminogen activator (t-PA), the molecule responsible for the 
degrading of fibrin into soluble fragments, is indicative of this inconsistency, with 
studies reporting increases [189,196], no change [193] and decreases follow acute 
psychological stress [187,199]. 
 
Studies examining the effect of acute stress on platelets have largely been concerned 
with alteration in platelet counts and secretion of platelet specific products, with a few 
earlier studies focusing on its effect on platelet aggregation.  Results have generally 
shown that platelet count [190,196-197], the secretion of platelet specific products 
[192,200-201] and platelet aggregation [194-195,197,200,202] increases significantly 
following acute psychological stress.  In contrast to Grignani and colleagues [202], 
Markovitz et al. found that platelet activation was significantly elevated following an 
acute stress task in healthy males, although no change was observed in coronary artery 
disease (CAD) patients [201].  Platelet responsiveness may also vary within a patient 
population [200]; WHO stage I hypertensive patients, although having comparable 
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 levels of platelet aggregation and β-TG at baseline had an increased response to the 
stress task compared to normotensive controls.  Interestingly, WHO stage II 
hypertensive patients showed no increase in platelet reactivity following the stress task 
although having elevated baseline parameters.  To date, only one study [203] has used 
flow cytometric analysis to examine the platelet response to acute psychological stress 
and failed to demonstrate any significant changes in GPIbα and GPIIb/IIIα expression 
on the platelet membrane or any increases in fibrinogen binding index. 
 
von Willebrand Factor (vWF), a protein of significant importance in haemostasis 
through its role in platelet-platelet and platelet-sub-endothelium adhesion, is the 
biochemical marker that has received the most attention in this context.  The majority of 
studies have found significant increases following psychological stress exposure [185-
186,189,196], possibly through increases in sheer stress leading to alterations in 
endothelium cell morphology and function. 
 
1.3.3 Effects of acute change of posture on haemorheology, coagulation, 
fibrinolysis and platelet reactivity 
To date, 20 studies have reported data on haemorheological change when an individual 
assumed an upright posture, predominately changes in haematoctrit [205,207-211, 
213,215,217,220-221,226] and plasma volume [205-208,210,212,215,217-219,221-
226].  Eleven studies reported absolute increases in haematocrit of between 1.3% to 
4.6% [205,207-211,217,220-221,226], with two studies reporting relative changes in 
haematocrit between 7% and 8% [213-215] during postural challenges (head up tilt or 
upright standing) lasting between 15 and 120 minutes.  The 15 studies examining acute 
changes in plasma volume report significant mean decreases of between 7% and 17%, 
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 corresponding to a fluid loss of between 200 and 640 mL [205-207,210,212,215,217-
219,221-226].  Four studies measured changes in haematocrit and/or plasma volume at 
multiple time points throughout the postural challenge [205-206,219,211].  Two of 
these studies demonstrated that the haemoconcentration was complete within 20 to 25 
minutes [205,211], with Raj and colleagues reporting that 75% of the response was 
complete with the first five minutes of their head-up tilt protocol [206].  Sex differences 
in postural-induced haemoconcentration have received little attention.  The two studies 
to date have produced conflicting findings, with one study reporting that men and 
women exhibited a similar haemorheological response [217] and the other 
demonstrating an exaggeration response in female participants [207].   
 
One of the major factors determining an individual’s orthostatic tolerance is their 
magnitude of blood volume [227], making it entirely plausible that intolerant 
individuals would demonstrate an exaggerated haemorheological response to acute 
changes in posture.  Two [208,212] of the four studies [206,208,210,212] addressing 
this issue found that individuals with orthostatic intolerance displayed a greater decrease 
in plasma volume [208] and blood volume [212] compared to controls.  Further, four 
studies have examined whether hypertensive [224,226] and nephrotic syndrome patients 
[221] differ from healthy controls, with one study examining whether age was a 
contributing factor [223].  Although nephrotic patients demonstrated a greater degree of 
haemoconcentration compared to healthy individuals [221], the studies on hypertensive 
[224,226] and elderly individuals were inconclusive [223].  
 
Five studies have examined the effect of an acute change in posture on haemostasis and 
platelet reactivity [213-216,227].  Two of these studies examined the effect of standing 
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 (>30 minutes) on whole blood platelet aggregation and the expression of various 
glycoproteins on the platelet membrane (flow cytometric) [211,213].  Although an 
increase in platelet count (approx. 15%) and platelet aggregation was demonstrated, no 
change in the surface expression of the activation-dependent antibodies (i.e. P-selectin, 
activated GPIIb/IIIa, vWF, fibrinogen) was detected [213].   In vitro experiments have 
also been conducted to examine whether the increase in platelet aggregation was due to 
the increase in haematocrit and/or platelet count accompanying the change in posture 
[213].  Platelet aggregation was significantly increased when whole blood samples were 
treated with platelet rich plasma, suggesting that the haemoconcentration and increased 
platelet count may partly explain the increased levels of platelet aggregation [213].  The 
only research to date examining soluble platelet markers demonstrated an increase in 
beta-thromboglobulin in a hypertensive group, however, no change in platelet factor-4 
was observed [215].  Soluble coagulation and fibrinolytic markers have also received 
minimal attention, although increases in prothrombin fragments 1 + 2 [204], euglobulin 
clot lysis time [215], tissue-plasminogen activator [213,215] have been reported.   
 
 
1.3.4 Effects of physical activity on haemorheology, coagulation, fibrinolysis and 
platelet reactivity 
There is a paucity of research investigating the effects of acute physical activity on 
haemorheology, however the available evidence indicates a significant increase in 
haematocrit of between 1 and 10 % [228-236], which is associated with a significant 
increase in blood and plasma viscosity [229,234,236].   
 
Table 1.13 summarises the studies that have examined the effects of acute low, 
moderate, and high intensity exercise on haemostasis and platelet reactivity.  
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 1.3.4.1 Low Intensity Exercise (< 55% VO2 Max) 
To our knowledge, only two studies have examined the haemostatic response to low 
intensity exercise, one conducted on female post-MI patients [238] and the other in 
physically active and inactive males [237].  Eriksson-Berg and colleagues demonstrated 
that although markers of coagulation (D-dimer, TAT) and endothelium dysfunction 
were unaffected by the exercise, fibrinolytic activity was increased through an increase 
in t-PA antigen and activity level [238].  Szymanski and colleagues [237] demonstrated 
that t-PA activity was elevated following 30-minutes of exercise in both physically 
active and inactive participants, and that this increase was significantly greater when the 
exercise was performed in the evening compared to the morning.   
 
1.3.4.2 Moderate Intensity Exercise (56 to 75% VO2 Max) 
Much of the research examining the effects of moderate intensity exercise has been 
conducted on patient populations, including stroke, metabolic syndrome, hypertensive 
and peripheral vascular disease (PVD) patients.  Moderate intensity exercise has been 
observed to elicit changes in t-PA (antigen and activity) [243,245-246], although 
findings on its inhibitor, PAI-1, are inconsistent, with some studies reporting decreases 
[243,245] or no change [246] in activity levels, as well as increases [244] or no change 
[245-246] in antigen concentration.  Drawing definitive conclusions from these studies 
is difficult, as they have often failed to employ adequate control groups [239-
240,243,245], or have tested only a small numbers of participants [241,244-245].  
Morris and colleagues [244] demonstrated that individuals with metabolic syndrome 
were hypofibrinolytic, both at rest and during exercise in comparison to healthy 
controls, which they suggested might play a part in increasing their acute thrombotic 
risk.  Desouza et al. [246] suggested that this risk might not be uniform across patients 
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 groups, finding no difference in the fibrinolytic response between hypertensive and 
normotensive males.  The few studies examining the effect of moderate intensity 
exercise on coagulation and platelet reactivity have also produced inconsistent findings, 
with some studies demonstrating increases in platelet count [239], aggregation [239] 
and reactivity [240], while others demonstrate no change [241]. 
 
1.3.4.3 High Intensity Exercise (> 75% VO2 Max & Incremental Exercise Tests) 
Research examining high intensity exercise is more suggestive of the development of a 
prothrombotic state.  A hyperfibrinolytic state has consistently been demonstrated 
following this type of exercise, with the majority of studies observing decreases in 
euglobulin clot lysis time [258,267,269,282,289], PAI-1 antigen [272,279,282] and 
activity [248,250,254,260,262] levels, as well as increases in t-PA antigen 
[248,250,255,260-262,265,275-277,279,282] and activity levels [248,254,258-260], 
plasminogen α2-antiplasminogen (PAP) complexes [253,275], and plasminogen 
activator activity (PAA) and activator-inhibitor complex [279].   
 
Research examining the effect of high intensity or incremental exercise on coagulatory 
markers and indices have reported increases in D-dimer [275] fibrinogen [250,271-272], 
TAT complex [275,277-278], antithrombin III [250], F1+2 [250,253,255,278] and an 
array of clotting factors [259,264,268,288], with subsequent decreases in PT [259,267] 
and aPTT [250,259,267].   
 
Although high intensity exercise has been associated consistently with increases in 
platelet count, in the region of 10 to 40% [256], with a recent study demonstrating an 
increase in mean platelet volume (MPV) in a patient population [270], the results for 
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 platelet function are still equivocal.  High intensity exercise has been shown by some 
[248-249,256,263], but not all [258,281], to increase platelet aggregation to ADP, 
collagen, epinephrine, and sheer stress.  Studies examining the secretion of plasma 
specific proteins have also produced inconsistent findings, with some investigators 
reporting increases [257,280,283-285,287], no changes [258,263,271-272,285-286,289], 
and differences between patients and healthy individuals [281,286-287].  Studies 
examining platelet responses using flow cytometric analysis, have provided some 
positive findings with reported increased expression of P-selectin, GPIb, GPIV and 
GPIIb/IIIa [249,253,261]. 
 
It would appear reasonable to assume that healthy and physically active individuals 
would exhibit a more unfavourable haemostatic profile following heavy exercise 
compared to sedentary and diseased individuals.  Research examining whether patients 
exhibit an attenuated fibrinolytic response have yielded conflicting findings, with 
studies reporting no differences [275], an impaired fibrinolytic response [276,290], as 
well as an exaggerated fibrinolytic response in patients [277,279]. Similar 
inconsistencies have also been demonstrated in studies examining changes in 
coagulatory and platelet variables [270,274-275,283,285,287,289].  Studies examining 
whether an individuals level of physical activity can affect the haemostatic response to 
physical activity have provided much more conclusive evidence. The majority of 
studies to date have demonstrated that sedentary individuals or those performing little 
physical activity have an attenuated fibrinolytic response, in combination with 
exaggerated changes in coagulatory and platelet variables compared to trained 
individuals, or those engaged in high levels of physical activity [251,255,257,260-
261,267]. 
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1.4 Aims and objectives 
This thesis aims to explore the psychosocial and psychophysiological characteristics of 
AF patients and their effect on the prothrombotic state and prognosis.  The main 
objectives are to: 
 
1. Determine the level of psychosocial impairment in patients with AF in 
comparision to a hypertensive disease control group. 
2. Examine whether the psychological status of AF patients can predict future 
quality of life, cardiovascular morbidity, and mortality. 
3. Determine the effects of acute psychological stress and postural change on 
haemorheology and markers of endothelial dysfunction and platelet activation in 
patients with AF, in comparision with hypertensive and health individuals. 
4. Examine whether hydration status can attenuate an individual’s haemodynamic, 
rheological, endothelial, and platelet reactivity to acute psychological stress and 
postural change. 
 
 
 
 
 
 
 Table 1.5: Studies examining whether depression is a predictor for cardiovascular events and mortality in patients with coronary heart 
disease 
 
Author, year, place Participants (Mean 
+ SD age, years) 
Female 
(%) 
Follow-up 
(months) 
Method of assessing 
depression (cut-off 
employed to indicate 
depression) 
Outcome variables Unadjusted results (95% 
CI) 
Variables adjusted 
for 
Adjusted Results 
(95% CI) 
Carney et al., 198845 
USA 
52 patients with 
CAD (56.2) 
27 12 DSM-III-R All-cause mortality 
 
All-cause mortality:  
OR 2.65 (0.21-31.46) 
  
Schleifer et al., 198946 
USA 
283 patients post 
AMI (63.7; 27-90) 
36 3 Schedule for Affective 
disorders and 
Schizophrenia  
CV-mortality CV-mortality:  
OR 0.59 (0.20-1.74) 
  
Ladwig et al., 199147 & 
199448 
Germany 
560 male patients 
post AMI (54; 29-
65) 
0 12 Zerssen Self Rating 
Scale (scores †) 
 
CV mortality  CV mortality:  
OR 5.3 (1.42-19.69) 
 
Age, social status, 
previous CV events, 
helplessness 
CV mortality:  
HR 4.9 (1.11-21.59) 
Frasure-Smith et al., & 
Lesperance et al., 
199349, 1995a50, 
1995b51, 199652 
Canada 
222 patients post 
AMI (60; 24-88) 
22 6 BDI (scores > 10) CV mortality 
CV events 
CV mortality:  
OR 6.24 (1.88-20.67) 
CV events:  
OR 3.32 (1.69-6.53) 
 
Previous MI, Killip 
class, PVCs  
CV mortality:  
HR 4.29 (3.14-5.86) 
CV events:  
HR 1.99 (0.92-4.31) 
Jenkinson et al., 199353 
UK 
1376 patients post 
AMI (59; 25-84) 
22 6, 12, 36 3 items in the psycho-
social questionnaire of 
the ASSET study 
(scores †) 
All-cause mortality  6-month all-cause 
mortality:  
OR 1.0 (0.35—2.83) 
12-month all-cause 
mortality:  
OR 1.0 (0.42-2.37) 
36-month all-cause 
mortality:  
OR 0.9 (0.47-1.76) 
  
Barefoot et al., 199654 
& 200055 
USA 
1250 patients with 
CAD (52; 46 – 58) 
18 15.2 Zung SDS (scores > 50) CV mortality CV mortality: 
OR 1.26 (1.07-1.48) 
 
Severity of disease, 
treatment 
 
CV mortality:  
HR 1.42 (1.14-1.76) 
Denollet et al., 199656 
Belgium 
303 patients with 
CAD (55; 31-79) 
12 84 MBHI (scores †) CV mortality CV mortality:  
OR 2.69 (1.33-5.45) 
  
Denollet et al., 199857 
Belgium 
87 patients with 
CAD (55.1;41-65) 
7 96 MBHI (scores > 10 
pessimism scale; scores 
> 12 despair scale) 
CV mortality CV mortality:  
OR 7.46 (1.56-35.80) 
  
Frasure-Smith et al., 222 patients post 22 18 Modified DIS CV mortality  CV mortality:    
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 199958 
Canada 
AMI (60; 24-88) OR 3.64 (1.32-10.04) 
Frasure-Smith et al., & 
Lasperance et al., 
199958, 200059, 200260 
Canada 
887-896 patients 
post AMI  
32 12, 60 BDI (scores > 10) CV mortality 12-month CV mortality:  
OR 3.22 (1.65-6.31) 
 
 
Age, smoking, non-
Q-wave MI, LVEF, 
Killip class 
60-month CV mortality:  
OR 3.16 (1.78-5.59) 
Kaufmann et al., 
199961 
USA 
331 patients post 
AMI (65; 28-92) 
34 6, 12 DIS All-cause mortality 6-month all-cause 
mortality:  
OR 2.46 (0.86-6.98) 
12-month all-cause 
mortality:  
OR 2.34 (1.18—4.65) 
  
 
Irvine et al., 199962 
Canada 
634 patients post 
AMI (63.8+10.8) 
17 24 BDI (scores > 10) Sudden cardiac death  Previous MI, 
significant biological 
predictors (†) 
Sudden cardiac death:  
HR 2.45 (1.14-5.35) 
Hermann et al., 200063 
Germany 
5017 patients 
referred for 
exercise tests 
(53.8+12.7) 
15 60-72 HADS (scores > 8 on 
depression subscale) 
All-cause mortality  Age, sex, previous 
MI, ECG 
All-cause mortality:  
HR 1.21 (1.04-1.42) 
Mayou et al., 200064 
UK 
344 patients post 
AMI (30-79) 
27 6, 18 HADS (scores > 19) All-cause mortality 6-month all-cause 
mortality:  
OR 1.60 (0.43-5.95) 
18-month all-cause 
mortality:  
OR 1.64 (0.64-4.20) 
  
Welin et al., 200065 
Sweden 
275 patients post 
AMI (>65; 30-65) 
16 120 Zung SDS (scores > 40) 
and BDI (scores > 10) 
CV-mortality CV mortality:  
OR 3.54 (1.85-6.77) 
 
Sex, smoking, LVEF, 
hypertension, 
hypercholesterolemia
, social support 
CV mortality:  
HR 3.16 (1.38-7.23) 
Connerney et al., 
200166 
USA 
309 patients with 
CAD (63.1+10.1) 
33 12 BDI (scores > 10) 
Modified DSM-IV 
CV mortality 
 
CV mortality:  
OR 2.31 (1.17-4.56) 
  
Lane et al., 200167 & 
200268 
UK 
288 patients post 
AMI (62.7+11.5) 
25 12,36 BDI (scores > 10) CV mortality 12-month CV mortality:  
OR 1.15 (0.49-2.70) 
36-month CV mortality:  
OR 0.84 (0.37-1.91) 
Non-adjusted  
Borowicz et al., 200269 
USA 
172 patients with 
CAD (63.4) 
22 60 CES-D scale (scores > 
16) 
CV mortality CV mortality:  
OR 2.29 (0.74-7.11) 
  
Romanelli et al., 200270 153 patients post 44 4 BDI (scores > 10) or All-cause morality All-cause mortality:    
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 USA AMI (65-93) DSM-III-R OR 4.71 (1.67-13.31) 
Shiotani et al., 200271 
Japan 
1,042 patients post 
AMI (63+11) 
64 12 Zung SDS (scores > 40) CV events  Age, sex, smoking, 
severity of 
myocardial 
infarction, 
hypertension, 
diabetes  
CV event:  
HR 1.41 (1.03-1.92) 
Carney et al., 200372 
USA 
766 patients post 
AMI (58.9) 
40 30 DSM-IV All-cause mortality All-cause mortality: 
OR 2.8 (1.50-5.30) 
Age, smoking, 
LVEF, diabetes, 
bypass surgery after 
MI 
All cause mortality:  
HR 2.4 (1.20-4.70) 
Lauzon et al., 200373 
Canada 
550 patients post 
AMI (60) 
21 12 BDI (scores > 10) All-cause mortality 
CV events 
 Age, sex, smoking, 
previous AMI, 
diabetes, 
hypertension, 
All-cause mortality:  
HR 1.3 (0.59-3.03) 
CV events:  
HR 1.4 (1.05-1.86) 
Strik et al., 
200374 
The Netherlands 
318 males post 
AMI (58+11) 
0 41 SCL-90 (scores > 23 on 
depression subscale 
CV events  Age, LVEF, use of 
anti-depressants 
CV events:  
HR 2.32 (1.04-5.18) 
Steeds et al., 200475 
UK 
131 patients post 
AMI (<75) 
n.s 32 BDI (scores > 12) All-cause mortality All-cause mortality: 
OR = 1.8 (0.56-0.60) 
  
 
AMI = acute myocardial infarction; BDI = Beck Depression Inventory; CAD = coronary artery disease; CES-D = Centre for Epidemiological Studies Depression scale; 
CV = cardiovascular; DIS = Diagnostic Interview Schedule; DSM-III-R/IV = Diagnostic Statistical Manuals versions III-revised & IV; ECG = electrocardiogram; 
HADS = Hospital Anxiety and Depression scale; LVEF = left ventricular ejection fraction; MBHI = Million Behaviour Health Inventory; MI = myocardial infarction; 
SCL-90 = 90-item Symptom Checklist; SDS = Self-rating Depression Scale; > = greater than or equal to; † = not reported 
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Table 1.6: Studies examining whether anxiety is a predictor for cardiovascular events and mortality in patients with coronary heart disease 
 
Author, year, place Participants (Mean 
+ SD age, years) 
Female 
(%) 
Follow-up 
(year) 
Method of assessing 
anxiety (cut-off employed 
to indicate anxiety) 
Outcome variables Unadjusted results (95% 
CI) 
Variables adjusted 
for 
Adjusted results 
(95% CI) 
Ahern et al., 199078 
USA 
353 patients post 
MI (†) 
† 12 STAI (scores >40) CV mortality  Age, LVEF, previous 
MI 
† 
Denollet et al., 
199879 
Belgium 
 
87 patients post 
AMI with LVEF 
<50% (41-69) 
7 8 STAI-S (scores >48) CV mortality 
CV event 
CV-mortality: 
OR = 3.7 (1.1-12.4) 
CV event: 
OR = 3.4 (1.2-9.6) 
  
Hermann et al., 
200065 
Germany 
5017 patients 
(53.8+12.7) 
15 5 HADS (scores >10 on 
anxiety scale subscale) 
All-cause mortality  Age, sex, previous 
MI, ECG 
† 
Mayou et al., 200066 
UK 
344 patients post 
AMI (30-79) 
27 0.5, 1.5 HADS (scores >10) All-cause mortality 6 & 18-month all-cause 
mortality:  
† 
Non-adjusted  
Lane et al., 200167 
UK 
288 patients post 
AMI (62.7+11.5) 
25 1 STAI (scores >10) All-cause mortality 
CV mortality 
All-cause mortality: 
OR = 0.99 (0.96-1.03) 
for state anxiety 
OR = 0.98 (0.94-1.02) 
for trait anxiety 
CV-mortality: 
† 
  
Frasure-Smith et al., 
200380 
USA 
896 patients post 
AMI (59.4+11.2) 
26 5 STAI-S (scores >40) CV mortality CV-mortality: 
OR = 1.21 (1.01-1.46) 
 
All baseline 
characteristics and 
treatment variables 
CV-mortality: 
HR = 1.14 (0.93-1.38) 
Strik et al., 200374 
The Netherlands 
318 males post 
AMI (58+11) 
0 3.4 SCL-90 (scores  > 12 on 
anxiety subscale) 
CV events  Age, LVEF, use of 
anti-depressants 
CV events:  
HR 3.01 (1.20-7.60) 
Pfiffner et al., 
200481 
Switzerland 
222 inpatients 
following an AMI 
(56.2+6.4) 
0 7 MAS (scores >24) All-cause mortality All-cause mortality: 
OR = 1.19 (†) 
  
 
AMI = acute myocardial infarction; CV = cardiovascular; ECG = electrocardiogram; HADS = Hospital Anxiety and Depression scale; LVEF = left ventricular ejection 
fraction; MI = myocardial infarction; SCL-90 = Symptom checklist-90-item; STAI = state-trait anxiety inventory; STAI-S = state anxiety; STAI-T = trait anxiety; > = 
greater than or equal to; not specified = †
 Table 1.7:  Summary of non-interventional studies examining quality of life in AF patients 
 
 
Author, year, place  Study design 
(follow-up period) 
Participants 
(mean + SD age, years) 
Measure of quality of life Results Study limitations 
Dorian et al 
(2000)107 
Canada 
Cross-sectional 152 PAF pts. (52 + 12) vs. 47 
healthy controls (54 + 14) vs. 69 
PTCA pts. (62 + 9) 
¾ SF-36 
 
¾ AF pts. reported a significant ↓ QoL 
compared to healthy controls (p<0.001) and 
PTCA pts (†) 
 
¾ Fewer healthy controls than pts. 
Paquette et al  
(2000)108 
USA 
Prospective 
(12- months) 
170 AF pts. 
62 women (68 + 9) vs. 108 men 
(62 + 11)   
 
¾ SF-36 
 
¾ Men and women  demonstrated similar MCS 
at baseline (48.0+ 10.0 vs. 47.6+10.8); 
p>0.05) 
¾ Women had significantly ↓ PCS at baseline 
compared to men (36.1+8.8 vs. 45.2+7.8; 
p<0.01)  
¾ Women demonstrated a significant ↑in PCS 
only over 12-months follow-up (36.1+8.8 to 
38.5+9.5; p<0.05) 
¾ Men demonstrated a significant ↑in MCS 
only over 12-months follow-up (47.6+10.6 to 
50.4+10.9; p<0.05) 
 
¾ Males and females not age matched 
¾ No appropriate control group 
Howes et al  
(2001)109  
USA 
Prospective  52 chronic male AF pts. (77 + 
7.2) vs. 48 males in SR (76 + 
6.4) 
¾ SF-36 
 
¾ Pts. and controls had similar PCS (43.0+11.0 
vs. 45.9+10.4; p=0.24) and MCS (52.5+9.6 
vs. 55.3+8.4; p=0.07)  
¾ Small sample size 
van den Berg et al 
(2001)110 
The Netherlands 
Cross-sectional  73 PAF pts. (54.1 + 13.4)  vs. 
age- and sex-matched healthy 
controls (45 – 55) 
 
¾ SF-36 
 
¾ AF pts. had a significant ↓ QoL (p<0.05), 
except on pain subscale (p=0.73), compared 
to healthy controls 
¾ Small sample size 
 
Kang et al  
(2004)111 
USA 
Prospective  81 newly diagnosed (<3 months) 
AF pts. (67.3) 
¾ SF-36 ¾ PCS and MCS were significantly ↓ in AF 
patients than US general population 
(38.5+11.5 vs. 50.0 and 48.7+11.5 vs. 50.0; 
p<0.05, respectively) 
 
¾ Small sample size 
¾ No control group 
¾ Reported only mental and physical 
health summary scores 
AF = atrial fibrillation; MCS = mental component summary score on the SF-36; MI = myocardial infarction; PAF = paroxysmal atrial fibrillation; PCS = physical 
component summary score on the SF-36;PTCA = percutaneous transluminal coronary angioplasty; pts. = patients; QoL = quality of life; SD = standard deviation; SF-
36 = Medical Outcome Survey Short Form-36; SR = sinus rhythm; ↑ = increased; ↓ = decreased; < = less than; < = greater than; † = p-value not reported 
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 Table 1.8: Summary of studies examining the effect of rate control on quality of life in AF patients 
 
Author, year, place Study design 
(follow-up period) 
Participants 
(mean + SD age, 
years) 
Intervention Measure of quality 
of life 
Results Study limitations 
Studies examining rate control strategies alone 
AV node/ junction and bundle of HIS ablation + pacing 
Kay et al  
(1988)112 
USA 
Prospective 
(6-weeks) 
12 PAF pts. (67)  Radio-frequency catheter 
ablation of AV junction and 
pacing 
¾ McMaster 
Health Index 
¾ PGWB 
questionnaire 
¾ Significant ↑ in QoL (p=0.002) 
and well-being (p=0.001) 
following intervention 
¾ Small sample size 
¾ No control group 
¾ Short follow-up period 
 
Natale et al 
(1996)113 
USA  
Prospective 
(12- months) 
12 chronic AF 
pts. (69 + 9) 
Radio-frequency catheter 
ablation of AV junction and 
pacing 
¾ Customised 
questionnaire to 
assess physical 
functional 
capacity and 
well-being 
 
¾ Significant ↑ in well-being 
(p<0.001) post-intervention 
¾ Small sample size 
¾ No control group 
¾ Non-validated QoL instrument 
Kay et al 
(1998)114 
USA 
 
Ablate & Pace  
Trial 
 
Prospective 
(12-months) 
156 chronic 
symptomatic AF 
pts. (61.1 + 11.5) 
Radio-frequency catheter 
ablation of bundle of HIS and 
permanent pacemaker 
implantation 
¾ Health status 
questionnaire 
¾ QoL index – 
cardiac version 
III 
 
¾ Significant ↑ in QoL (p<0.001) 
on all 8 health status subscales 
post-intervention 
¾ Significant ↑ in QoL from 
baseline to 3 months (p<0.05), 
with no further improvement at 12 
months (p>0.05) 
¾ Significant ↑in QoL index over 
time (20.4+4.7 to 23.0+5.2; 
p=0.0001) 
 
¾ Highly symptomatic pts. 
¾ No control group 
Marshall et al 
(1998)115 
UK 
Prospective 
(6-weeks) 
18 PAF pts. (63)  Radio-frequency catheter 
ablation of AV node and 
pacemaker implantation 
¾ PGWB 
Questionnaire 
¾ McMaster 
Health Index 
 
¾ Significant ↑ in QoL assessed by 
PGWB after intervention (59.4 to 
77.2; p<0.01) 
¾ Small sample size 
¾ Highly symptomatic pts. 
¾ No control group 
Levy et al 
(2000)116 
UK 
Prospective 
(1-month) 
15 PAF pts. (62 + 
9) 
Radio-frequency catheter 
ablation of AV node and 
pacemaker implantation 
¾ Modified 
Karolinska 
questionnaire 
¾ Significant ↑ in QoL after 1 
month of pacing (59.0+24.0 to 
36.0+24.0; p=0.001) 
¾ Small sample size 
¾ Highly symptomatic pts. 
¾ Short follow-up period 
¾ No control group 
 
Takahashi et al 
(2003)117 
Japan 
Prospective 
(6 months) 
38 symptomatic 
PAF and 
persistent AF pts. 
(69 ± 12) 
 
Radio-frequency catheter 
ablation of AV node and 
pacing 
 
¾ WHO-26 ¾ Significant ↑ in QoL and general 
health (2.4+0.5 to 3.1+0.8; 
p<0.01) and physical health 
(2.8+0.8 to 3.5+0.8; p<0.01) post-
ablation therapy 
¾ Small sample size 
¾ No control group 
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 Studies comparing different rate control strategies 
(a) AV node/junction ablation/modification ± pacing and/or pharmacological rate control  
Fitzpatrick et al 
(1996)118 
USA 
Retrospective 
(2.3 + 1.2 years) 
90 AF pts.: 
36 PAF pts. (59 + 
12) and 54 chronic 
AF pts. (61 + 16) 
Radio-frequency catheter 
ablation of AV junction with 
single pacing in chronic AF pts. 
vs. radio-frequency catheter 
ablation of AV junction with 
dual chamber pacing in PAF pts. 
 
¾ Customised QoL 
questionnaire 
 
¾ Significant ↑ in QoL and ease of 
daily living post-intervention 
(1.9+1.2 to 3.6+1.1; p<0.001) 
¾ No control group 
¾ Non-validated QoL instrument 
 
Lee et al 
(1998)119 
Taiwan 
Prospective, 
randomised 
(6-months) 
60 PAF/ 
permanent AF pts. 
(AV ablation 
group: 69 + 9, AV 
junction 
modification 
group: 66 + 10) 
 
 
30 pts. to AV junction ablation 
with permanent pacing vs. 30 
pts. to AV junction modification 
¾ QoL diaries  ¾ Significant ↑ QoL in both  the 
ablation (3.2+1.2 to 1.0+0.8; p<0.05) 
and modification groups (3.1+1.1 to 
1.7+0.7; p<0.05) post-intervention 
¾ Greatest ↑ in Qol in AV junction 
ablation and pacing group (p<0.05) 
¾ Non-validated QoL instruments 
Twidale et al 
(1998)120 
USA  
Prospective 
(4-weeks) 
44 chronic AF pts. 
with congestive 
heart failure 
(69.7 + 10.2) 
22 pts. to radio-frequency 
catheter ablation of AV node 
and pacemaker implantation vs. 
22 pts. radio-frequency catheter 
AV node modification 
 
¾ Minnesota LHFQ ¾ Significant ↑ in QoL in AV node 
ablation and pacing group post 
intervention (66.1+22.6 to 36.9+17.1; 
p<0.01) 
¾ No change in QoL for pts. who had 
successful AV node modification 
(p>0.05) 
 
¾ Highly symptomatic pts. 
¾ Non-randomised 
¾ Groups not age matched 
 
Natale et al  
(1999)121 
USA  
Prospective (6-
months) 
75 chronic AF pts. 
(Group 1: 68.4 + 7 
Group 2: 69.2 + 
10.1 
Group 3: 69.8 + 
11.3) 
Group 1: AV node ablation, 
pacemaker implantation plus 
drug therapy  
 
Group 2: AV node ablation, 
pacemaker implantation without 
drug therapy 
 
Group 3: Pacemaker 
implantation and drug therapy 
 
¾ QoL enjoyment 
and satisfaction 
questionnaire  
¾ Perception of 
well-being 
 
¾ Significant ↑ in QoL from baseline 
to 6-months for groups 1 (24+2.1 to 
55+3.0; p<0.001) and 2 (22+2.0 to 
30+4.6; p<0.001) 
¾ Significant ↑in well-being from 
baseline to 6-months for groups 1 
(1.2+0.3 to 3.1.1+0.4; p<0.001) and 2 
(1.3+0.4 to 2.0+0.4; p<0.05) 
¾ No change in QoL for group 3 
(p>0.05) 
 
¾ Not randomised to treatment 
arms 
¾ No placebo medication for pts. 
in Group 2. 
 
Levy et al  
(2001)122 
UK  
Prospective, 
randomised 
(12- months) 
36 permanent AF 
pts. (69 + 7) 
18 pts. to Bundle of HIS ablation 
and permanent pacing vs. 18 pts. 
to permanent pacing and AV 
modifying drugs 
¾ Karolinska 
questionnaire 
¾ Nottingham 
Health Profile 
 
¾ Baseline QoL similar in both groups 
(p>0.05) 
¾ Significant ↑ in QoL in both groups 
post-intervention (p<0.05) 
 
¾ Small sample size 
 
Brignole et al 
(2002)123 
Italy 
Prospective, 
randomised 
longitudinal 
141 PAF pts. 
(Anti-arrhythmics 
group: 67 + 8; no 
AV junction ablation and 
pacing ±  anti-arrhythmic drugs 
post-intervention 
¾ Minnesota LHFQ 
 
¾ Significant ↑ in QoL in both groups 
over time following intervention 
(p<0.05) 
¾ Heart failure-specific QoL 
instrument (although 27 pts. 
also had heart failure) 
- 44 - 
  
PAF-2 trial 
(12-months) drug therapy 
group: 69 + 8) 
 
¾ No differences in improvement in  
QoL between groups following 
intervention (p=0.54)   
 
Duff et al 
(2003)124 
Canada 
Prospective 
(6-months) 
28 drug refractory 
AF pts 
 
AV junction ablation and pacing 
with rate responsive mode on 
(n=14) or off (n=14) 
 
¾ SF-6 
¾ Arrhythmia 
Syndrome Scale 
¾ Ladder of Life 
¾ Significant ↑ QoL for both groups in 
10/12 QoL questions (p<0.001) 
¾ No significant differences in QoL 
between groups (p>0.05) 
 
¾ Small sample size 
¾ Highly symptomatic pts. 
Weerasooriya et al 
(2003)125 
Australia 
 
AIRCRAFT 
Prospective 
(12-months) 
99 permanent AF 
pts. (68 + 8.6) 
49 pts. to AV junction ablation 
and pacing vs. 50 pts. to 
pharmacological ventricular rate 
control 
¾ AQoL 
¾ CAST QoL 
Questionnaire 
¾ Significant ↑ in QoL on AQoL for 
both groups (p<0.05) 
¾ Significant ↑ in QoL on CAST QoL 
questionnaire in AV junction ablation 
group (p<0.05) only 
 
 
(b) Pharmacological rate control vs. pharmacological rate control 
Tse et al 
(2001)126 
Hong Kong 
Prospective, 
randomised 
(6 months) 
 
16 chronic AF pts. 
(63 ± 9) 
7 pts. to digoxin vs. 9 pts. to 
amiodarone 
¾ SF-36 ¾ No significant effect on QoL at 
follow-up for either groups (p>0.05) 
¾ Small sample size 
 
(c) Pacing alone       
Tse et al 
(2004)127 
Hong Kong 
Prospective, 
randomised 
(6 weeks) 
38 PAF (74 ± 9) 
and 39 persistent 
AF pts (70 ± 11) 
 
VVIR or DDDR pacemaker 
implantation with VRP on or off 
¾ SF-36 ¾ No significant differences on any of 
the SF-36 subscales between VRP on 
or off groups (†) 
¾ Short-term follow-up period 
 
AF = atrial fibrillation; AIRCRAFT = Australian Intervention Randomised Control of Rate in Atrial Fibrillation Trial; AQoL = Assessment of Quality of Life; AV = 
atrio-ventricular; CAST = Cardiac Arrhythmia Suppression Trial; CTAF = Canadian Trial of Atrial Fibrillation; DC = direct current; LHFQ = Living with Heart 
Failure Questionnaire; PAF = paroxysmal atrial fibrillation; PAF-2 = Paroxysmal Atrial Fibrillation-2 trial; PGWB = Psychological General Well Being; pts. = 
patients; QoL = quality of life; SD = standard deviation; SF-6 = Medical Outcome Survey Form-6, SF-36 = Medical Outcome Survey Short Form-36; SR = sinus 
rhythm; VRP = ventricular response pacing; WHO-26 = World Health Organisation 26-item Questionnaire, ↑ = increased; ↓ = decreased; < = less than; > = greater 
than; † = p-value not reported. 
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 Table 1.9: Summary of studies examining the effect of rhythm control on quality of life in AF patients 
 
Author, year, place Study design 
(follow-up period) 
Participants 
(mean + SD age, 
years) 
 
Intervention Measure of quality 
of life 
Results Study limitations 
Studies examining rhythm control strategies alone 
(a) Percutaneous interventional studies  
Dierkes et al  
(2003)128 
Germany  
 
Prospective 
(2.1 years) 
33 drug refractory 
PAF pts. 
(56.1 ± 9.9) 
Radio-frequency catheter 
ablation of right atrial isthmus 
region 
¾ SF-36 ¾ Significant ↑ QoL post-ablation 
(p<0.05) 
¾ No control group 
Erdogan et al.  
(2003)129 
Germany  
Prospective (33.9 + 
11 months) 
33 PAF pts. 
(54.1 + 9.5) 
Radiofrequency catheter 
ablation of atrial foci 
¾ SF-36 
 
¾ Baseline QoL scores ↓ than 
age-matched general German 
population 
¾ Successful ablation significantly 
↑ QoL scores on 7/8 subscales 
(p<0.05) 
¾ Non successful ablation 
significantly ↑ QoL in only 2/8 
subscales (p<0.05) 
 
¾ No control group 
 
Goldberg et al 
(2003)130 
USA 
Prospective 
(36- months) 
33 PAF pts. 
(51 + 18) 
Radio-frequency catheter 
ablation of right atrial foci 
and PV 
¾ SF-36 
 
¾ Significant ↑ in QoL on 7/8 
subscales 12 months post-
ablation (p<0.05), except bodily 
pain (p>0.05) 
 
 
¾ No control group 
 
Nilsson et al 
(2003)131 
Denmark  
Retrospective 
(6-months) 
30 PAF pts. 
(51 + 9) 
 
PV isolation ¾ SF-36 ¾ Significant ↓ QoL scores in 5/8 
subscales prior to PV isolation 
compared to healthy population 
(p<0.05) and ↓ in 6/8 subscales 
compared to hypertensive pts. 
(p<0.05) 
¾ Significant ↑ QoL scores in 7/8 
subscales after PV isolation 
(p<0.05), except bodily pain 
(p>0.05) 
 
¾ Highly symptomatic pts. 
¾ Retrospective study 
¾ No control group 
Tada et al  
(2003)132 
Japan  
Prospective 
(6 + 3 months). 
50 PAF pts. 
(58 + 7) 
Segmental PV isolation + 
antiarrythmic drug therapy 
post intervention 
¾ SF-36 ¾ Significant ↑in PCS and MCS 
post ablation therapy regardless 
of drug therapy (p<0.001) 
 
¾ No control group 
Calo et al Prospective 74 Radio-frequency catheter ¾ SF-36 ¾ QoL scores prior to ablation ¾ Highly symptomatic pts. 
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 (2004)133 
Italy  
(3 months & every 
3 months 
thereafter) 
PAF/permanent 
AF pts. (57 + 7) 
ablation of multiple regions 
around the right atrium 
 significantly ↓ than general 
population (p<0.05) 
¾ Significant ↑ on all subscales of 
SF-36 post ablation (p<0.001) 
 
¾ No control group 
Chen et al  
(2004)134 
USA 
Prospective 
(6-months) 
193 AF pts. with 
(55 + 11) or 
without (57 + 8) 
impaired systolic 
function 
PV isolation  ¾ SF-36 ¾ Significant ↑ QoL post PV 
isolation in all QoL domains for 
those without impaired systolic 
dysfunction (p<0.05) 
 
¾ Pts. not randomised 
¾ No control group 
Purerfellner et al 
(2004)135 
The Netherlands  
Prospective 
(6-months) 
75 AF pts. 
(53 + 11) 
 
PV isolation ¾ SF-36 ¾ Baseline QoL scores 
significantly ↓ than healthy 
controls and AF controls 
(previously published data) 
(p<0.001) except for physical 
functioning (p=0.13) and bodily 
pain (p=0.39) 
¾ Significant ↑ in PCS (45.4+9.7 
to 51.7+6.5; p<0.0001) and 
MCS (44.5+11.3 to 51.7+8.7; 
p<0.0001) 
 
¾ Recruited no control group 
¾ Highly symptomatic pts. 
Gerstenfeld et al 
(2001)136 
USA 
Prospective 
(6-months) 
30 PAF/persistent 
AF pts. (SR 
group: 52 + 10; 
AF recurrence 
group: 48 + 14) 
Radio-frequency catheter of 
ablation of atrial foci ablation 
vs. electrophysiological 
mapping without ablation 
¾ Modified SF-36 
 
¾ Significant ↑ in all QoL 
subscales in pts. who underwent 
mapping with ablation (p<0.05) 
¾ Significant ↑ in health distress 
only in pts. who underwent 
mapping without ablation 
(p<0.05) 
¾ Similar ↑ in QoL regardless of 
whether the procedure was a 
success or not (p<0.05) 
 
¾ Highly symptomatic pts. 
 
(b) Surgical interventional studies 
Jessurun et al  
(2000)137 
The Netherlands  
Prospective 
(12-months) 
41 PAF pts. 
(49 + 8) 
 
Maze operation ¾ SF-36 ¾ Significant impairment in QoL 
pre-surgery (p<0.05) 
¾ Significant ↑ QoL in 6/8 
subscales 3-months after 
successful operation, except 
bodily pain (p=0.85) and role 
limitation due to emotions 
(p=0.09) 
¾ No significant ↑QoL from 3 to 
12-months (p>0.05)  
 
¾ Small sample size (QoL only assessed 
in 18 pts.) 
¾ No control group 
 
- 47 - 
 Lonnerholm et al 
(2000)138 
Sweden  
 
Prospective 
(12-months) 
30 PAF/persistent 
pts. and 18 
permanent AF 
pts. 
Maze operation ¾ SF-36 ¾ Pre-surgery QoL significantly ↓ 
than general Swedish population 
(†) 
¾ Significant ↑ in QoL at 6 and 
12-months on all scales 
(p<0.001) except for bodily pain 
(p=0.09) 
 
 
¾ No control group 
 
Jessurun et al 
(2003)139 
The Netherlands  
Prospective, 
randomised 
(12-months) 
 
35 AF pts. (64) Randomised 2.5:1 ratio to 
maze operation or no maze 
operation following MV 
surgery 
¾ SF-36 ¾ Significant ↑ QoL post MV 
surgery (p<0.05) 
¾ Maze operation post MV 
surgery did not ↑ QoL further 
(p>0.05) 
 
¾ Highly symptomatic pts. 
(c) Internal/external cardioversion and pacing studies 
Berry et al 
(2001)140 
UK  
Prospective 
(12-months) 
111 persistent AF 
pts. (66.8 + 11) 
DC cardioversion ¾ EuroQuoL 
visual analogue 
scale 
 
¾ Significant ↑ in QoL in pts. 
who remained in SR 
(+10.3+3.5%;  P=0.01) 
 
¾ No control group 
Kale et al 
2002141 
UK 
Prospective 
(<24-months) 
28 PAF pts. (58) Atrial septal pacemaker 
implantation 
¾ Customised 
QoL 
questionnaire 
¾ 79% pts. reported some 
improvement in QoL at follow-
up (†) 
¾ Highly symptomatic pts. 
¾ No control group 
¾ Non-validated QoL instrument 
 
Newman et al 
(2003)142 
USA 
Prospective 
(12 months & every 
6 months 
thereafter) 
173 AF pts. vs. 
269 healthy 
controls 
Implanted atrial defibrillator ¾ SF-36 
 
¾ Baseline QoL significantly ↓ 
compared to healthy controls 
(p<0.05) 
¾ Intervention significantly ↑ 
QoL on 5/8 subscales (p<0.05), 
irrespective of number of 
shocks applied 
 
¾ No control group  
¾ Highly selected symptomatic pts. 
 
Ricci et al 
(2004)143 
Italy  
 
Prospective 
(15 ± 4 months) 
 
40 drug refractory 
AF pts. (64 ± 10) 
Dual defibrillator 
implantation 
¾ SF-36 ¾ Significant ↑ QoL after 
implantation (p<0.05) 
¾ Early delivery of atrial shock 
led to greater improvement in 
QoL (†) 
¾ No control group 
Studies comparing various rhythm control strategies 
(a) Rhythm control vs. rhythm control 
Dorian et al 
(2002)144 
Canada 
 
CTAF trial  
Prospective, 
randomised 
(3 & 12 months) 
294 PAF or 
persistent AF pts. 
(65 ± 10) 
50% on amiodarone vs. 25% 
on sotalol vs. 25% on 
propafenone (+ DC 
cardioversion if needed) 
¾ SF-36 ¾ Significant ↑ QoL from 
baseline to 3 months in all three 
groups (p<0.05) 
¾ No significant between group 
differences in QoL  (p>0.05) 
¾ No significant changes in QoL 
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 between 3 and 12 months 
follow-up (p>0.05) 
¾ No significant differences in 
QoL at 3 months between those 
cardioverted or not (p>0.05) 
 
Krittayaphong et al 
(2003)145 
Bangkok  
Prospective, cross-
sectional 
(12 months) 
38 symptomatic 
AF pts. 
(ablation group: 
55.3 ± 10.5; drug 
therapy: 48.6 ± 
15.4) 
15 pts. to radio-frequency 
catheter ablation therapy of 
left atrium and PV vs. 15 pts. 
to amiodarone 
¾ SF-36 ¾ Significant ↑ QoL in ablation 
group (p=0.007) 
¾ No improvement in QoL in 
amiodarone group (p=0.86) 
¾ Small sample size 
¾ Highly symptomatic pts. 
Pappone et al 
(2003)146 
Italy 
 
Prospective 
(12 months & every 
6 months 
thereafter) 
211 AF pts. 
(65 + 10) 
 
 
109 pts. to radio-frequency 
PV ablation vs. 102 pts. to 
anti-arrhythmic drug therapy 
¾ SF-36 ¾ Baseline QoL similar in both 
groups (p>0.05) 
¾ Significant ↑ QoL in ablation 
group (p<0.05); QoL at 
normative levels by 6-months 
(p=0.004), no further changes at 
1 year (p>0.05) 
¾ Little improvement in QoL in 
medically treated group over 
12-months (†) 
 
¾ Not randomised to treatment 
¾ Highly selected symptomatic patients 
¾ QoL data available on only 18% of 
total study population 
Channer et al 
(2004)147 
UK  
Prospective, 
randomised, 
placebo controlled  
(12 months)  
161 persistent AF 
pts. 
(Placebo: 68 + 8, 
Short-term 
amiodarone: 65 + 
10, Long-term 
amiodarone: 66 + 
10) 
Placebo: Placebo for 2 
weeks prior to and 52 weeks 
after successful DC 
cardioversion 
Short-term amiodarone: 
Amiodarone for 2 weeks 
prior to and 8 weeks after 
successful DC cardioversion, 
followed by placebo for 44 
weeks 
Long-term amiodarone: 
Amiodarone for 2 weeks 
prior to and 52 weeks 
following successful DC 
cardioversion 
 
¾ SF-36 ¾ Similar QoL scores in all three 
groups at baseline (†) 
¾ Similar ↑ in QoL in all three 
groups at 8 and 52 weeks 
follow-up (†) 
¾ Placebo group not sex-matched with 
two amiodarone groups 
 
AF = atrial fibrillation; AV = atrio-ventricular; CTAF = Canadian Trial of Atrial Fibrillation; DC = direct current; EuroQoL = EuroQoL visual analogue scale; LHFQ = 
Living with Heart Failure Questionnaire; MCS = mental component summary score on SF-36; MV = mitral valve; PAF = paroxysmal atrial fibrillation; PGWB = 
Psychological General Well-Being; pts. = patients; PCS = physical component summary score on SF-36; PV = pulmonary vein; QoL = quality of life; SD = standard 
deviation; SF-36 = Medical Outcome Survey Short Form-36; SR = sinus rhythm; ↑ = increased; ↓ = decreased; < = less than; > = greater than; † = no p-value reported. 
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 Table 1.10: Summary of studies examining the effect of rate vs. rhythm control on quality of life in AF patients 
 
Author, year, place Study design 
(follow-up period) 
Participants (mean 
+ SD age, years) 
Intervention Measure of quality of 
life 
Results Study limitations 
(a) Pharmacological rate control + AV node ablation vs. cardioversion (DC or pharmacological) + pharmacological rhythm control 
Carlson et al 
(2003)148 
Germany 
 
STAF 
Prospective, 
randomised  
(36- months) 
200 persistent AF 
pts. 
 
Rate: beta-blockers, digitalis, 
calcium antagonists 
 
Rhythm: Serial cardioversion, 
antiarrhythmic drugs or beta-
blocker 
 
¾ SF-36 ¾ Significant ↓ QoL in AF pts. 
compared to healthy age-matched 
controls in SR (from previous 
research) (p<0.01) 
¾ Significant ↑ in 2/8 subscales in 
rhythm control group (p<0.05) vs. 
5/8 in rate control group (p<0.05) 
 
¾ Two groups not sex-matched 
¾ Poorer QoL baseline scores in rate 
control group 
¾ No placebo group 
Gronefeld et al 
(2003)149 
Germany 
 
PIAF trial 
Prospective 
randomised 
(12- months) 
252 persistent AF 
pts. (60.5)  
Rate: 
Pharmacological ventricular rate 
control or AV node ablation 
 
Rhythm: 
Pharmacological or electrical 
cardioversion 
 
¾ SF-36 ¾ No significant differences in baseline 
QoL between rate and rhythm group 
(p>0.05) 
¾ Significant ↓ QoL in AF pts. 
compared with healthy individuals 
(p<0.05) 
¾ Significant ↑ in 6/8 and 5/8 QoL 
domains for rate (p<0.05) and rhythm 
control group (p<0.05), respectively 
¾ Significantly more pts. in rhythm 
control arm were newly diagnosed 
¾ No placebo group 
Hagens et al 
(2004)150 
The Netherlands 
 
RACE trial 
Prospective, 
randomised 
(36- months) 
352 persistent AF 
pts. (68 + 9) 
Rate: Rate controlling drugs and 
oral anticoagulation 
 
Rhythm: Serial DC 
cardioversion, anti-arrhythmic 
drugs and oral anticoagulation 
 
¾ SF-36 ¾ Significant ↓ QoL in AF pts. at 
baseline compared to healthy controls 
(p<0.05), but similar for rhythm and 
rate control (p>0.05) 
¾ Rate control group ↑ significantly in 
3/8 domains (role physical, mental 
health, and social functioning; 
p<0.05) 
¾ Rhythm control group did not show a 
significant improvement in any QoL 
domain (p>0.05) 
 
¾ Two groups were not sex-matched 
¾ No placebo group 
Vora et al. 
(2004)151 
India (49) 
Cross-sectional  
(12-months) 
144 chronic AF 
pts. (38.6 + 10.3) 
Rate: 48 pts. randomised to 
receive 90 mg of diltiazem twice 
daily to maintain resting 
ventricular rate <130 beats/min  
 
Rhythm: 48 pts. to amiodarone 
 
Control: 48 pts. to placebo 
 
¾ Unspecified QoL 
instrument 
¾ Significantly greater ↑ in QoL in 
rhythm control group than rate 
control group (†) 
¾ Sub-group analysis revealed that 
whether or not the pts. remained in 
SR at follow-up predicted QoL (†) 
¾ Non-specified/non-validated QoL 
instrument 
¾ Very young AF group 
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 Jenkins et al 
(2005)152 
 
AFFIRM trial 
Prospective, 
randomised 
(72-months) 
716 PAF and 
chronic AF pts. 
(70 + 9) 
Rate: Rate controlling drugs and 
oral anticoagulation 
 
Rhythm: Serial DC 
cardioversion, anti-arrhythmic 
drugs and oral anticoagulation 
 
¾ SF-36 
¾ QoL Index 
(Cardiac Version) 
¾ Cantril Ladder of 
Life 
 
¾ QoL was similar in both treatment 
groups at baseline (p>0.05) 
¾ Significant ↑ in QoL from baseline 
to follow-up in both groups (p<0.05) 
¾ Similar ↑ in QoL for both groups 
(p>0.05) 
 
(b) AV node/junction and bundle of HIS ablation + pacing vs. pharmacological therapy  
Brignole et al 
(1997)153 
Italy 
Prospective, 
randomised 
(6-months) 
43 severely 
symptomatic PAF 
pts. 
(ablation group: 
66 + 10, medical 
group: 64 + 10) 
 
Rate: 22 pts. to AV junction 
ablation and pacing 
 
Rhythm: 21 pts. to anti-
arrhythmic drug therapy 
 
¾ Minnesota LHFQ ¾ Greater ↑ in QoL and ↓ in symptoms 
in ablate and pace group (50+19 to 
20+16; p<0.0001) compared to anti-
arrhythmic group (50+19 to 43+22; 
p=0.0006) 
 
¾ Highly selected symptomatic pts. 
¾ Heart failure-specific QoL 
instrument employed 
Marshall et al 
(1999)154 
UK  
Prospective, 
randomised 
(18-weeks) 
56 symptomatic 
PAF pts. (ablate 
and pace group: 65 
2 + 7.5, medical 
group: 60.3 + 9.8) 
Rate: 37 pts. to AV junction 
ablation and pacemaker 
implantation  
 
Rhythm: 19 pts. to medical 
therapy 
 
¾ PGWB 
questionnaire 
¾ McMaster Health 
Index 
¾ Similar baseline scores on PGWB 
questionnaire and McMaster Health 
index (p>0.05) 
¾ Significant ↑ in QoL in ablate and 
pace group from baseline to 18-
weeks (PGWB: 68.8+18.1 to 
77.4+21.6; p<0.05 and MHI: 
14.8+3.3 to 16.1+3.2; p<0.05) 
¾ No change in QoL for medical 
therapy group from baseline to 18-
weeks (PGWB: 69.48+14.3 to 
68.5+13.6; p>0.05 and MHI: 
15.5+3.7 to 15.7+3.0; p.0.05) 
 
¾ Highly selected and symptomatic pts. 
 
Ueng et al 
(2001)155 
Taiwan 
Prospective, cross-
sectional  
(12-months) 
50 chronic lone 
AF pts. 
(ablation group: 
68 + 6, medical 
group: 65 + 8) 
 
Rate: 21 pts. to radio-frequency 
catheter ablation of AV junction 
and pacemaker implantation  
 
Rhythm: 29 pts. to medical 
therapy 
¾ Detailed QoL 
diary 
¾ Medically treated showed no change 
in QoL (2.7+0.6 to 2.8+0.7; p>0.05) 
¾ Significant ↑in QoL in ablate and 
pace group (2.8+0.6 to 2.1+0.5; 
p<0.05) 
¾ Non-validated QoL instrument 
¾ Pts. not randomised to treatment 
 
AF = atrial fibrillation; AFFIRM = Atrial Fibrillation Follow-up Investigation of Rhythm Management; AV = atrio-ventricular; AF = atrial fibrillation; DC = direct 
current; LHFQ = Living with Heart Failure Questionnaire; MHI = McMaster health index; PAF = paroxysmal atrial fibrillation; PGWB = Psychological General Well 
Being; PIAF = Pharmacological Intervention in Atrial Fibrillation trial; pts. = patients; QoL = quality of life; RACE = RAte Control versus Electrical cardioversion 
trial; SD = standard deviation; SF-36 = Medical Outcome Short Form-36; SR = sinus rhythm; STAF = Strategies of Treatment of Atrial Fibrillation; ↑ = increased; ↓ = 
decreased; < = less than; > greater than; † = no p-value reported 
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 Table 1.11: Summary of the studies examining the haemostatic and platelet response to acute psychological stress 
 
Author, year, 
place 
Participants (Mean 
+ SD age, years) 
Study Design Stress Task Measurements Results Study limitation 
Healthy Participants Studies 
Zgraggen et al., 
2005 
Switzerland185 
22 healthy males 
(47 + 0.8) 
¾ 1 visit 
¾ 30 mins seated rest 
followed by a 13 mins 
stress task 
¾ TSST ¾ Tissue Factor 
¾ vWF antigen 
¾ D-dimer 
¾ Fibrinogen 
¾ FVII:C activity 
¾ FVIII:C activity 
¾ FXII:C activity 
¾ FVII:C, FVIII:C, and  FXII:C activity 
and vWF all significantly ↑ following the 
stress task 
¾ No females included 
¾ No recovery period 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
von Kanel et al., 
2004 
Switzerland186 
24 healthy males 
(47.1 + 7.4) 
¾ 2 visits (approx. 2 week 
apart) 
¾ 30 mins seated rest, 13 
mins stress task, and 
105 mins recovery 
 
¾ TSST 
 
¾ vWF antigen 
¾ Fibrinogen 
¾ FVII:C activity 
¾ FVIII:C activity 
¾ FXII:C activity 
¾ D-dimer 
¾ aPTT 
¾ PT 
¾ vWF, fibrinogen, FVII:C, FXII:C all  ↑ 
significantly during the task and ↓ during  
recovery 
¾ D-dimer, FVIII:C, aPPT and PT showed 
no significant change during  stress task 
¾ No stress induced habituation to the task 
¾ No females included 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
 
von Kanel et al., 
2004 
Switzerland187 
 
48 elderly 
participants (71 + 9) 
¾ 1 visit 
¾ 15 mins seated rest, 9 
mins stress task, and 14 
mins recovery 
¾ Two 
standardised 
speech stress 
tasks where 
participant was 
accused of 
shoplifting 
¾ TAT antigen 
¾ vWF antigen 
¾ D-dimer 
¾ t-PA antigen 
¾ PAI-1 antigen 
¾ TAT and D-dimer significantly ↑ 
following the stress task 
¾ t-PA significantly ↓ following the stress 
task 
¾ PAI remained unaltered by stress task 
 
¾ Short recovery period 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
 
Steptoe et al., 
2003 
UK188 
125 men and 96 
women (45 – 59) 
¾ 1 visit 
¾ 30 mins rest, 10 mins 
stress task, and 45 mins 
recovery 
¾ Computerised 
SCW Test 
¾ Mirror tracing 
task 
¾ Fibrinogen 
 
¾ Fibrinogen levels significantly ↑ during 
the stress task and remained elevated 
over the 45 mins recovery 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
von Kanel et al., 
2003 
Switzerland189 
37 care givers 
(72 + 6) 
¾ 1 visit 
¾ 20 mins seated rest 
followed by two 9 mins 
stress tasks 
¾ 1 task involved 
being falsely 
accused of 
shoplifting  
¾ 1 task was an 
upsetting event 
related to care 
giving 
¾ TAT 
¾ D-dimer 
¾ t-PA antigen 
¾ PAI-1 antigen 
¾ vWF antigen 
 
¾ TAT, D-dimer, vWF and t-PA antigen all 
significantly ↑ following the stress tasks 
¾ No recovery period 
¾ Failed to correct alterations in 
coagulatory markers for ∆ plasma 
volume 
¾ Failed to control for female 
menstrual cycle 
von Kanel et al.,  19 participants ¾ 1 visit ¾ Speech stress ¾ TAT ¾ TAT and D-dimer significantly ↑ ¾ Small sample size 
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 2002 
Switzerland190 
(39 + 5)  ¾ 30 mins seated rest, 6 
mins stress task, 15 
mins rest, and 3 mins 
stress task 
task 
¾ Mirror tracing 
task 
¾ D-dimer following stress task 
¾ ∆ TAT significantly correlated with β2-
adrenoreceptor, ∆ norepinephrine, and ∆ 
epinephrine 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
¾ Failed to control for female 
menstrual cycle 
Mundal et al, 
1996 
Norway191 
26 healthy male 
controls  
¾ 1 visit 
¾  Supine rest, 5 mins 
mental stress task 
followed by 15 mins 
recovery 
¾ Time-pressured 
mental 
arithmetic 
¾ Platelet count 
¾ β-TG 
 
¾ Platelet count significantly ↑ during 
stress task, whereas β-TG demonstrated 
no change 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
¾ Mental stress task too soon after 
CPT 
Patterson et al., 
1995 
USA192 
27 healthy males 
(32 + 8) 
¾ 1 visit 
¾ 22 participants given 
stress intervention vs. 5 
participants given no 
intervention (control) 
¾  30 mins supine rest, 10 
mins mental stress, 30 
mins recovery  
¾ Time pressured 
mental 
arithmetic task  
¾ PF-4 
¾ β –TG 
¾ PF-4 and β-TG significantly ↑following 
the stress task 
¾ ↑in β-TG was positively correlated with 
↑ in norepinephrine 
¾ No females included 
Jern et al., 
1994 
Sweden193 
11 healthy males 
(27.3; 22 – 36) 
¾ 1 visit 
¾  60 mins rest, 10 mins 
stress task followed by 
20 mins recovery 
¾ Time pressured 
mental 
arithmetic task  
¾ t-PA antigen 
¾ PAI-1 antigen 
¾ t-PA and PAI-1 antigen exhibited no 
change following the mental stress task 
¾ No females included 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
 
Malkoff et al., 
1993 
USA194 
40 healthy male 
participants (21.4) 
¾ 1 visit 
¾ 30 mins rest and 21 
mins stress task or 21 
mins more seated rest 
¾ SCW Task ¾ Platelet 
aggregation 
¾ Platelet secretion 
of ATP 
¾ Platelet secretion of ATP significantly ↑ 
during the stress task 
¾ No change in platelet secretion of ATP in 
those with continued rest 
¾ ADP-induced platelet aggregation 
demonstrated no significant change 
during the stress task 
¾ No recovery period 
¾ No females included 
Naesh et al., 
1993 
Denmark195 
8 healthy males 
(22 – 42) 
¾ 1 visit 
¾ 30 mins rest, 20 mins 
stress task followed by 
60 mins recovery 
¾ SCW Test ¾ Platelet count 
¾ Platelet 
aggregation 
¾ β-TG 
¾ PF-4 
¾ ECLT 
 
¾ No significant change in platelet count  
following  stress task 
¾ No change in β-TG and PF-4 following  
stress task but  significant ↑at 30 and 60 
mins recovery 
¾ No change in ADP-induced platelet 
aggregation during stress task but 
significant ↑at 30 mins recovery 
¾ Significant ↓ in ECLT following stress 
task which remained ↓during recovery 
¾ Small sample 
¾ No females included 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
 
Jern et al., 9 healthy women ¾ 2 visits: 1 in follicular ¾ SCW Test ¾ Platelet count ¾ Significant ↑ in platelet count and vWF ¾ Small sample size 
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 1991 
Sweden196 
(28: 24 – 30) phase and 1 in luteal 
phase of menstrual 
cycle 
¾ 30 mins seated rest, 2 x 
10 mins stress tasks, 
followed by 10 mins 
recovery 
¾ Time pressured 
mental 
arithmetic task 
¾ FVII:C antigen and 
activity 
¾ vWF antigen 
¾ Fibrinogen 
¾ t-PA antigen and 
activity 
¾ PAI activity 
at rest in follicular phase compared to 
luteal phase 
¾ Significant ↑ in fibrinogen following 
stress task; change > in luteal phase 
¾ Significant ↑ in vWF, t-PA antigen and 
activity following stress task; no 
differences between the two phases of 
menstrual cycle 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
 
Larsson et al., 
1990 
Netherlands197 
8 healthy males 
(24 – 38) 
¾ 1 visit 
¾ 30 mins rest, 17 – 25 
mins stress task, 
followed by 60 mins 
recovery 
¾ SCW Test ¾ Platelet count 
¾ Platelet 
aggregation 
¾ Significant ↑ in platelet count following 
stress task 
¾ Platelet aggregation significantly ↑ by 
31% following stress task 
¾ Small sample size 
Patient Population Studies 
Strike et al.,  
2004 
UK198 
17 male CAD pts. 
(52.8 + 4.5) and 22 
male healthy controls 
(50.2 + 5.0) 
¾ 1 visit 
¾ 30 mins rest, 10 mins 
stress task, and 120 mins 
recovery 
¾ Computerised 
SCW test 
¾ Mirror tracing  
    task 
¾ PLA ¾ % of PLA ↑ significantly in both groups 
during the stress task 
¾ % of PLA remained elevated during recovery 
in the CAD group but returned to baseline 
levels in  healthy controls 
¾ No females included 
Hevey et al., 
2000 
Ireland199 
11 post CABG 
patients (61.8 + 5.7) 
¾ 2 visits 
¾ Rest, followed by stress 
task  
¾ 1 visit: SCW test 
and PASAT test 
¾ 1 visit: 
relaxation  
¾ t-PA/PAI-1 
complexes 
¾ t-PA antigen 
¾ t-PA and t-PA/PAI-1 complexes significantly 
↓ following the stress task 
¾ Small sample size 
¾ No control group 
¾ No females included 
¾ Failed to correct 
alterations in 
coagulatory markers for 
∆ in plasma volume 
Tomada et al 
1999 
Japan200 
24  hypertensive 
patients, WHO stage 
I (40 + 4) and WHO 
II (49 + 3) vs. 14 
normotensives  (42 + 
4) 
¾ 1 visit 
¾ 60 mins supine rest 
followed by 10 mins 
mental stress test 
¾ Time-pressured 
mental 
arithmetic 
¾ Platelet aggregation 
¾ β –TG 
¾ Normotensive individuals demonstrated no 
significant changes following the stress task 
¾ WHO Stage I hypertensives had similar 
baseline aggregation and β –TG to 
normotensive individuals but demonstrated a 
significant ↑in platelet aggregation and β –TG 
following the stress task 
¾ WHO Stage II hypertensives had ↑baseline 
platelet aggregation and β –TG but 
demonstrated no change following the stress 
task 
¾ Failed to correct 
alterations in 
coagulatory markers for 
∆ in plasma volume 
¾ No recovery period 
 
Markovitz et al., 
1996 
USA201 
 14 post-MI patients 
(54.9) vs. 15 healthy 
male controls (53.5) 
¾ 1 visit 
¾  30 mins rest, two stress 
tasks followed by 10 mins 
recovery 
¾ Structured 
interview 
followed by 4 
mins speech task 
¾ β –TG ¾ β-TG significantly ↑ following stress tasks in 
healthy controls but showed no change in 
post-MI patients 
¾ ↑ in β-TG was correlated with ↑ in hostility 
¾ No females 
¾ Failed to correct 
alterations in 
coagulatory markers for 
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 and type A behaviour scores ∆ in plasma volume 
 
Grignani et al., 
1991 
Italy202 
25 post-MI patients  
(51 + 8) vs. 10 
healthy controls 
(51 + 8) 
¾ 1 visit 
¾ 30 mins rest, 10 mins 
stress task followed by a 
variable recovery time 
¾ Time pressured 
mental 
arithmetic task 
¾ Platelet aggregation 
¾ TxB2 
¾ Significant ↑in platelet aggregation and TxB2 
following stress task.  These effects were 
rapidly reversible 
¾ Effects were more pronounced in post-MI 
patients than healthy controls 
¾ Failed to correct 
alterations in 
coagulatory markers for 
∆ in plasma volume 
 
 
ADP = Adenosine Diphospate, ATP = Adenosine Triphosphate, β-TG = Beta Thromboglobulin, CABG = Coronary Artery Bypass Graft, CAD = Coronary Artery 
Disease, CPT = Cold Pressor Test, ECLT = Euglobulin Clot Lysis Time, FVII:C = Clotting Factor VII, FVIII:C = Clotting Factor VIII, FXII:C = Clotting Factor XII, 
Mins = minutes, MI = Myocardial Infarction, PASAT = Paced Auditory Serial Arithmetic Task, t-PA = tissue-type Plasminogen activator, PAI -1 = Plasminogen 
Activator Inhibitor, PF-4 = Platelet Factor-4, PLA = Platelet-Leukocyte Aggregates, aPTT = activated Partial Thromboplatin Time , PT = Prothrombin Time, SCW = 
Stroop Colour Word, TAT = Thrombin-Antithrombin, TxB2 = Thromboxane B2, TSST = Trier Social Stress Test, vWF = von Willebrand Factor, WHO = World Health 
Organisation,↑ = increased , ↓ = decreased, ∆ = change  
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 Table 1.12: Haemorheological, haemostatic and platelet response to postural change (Supine to upright) 
Author, year, place Participants (Mean + 
SD age, years) 
Study Design Measurements Results 
Jacob et al, 2005 
USA205 
28 healthy individuals 
(33.6+8.0) 
¾ Supine rest overnight 
¾ 30 min HUT (600) in 18 participants & 60 min 
unsupported standing in 10 participants  
¾ Measured taken at min 2.5, 5, 7.5, 10, 15, 20, 30, 
45 & 60 (when applicable) 
¾ Hct 
¾ PVol (radio-labelled 
albumin/EB dye) 
¾ ∆ PVol (Hct/Hb 
method) 
¾ Hct  ↑ 4.1  
¾ PVol ↓ by 417 mL (6-25%) 
¾ Haemoconcentration was complete within 20 mins of standing, with 
most occurring within the first 10 - 15 min 
Raj et al., 2005 
USA1206 
15 patients with POTS 
(36+11.0) and 14 
healthy controls 
(34+7.0) 
¾ 60 min supine rest  
¾ 30 min HUT (600) 
¾ Measurements taken at min 5 and 30 
¾ PVol (radio-labelled 
albumin) 
¾ ∆ PVol (Hct/Hb 
method) 
¾ PVol ↓ by 432 mL (15.3%) and 390 mL (16.6% ) at the end of tilt in 
control and POTS patients, respectively (NS) 
¾ Combined data demonstrated an 11.05% ↓ after 5 min & a  15.9% ↓ 
after 30 min (NS) 
Veldhuijzen et al., 
2005 
UK207 
24 healthy males 
(21.0+1.1) 
¾ 44 min supine rest 
¾ 12 min HUT (640) 
¾ Hct 
¾ ∆ PVol (Hct/Hb 
method) 
¾ Hct ↑ Approx. 3%  
¾ PVol ↓ Approx. 7% 
Lagi et al., 2003 
Italy208 
50 recurrent fainters 
(27; 18-41) vs. 37 
healthy individuals (29; 
18-43)  
¾ Unspecified supine rest 
¾ 45 min HUT (600) 
¾ Measurements take at min 10 
¾ Hct 
¾ ∆ PVol (Hct/Hb 
method) 
¾ Hct ↑ 2.5% and 1.3% in recurrent fainters and controls, respectively  
¾ PVol ↓ 17.1%  and 8.6% in recurrent fainters and controls, 
respectively  
¾ Females demonstrated a greater change in Hct with respect to male 
controls (3.5% vs. 2.6%, respectively)  
Laszlo et al., 2001 
Czech Republic209 
7 healthy males (24-38) ¾ 40 min supine rest 
¾ 30 min HUT (00,120,300,530,700) 
¾ Measurements taken at 20 min and 40 min during 
supine rest, throughout the 30 min tilt, and up to 
20 min after tilt 
¾ Hct ¾ Hct ↑ by 0.3, 1.1, 2.7, and 3.2% at angles 120,300,530,700, 
respectively 
Gabbett et al., 2000 
Australia210 
12 males with 
orthostatic hypotension 
(68+1) vs. 12 healthy 
male controls (69+1) 
¾ 20 min supine rest 
¾ >15 min HUT (900) 
¾ Hct 
¾ PVol (∆ Hct/Hb 
method) 
¾ Hct ↑ 2.5% in both the hypotensive and healthy control group 
¾ PVol ↓ 9.2% and 8.3% in the hypotensive group and healthy control 
group (NS) 
Andrews et al., 1999 
USA211 
11 healthy individuals 
(34+3) 
¾ >60 min supine rest 
¾ 15 min standing upright 
¾ Hct 
¾ Platelet count 
¾ Platelet aggregation 
¾ Hct ↑ 3.3% 
¾ Mean platelet aggregation ↑ 150+69% 
¾ Platelet count ↑ from 197+10 to 229+9 
¾ Yohimbine (α2-receptor blocker) inhibited the ↑ in platelet 
aggregation upon assuming the upright posture 
Brown et al., 1999 
UK212 
12 healthy volunteers 
(20-67) vs. 14 patients 
with orthostatic 
intolerance (24-64) 
¾ 20 min supine rest 
¾ 20 min HUT (600) 
¾ Participants completed protocol twice; one using 
impedance plethysmography to determine fluid 
¾ Calf segment change 
(Blood volume 
change) 
¾ PVol (EB dye) 
¾ Greatest changes in calf segment change occurred within 1 min 
¾ Rate of volume change between 4 – 10 min was significantly greater 
in patients compared to controls (14.22+1.43 vs. 8.41+1.02, 
respectively) 
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 shifts and the other using Evans blue dye dilution 
technique  
Andrews et al., 1996 
USA213 
17 healthy individuals 
(33+3) 
¾ Over night supine rest 
¾ Stood upright for  26+4 min 
¾ Hct 
¾ Platelet count  
¾ Fibrinogen 
¾ F1+2 
¾ Platelet aggregation 
¾ t-PA antigen 
¾ PAI-1 antigen 
¾ Flow cytometry 
studies –  (i.e. vWF, 
thrombin, GPIV, 
activated GPIIbIIIa, 
fibrinogen, P-sel) 
¾ Hct ↑ 7+1%  (relative) 
¾ Platelet count↑15+3%  
¾ No change in plasma levels of fibrinogen when ∆Hct was taken into 
account 
¾ F1=2  ↑ 22+6%  which remained significant after ∆Hct was taken into 
account 
¾ t-PA antigen level ↑ 25+7% which remained significant after ∆Hct 
was taken into account 
¾ No change in plasma levels of PAI-1 antigen 
¾ Significant ↑ in platelet aggregation (ADP and collagen) 
¾ No change in any of the markers assessed by flow cytometric 
analysis 
Gebara et al.,1996 
USA214 
13 patients with mild to 
moderate hypertension 
(45+9) 
¾ Placebo controlled cross-over trial: Patients 
randomised to either placebo or verapamil for 4 
week prior to each of the sessions 
¾ 45 min supine rest 
¾ 45 min standing upright  
¾ vWF 
¾ t-PA antigen 
¾ PAI-1 antigen 
¾ Platelet aggregation 
¾ Platelet aggregation ↑ significantly during the placebo session but 
not during the verapamil session  
¾ No change in t-PA, PAI-1 and vWF antigen 
Bjerkhoel et al., 1995 
Sweden215 
7 healthy males (24-35) ¾ >60 min supine rest 
¾ 15 min HUT (850) 
¾ Measurements taken from arterial and venous 
blood at end of supine rest, at the end of 15 min 
HUT, and frequently throughout the supine 
recovery 
¾ Hct 
¾ PVol (radio-labelled 
albumin) 
¾ ∆ PVol  (HctHb 
method) 
¾ 7.5% ↑ Hct (relative) from arterial blood at end of tilt, which ↑ 10% 
within 90 seconds after being returned to supine 
¾ 16.9% ↓ PVol (638 mL) 
¾ 10.1 ↑ Hct (relative) from venous blood  
Gleerup et al., 1995 
Denmark216 
12 borderline 
hypertensive patients 
(58.8; 50-65) vs. 12 
healthy individuals 
(62.8; 51-70) 
¾ 30 min supine rest 
¾ 10 min standing upright 
¾ ECLT 
¾ PAI-1 antigen 
¾ t-PA antigen 
¾ Platelet aggregation 
¾ Β-TG 
¾ PF-4 
¾ ELCT ↓ in both groups to a similar degree 
¾ t-PA ↑ in both groups to a similar degree 
¾ B-TG ↑ in the hypertensive group 
¾ Platelet aggregation, PF-4, and PAI-1 demonstrated no change 
 
Hinghofer et al., 1995 
USA217 
8 healthy male 
individual (18-26) 
¾ 45 min supine rest 
¾ 45 min HUT (700) followed by a 45 min supine 
rest, and a second 45 min HUT (700) 
¾ Examined the effect of fluid ingestion (hypotonic, 
and isotonic) on PVol shifts 
¾ Hct 
¾ PVol (Mass 
densitometry 
apparatus) 
¾ Hct ↑ 4%  following the first HUT and 3% following the second 
HUT 
¾ PVol ↓ by between 9.7 – 16.7% 
¾ Fluid ingestion failed to attenuate the posture induced 
hemoconcentration 
Patterson et al.,1995 
USA218 
40 healthy individuals 
(30.05+7.36) 
¾ 30 min seated rest 
¾ 10 min standing upright 
¾ ∆ PVol (Hct/Hb 
method) 
¾ PVol ↓  
Lundvall et al.,1994 
Sweden219 
10 healthy male 
individuals (28;24-38)  
¾ 60 min supine rest 
¾ 15 min HUT (850) 
¾ Measurements obtained from both arterial and 
¾ PVol (radio-labelled 
albumin) 
¾ Atrerial blood samples significantly underestimated the loss of PVol 
during the HUT 
¾ PVol ↓ 336 mL at the end of the tilt 
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 venous circulation  
¾ Samples obtained at end of rest, at min 5, 10, and 
15 during the tilt, and frequently throughout the 
recovery 
¾ Samples obtained 1 min after being returned to the supine position 
demonstrated a PVol loss of 511 mL 
Muldoon et al.,1992 
USA220 
26 healthy male 
individuals (18-30) 
¾ Unspecified period of supine rest  
¾ 20 min standing upright 
¾ Hct ¾ Hct ↑ approx. 3.7%   
 
Geers et al., 1986 
Netherlands221 
12 patients with 
nephrotic syndrome 
(23; 14-33) vs. 12 
healthy individuals 
(22.8; 21-28) 
¾ 120 min supine rest 
¾ 110 min standing upright 
¾ Measurements taken prior to standing, and at 10, 
25, 45, and 110 min during task  
¾ Hct 
(microhaematocrit) 
¾ ∆ PVol (Hct/Hb 
method) 
¾ Hct ↑ 4.6% and 3.3% in the patients and controls, respectively 
¾ PVol ↓ 471 mL (16.3% ) and 347 mL (11.7% ) in patients and 
controls, respectively 
¾ PVol ↓ was maximum at 25 min 
Hinghofer et al.,1986 
USA222 
13 healthy individuals 
(19-30) 
¾ 45 min supine rest 
¾ 45 min HUT (700) followed by a 45 min supine 
rest, 45 min HUT (700), and a further 45 min 
supine rest 
¾ ∆ PVol (Mass 
densitometry 
apparatus) 
¾ PVol ↓ 14%   
Vargas et al.,1982 
UK223 
9 healthy young 
(31+3.2) vs. 8 healthy 
old individuals 
(71+5.1) 
¾ 20 min supine rest 
¾ 10 min HUT (700) 
¾ ∆ PVol (Hct/Hb 
method) 
¾ PVol ↓ 12.4% 
¾ No difference between groups 
Tarazi et al., 1970 
USA224 
12 healthy individuals 
vs. 21 hypertensive 
individuals  
¾ 35 – 45 min supine rest 
¾ 20 min HUT (500) 
¾ ∆ PVol ¾ Hypertensive and healthy individuals demonstrated a similar 
reduction in PVol during the tilt test 
Nielson et al., 1968 
Denmark225 
21 healthy males vs. 11 
healthy females (18-58) 
¾ 40 min supine rest 
¾ Stood upright for 40 min 
¾ ∆ PVol  (Colloid 
osmotic pressure) 
¾ PVol ↓ 16% (maximum change) 
Eisenberg et al., 1965 
USA226 
7 normotensive vs.14 
essential hypertensive 
individuals (40 – 68) 
¾ Unspecified baseline period 
¾ 20 min motionless standing  
¾ Hct  
¾ ∆ PVol 
¾ Hypertensive individuals demonstrated a significantly greater ↓ in 
PVol (7.3% vs. 13.2%, respectively) and ↑ in Hct compared to the 
healthy individuals 
Sloan et al., 1955 
South Africa227 
13 healthy male 
individuals (19-22) 
¾ 25 min supine rest 
¾ Stood upright for 10 min 
¾ Measurements taken at min 1 and 10 
¾ Platelet count  ¾ Significant ↓ in platelet count after 1 and 10 min 
 
β-TG = Beta Thromboglobulin, ECLT = Euglobulin Clot Lysis Time, F1+2 = Prothrombin Fragments 1+2, GP = Glycoprotein, Hct = Haematocrit, Hb, Haemoglobin, HUT = Head-
up tilt, mL = Millilitres, Min = minutes, NS = Non significant, P-Sel = P-selectin, PVol = Plasma volume, t-PA = tissue-type Plasminogen activator, PAI -1 = Plasminogen Activator 
Inhibitor, PF-4 = Platelet Factor-4, vWF = von Willebrand Factor, ↑ = increased , ↓ = decreased, ∆ = change, > = Greater, > = Greater than or equal to,  
 
 
 
 
- 58 - 
 Table 1.13: Summary of studies examining the haemostatic and platelet response to acute physical activity 
 
Author, year, place Participants (Mean + 
SD age, years) 
Study Design Stress Task Measurements Results Study limitation 
(a) Low Intensity Exercise 
Healthy Population Studies 
Szymanski et al., 
1994 
USA237 
14 healthy male 
sedentary participants 
(34.7 + 4) vs. 12 
regularly active 
participants (34.8 + 4) 
¾ 2 visits: 1 visit in 
the morning and 
1 visit in the 
evening 
¾ 30 mins low 
intensity exercise 
¾ 50% VO2Max  ¾ t-PA activity 
¾ PAI-1 activity 
¾ Significant ↑ in t-PA activity with 
exercise; largest ↑ in the evening  
¾ PAI-1 activity was significantly ↑in the 
inactive group compared to the active 
group 
¾ PAI-1 activity was significantly ↑in the 
morning compared to the evening 
¾ No females included 
¾ No recovery period 
Patient Population Studies 
Eriksson-Berg et 
al., 
2002 
Sweden238  
25 women with ACS 
(60; 54 – 67) vs. 25 
healthy women (60; 
55 – 67) 
¾ 1 visit 
¾ 60 mins supine 
rest, followed 
by30 mins 
exercise 
¾ 50%  Wmax on 
bicycle ergometer 
¾ Fibrinogen 
¾ vWF antigen 
¾ TAT 
¾ D-dimer 
¾ t-PA antigen and 
activity 
¾ PAI-1 activity 
¾ ↑ levels of  vWF, t-PA, PAI-1 in 
patients compared to controls 
¾ Significant ↑ in fibrinogen, vWF, and t-
PA antigen and activity  following 
exercise in patients 
¾ No recovery period 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
(b) Moderate Intensity Exercise  
Healthy Participants Studies 
Ersoz et al., 
2003 
Turkey239 
12 healthy sedentary 
females (19 – 24) 
¾ 2 visits: 1 in late 
follicular and 1 in 
mid-luteal phase 
of menstrual 
cycle 
¾ 15 mins of sub-
maximal exercise 
¾ 70% VO2Max on 
bicycle ergometer 
¾ Platelet count 
¾ Platelet aggregation  
¾ TxB2 
¾ Platelet count and platelet aggregation 
significantly ↑ following exercise. No 
difference between two phases of 
menstrual cycle 
¾ TxB2 levels were significantly ↑ in mid-
luteal phase compared to late follicular 
phase 
¾ TxB2 significantly ↑ following exercise 
in the late follicular phase 
¾ No recovery period 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
Ikarugi et al., 
1999 
Japan240 
Male participants 
(19 – 34) 
¾ 1 visit 
¾ 20 mins 
moderate 
intensity exercise 
¾ 60% VO2Max on 
bicycle ergometer 
¾ Ex vivo shear stress 
induced haemostatic 
plug formation 
¾ Shear stress induced platelet reactivity 
significantly ↑ following exercise 
 
¾ No details on participant numbers 
¾ No females included 
¾ No recovery period 
Todd et al., 9 young males (27.8 + ¾ 1 visit ¾ 70 – 75% ¾ TxB2 ¾ Resting TxB2 was significantly ↑in the ¾ Small sample 
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 1994 
USA241 
0.8) vs. 9 older males 
(55.4 + 1.3) 
¾ 15 mins rest, 30 
mins exercise, 
followed by 30 
mins recovery 
VO2Max on a 
treadmill 
¾ β-TG 
 
older group 
¾ No change in TxB2 following exercise 
but significant ↑in older group at 30 
mins recovery 
¾ No change in β-TG in either group 
following exercise  
¾ No females included 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
Dufaux et al., 
1984 
Germany242 
Group A: 12 
untrained elderly 
patients (60.6 + 4.3) 
vs. Group B: 
professional soccer 
players (26.2 + 3.7) 
vs. Group C 
moderately trained 
young subjects (23.3 
+ 1.9) 
¾ 1 visit 
¾ Moderate/high 
intensity exercise 
¾ Group A and B = 
maximal bicycle 
ergometer test; 
Group C = 45 
mins sub-
maximal bicycle 
ergometer test 
¾ FDP 
¾ Fibrinogen 
¾ No significant change following 
exercise in any of the 3 groups 
¾ No females in two groups 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
¾ Poorly defined and reported 
method and results 
Patient Population Studies 
Ivey et al., 
2003 
USA243 
18 stroke patients 
with hemiparetic gait 
deficits (66 + 8) 
¾ 1 visit 
¾ Rest, 20 mins 
exercise, 
followed by 60 
mins recovery 
¾ Walking on 
treadmill at 60% 
maximal HR  
¾ t-PA activity 
¾ PAI-1 activity 
¾ t-PA activity significantly ↑ following 
exercise. 
¾ t-PA activity remained significantly 
elevated 60 mins post exercise 
¾ PAI-1 activity significantly ↓ following 
exercise 
¾ PAI-1 activity remained significantly 
depressed 60 mins post exercise 
¾ No control group 
Morris et al., 
2003 
UK244 
10 obese sedentary 
individuals (43.3 + 
1.5) vs. 10 non-obese 
sedentary individuals 
(43.3 + 1.9) 
¾ 1 visit  
¾ 75 mins seated 
rest, 30 mins 
exercise, 
followed by 30 
mins recovery 
¾ 70% VO2Max on 
treadmill 
¾ PAI-1 antigen 
¾ t-PA antigen 
¾ Obese individuals had significant ↑ in 
resting, exercise and post exercise 
levels of PAI-1 compared to non-obese 
¾ t-PA significantly ↑ following exercise 
in the non-obese but showed no change 
in the obese group 
¾ PAI-1 significantly ↑ in the post 
exercise recovery in obese group 
¾ No females 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
 
Womack et al., 
2001 
USA245 
9 patients with PAD 
(70 + 6) 
¾ 1 visit 
¾ 30 mins rest, 30 
exercise, 
followed by 60 
mins recovery 
¾ Walking on a 
treadmill at 65% 
VO2 Max 
¾ t-PA antigen and 
activity 
¾ PAI-1 antigen and 
activity 
¾ t-PA activity significantly ↑ and PAI-1 
activity significantly ↓ following 
exercise without changing t-PA and 
PAI-1 antigen levels, which remained 
into recovery 
¾ Small sample size 
¾ No control group 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
Desouza et al., 
1997 
USA246 
12 hypertensive males 
(69 + 1) vs. 11 
normotensive (65 + 1) 
¾ 1 visit 
¾ 15 mins seated 
rest followed by 
¾ 65% VO2Max ¾ t-PA antigen and 
activity 
¾ PAI-1 antigen and 
¾ t-PA antigen and activity significantly 
↑following exercise 
¾ PAI-1 showed no change following 
¾ No females included 
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 30 mins 
moderate 
intensity exercise 
activity 
 
exercise 
¾ No differences observed between 
groups 
(c) High Intensity Exercise and Incremental Exercise to Exhaustion 
Healthy Participants Studies 
Cooper et al., 
2004 
USA247 
8 healthy males 
(21.5 + 1.5) 
¾ 1 visit 
¾ 30 mins rest, 
strenuous 
exercise, 
followed by 10 
mins recovery 
¾ VO2 Max test ¾ t-PA antigen and 
activity 
¾ PAI activity 
¾ t-PA antigen and activity significantly ↑ 
during  exercise task 
¾ t-PA antigen and activity began to 
return to resting levels 4 mins post 
exercise 
¾ PAI activity significantly ↓ following 
exercise but failed to return to return to 
resting levels within the 10 mins post-
exercise recovery period 
¾ Small sample size 
¾ Short recovery period 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
 
Di Massimo et al., 
2004 
Italy248 
15 healthy sedentary 
males (25; 20 – 28) 
¾ 1 visit 
¾ 60 mins rest, 
incremental 
exercise test, and 
24 hrs recovery 
¾ 3 mins warm-up at 
20 watts followed 
↑ of 40 watts every 
3 min until 
exhaustion on 
cycle ergometer 
¾ Platelet aggregation ¾ ADP and collagen-induced platelet 
aggregation significantly ↑ following 
exercise and returned to resting levels 
after 24 hours recovery 
¾ No females included 
Wang et al., 
2004 
Taiwan249 
18 healthy sedentary 
males (23.1 + 0.8) 
¾ 1 visit 
¾ 30 mins of rest 
followed by high 
intensity exercise 
¾ 80% VO2 Max on 
bicycle ergometer 
for 40 mins 
¾ vWF antigen and 
activity 
¾ Sheer stress induced 
platelet aggregation 
¾ vWF binding to 
platelets 
¾ GP IIb/IIIa expression 
¾ P-sel expression 
¾ Significant ↑ in vWF antigen and 
activity following exercise 
¾ Significant ↑ in shear stress induced 
platelet aggregation following exercise, 
accompanied by ↑ vWF binding, GP 
IIb/IIIa and P-sel expression 
¾ No females included 
¾ No recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
 
Cerneca et al., 
1999 
Italy250 
Healthy males: 
(1) 7 competition 
rowers vs. (2) 12 
marathon runners vs. 
(3) 7 competition 
weightlifters vs. (4) 7 
sedentary (not 
reported here) 
¾ 1 visit 
¾ Strenuous 
exercise 
¾ Tested to near-
maximal 
cardiovascular 
and muscular 
exertion 
¾ PT 
¾ aPTT 
¾ Fibrinogen 
¾ Antithrombin III 
¾ F1 + 2 
¾ t-PA antigen 
¾ PAI-1 activity 
¾ Group 1 demonstrated a significant ↑in 
fibrinogen, antithrombin III, F 1 + 2 
and t-PA with a concomitant ↓in aPTT 
and PAI-1 
¾ Group 2 demonstrated a significant 
↑fibrinogen, antithrombin III and t-PA 
with a concomitant ↓aPTT and PAI-1 
¾ Group 3 demonstrated no significant 
variation in variables 
¾ Small numbers in each group 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
Cuzzolin et al., 
1999 
Italy251 
12 healthy participant 
(6 inactive (21 + 2.4) 
vs. 6 active (22.5 + 
2.1) 
¾ 1 visit 
¾ Incremental 
exercise, steady 
state exercise, 
¾ Exercise on 
bicycle ergometer 
for 5 mins until 
reached 150 bpm 
¾ Platelet/neutrophil 
adhesion 
¾ Active participants demonstrated a 
significantly ↓in  adhesion following 
exercise 
¾ No change observed in the inactive 
¾ Small sample size 
¾ No control for female menstrual 
cycle 
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 followed by 60 
mins recovery 
followed by 10 
mins at same 
intensity 
group 
El-Sayad et al 
1999 
UK252 
8 moderately active 
males (26.6 + 3.6) 
¾ 1 visit 
¾ High intensity 
exercise followed 
by 30 mins 
recovery 
¾ Exercise on 
bicycle ergometer 
for 30 mins at 
75% VO2Max 
¾ Fibrinogen ¾ When corrected for plasma volume, 
exercise induced a significant ↓in 
fibrinogen levels 
¾ Small sample size 
¾ No females included 
Mockel et al., 
1999 
Germany253 
13 amateur triathletes 
(25: 19 – 44) vs. 5 
healthy male subjects 
(27 – 33) 
¾ 1 visit 
¾ 30 mins supine 
rest, followed by 
strenuous 
exercise.  Blood 
taken at rest, 
during aerobic 
and anaerobic 
exercise and 
during a 90 mins 
recovery 
¾ Exercise on cycle 
ergometer in 
supine position 
¾ 30 mins aerobic 
exercise followed 
by an anaerobic 
period with a 
gradual ↑in load 
of 40 watts every 
4 mins until 
exhaustion 
¾ P-sel 
¾ F 1+2 
¾ TAT 
¾ PAP 
¾ FM 
¾ P-sel expression significantly 
↑following aerobic exercise and was 
more pronounced after anaerobic 
exercise 
¾ P-sel expression returned to baseline 
level after 30 mins recovery 
¾ F 1+2, FM, and PAP significantly 
↑following aerobic exercise and was 
more pronounced after anaerobic 
exercise 
 
¾ No females included 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
Ottersetter et al., 
1999 
USA254 
14 female oral 
contraceptive users 
(26.4 + 1.1) vs. 14 
non-users (26.7 + 1.3) 
¾ 3 visit 
¾ 15 mins seated 
rest followed by 
strenuous 
exercise 
¾ Maximal graded 
exercise test on 
bicycle ergometer 
¾ PAI-1 activity 
¾ t-PA activity 
¾ F 1+2 
¾ t-PA significantly ↑ following exercise 
and although a trend was observed no 
significant difference was observed 
between groups 
¾ PAI-1 significantly ↓ following 
exercise with the decrease being 
significantly greater in the non-user 
group 
¾ F1=2 were elevated at baseline in the oral 
contraceptive users but no change was 
observed in either group with exercise 
¾ No recovery period 
Kvernmo et al., 
1997 
Norway255 
8 trained males (25 + 
0.9) vs. 8 non-trained 
males (20 + 0.2) 
¾ 1 visit 
¾ 10 mins warm up 
followed by 40 
mins strenuous 
exercise  
¾ 80% VO2Max ¾ F 1+2 
¾ TAT 
¾ t-PA antigen 
¾ PAI-1 antigen 
¾ F 1+2 significantly ↑in the non-trained 
group following exercise 
¾ t-PA was significantly ↓at rest in the 
trained group  
¾ ↑t-PA observed following exercise was 
significantly ↓ in the trained group 
compared to the non trained group 
¾  PAI showed no significant change in 
response to exercise 
¾ Small sample size 
¾ No females included 
¾ Groups not age-matched 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
Sakita et al., 
1997 
Japan256 
16 healthy males 
(22.6 + 1.9) 
¾ 1 visit 
¾ Incremental 
exercise task 
¾ Modified Bruce 
Protocol 
¾ Platelet aggregation 
¾ Platelet sensitivity to 
SIN-1 
¾ Collagen-induced platelet aggregation 
significantly ↑after vigorous exercise 
¾ ↑ in platelet aggregation was 
¾ No females included 
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 ¾ Cyclic GMP 
accumulation inside the 
platelets 
significantly ↓in the presence of SIN-1 
¾ Cyclic GMP inside the platelets showed 
no significant change after exercise 
Gonzales et al., 
1996 
Spain257 
24 healthy sportsmen 
(20 – 27) vs. 23 
healthy sedentary (22 
– 28) vs. 11 healthy 
adult sportsmen (40 – 
54) vs. 10 healthy 
sedentary adults (30 – 
48) vs. 10 healthy 
elderly (60 – 80) 
¾ 1 visit 
¾ Incremental 
strenuous 
exercise followed 
by 30 mins 
recovery 
¾ Bicycle 
incremental 
exercise starting 
at 50 watts ↑ by 
50 watts every 10 
mins until 
exhaustion 
¾ Platelet count  
¾ β-TG 
¾ Platelet count significantly ↑ in the 
sedentary adults and sedentary elderly 
group following exercise 
¾ β-TG at rest ↑ with age and is ↓in 
athletes compared to non-athletes 
¾  β-TG significantly ↑following exercise 
in all groups 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
Gleerup et al., 
1995 
Denmark258 
12 normotensive 
(62.8) vs. 12 
borderline 
hypertensive (58.8) 
¾ 1 visit 
¾ Supine rest, 10 
mins standing, 
followed by 5 
mins incremented 
exercise 
¾ 3 mins exercise at 
50 watts for one 
min ↑by a 50 
watts per min last 
2 mins 
¾ Platelet aggregation 
¾ β-TG 
¾ PF-4 
¾ ECLT 
¾ t-PA activity 
¾ PAI-1 
¾ ECLT and PAI-1 were significantly ↑at 
baseline in the hypertensive group 
compared to the healthy controls 
¾ ECLT was significantly ↓following 
exercise in both groups 
¾ t-PA was significantly ↑following 
exercise in both groups 
¾ Platelet aggregation, β-TG and PF-4 
were unchanged by exercise in both 
groups 
¾ No recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
van den Burg et 
al., 
1995 
Netherlands259 
29 sedentary males 
(24.6 + 0.6) 
¾ 1 visit 
¾ 30 mins high 
intensity  
¾ 10 mins cycling 
with load ↑ until 
70% VO2Max 
was reached (A), 
15 mins during 
which this work 
rate was 
maintained (B), 
stepwise ↑ in load 
until VO2Max 
was achieved (C) 
followed by 10 
mins active 
recovery and 15 
mins passive 
recovery (D) 
¾ FVII:C 
¾ FVIII:C 
¾ FIX:C 
¾ FXII:C 
¾ Fibrinogen 
¾ t-PA antigen and t-PA 
activity 
¾ PT 
¾ aPTT 
 
¾ Period A resulted in a significant ↑in all 
clotting factors and t-PA and a 
subsequent ↓in PT and aPTT  
¾ Period B resulted in a significant ↑ in t-
PA antigen and activity levels and a 
further ↑in FVIII:C and ↓in aPTT 
¾ Period C resulted in all clotting factors, 
clotting times and fibrinolytic variables 
showing the most pronounced changes 
¾ During recovery all clotting factors 
demonstrated a ↓ except FVIII:C which 
continued to ↑ 
¾ Correction for changes in  PVol did not 
effect the results for FVIII:C, t-PA 
antigen and activity but reversed the 
outcome for FVII:C 
¾ No females included 
Szymanski et al., 
1994 
USA260 
15 sedentary males 
(34.7 + 4) vs. 15 
active males (35.4 + 
4) vs. 15 highly active 
males (32.4 + 3.6) 
¾ 1 visit 
¾ 10 mins rest 
followed by an 
incremental 
exercise test 
¾ Modified Balke 
treadmill exercise 
protocol 
¾ t-PA activity 
¾ PAI-1 activity 
¾ At rest t-PA activity was similar among 
all groups 
¾ t-PA activity significantly ↑in all 
groups with exercise, although a greater 
response was observed in non-sedentary 
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 groups 
¾ PAI-1 activity was significantly ↓in 
highly active group at rest compared to 
other groups 
¾ PAI-1 significantly ↓in all groups 
following exercise 
Kestin et al., 
1993 
USA261 
12 physical active 
participants (39.3 + 
9.2) vs. 12 sedentary 
participants (37.9 + 
9.1) 
¾ 1 visit 
¾ Blood taken 
immediately pre- 
and post-exercise 
and after 15 mins 
recovery 
¾ Bruce Protocol ¾ GP1b (6D1) 
¾ GPIIbIIIa (PAC-1) 
¾ GPIV (OKM5) 
¾ GMP-140 (S12) 
¾ Platelets from physically active and 
sedentary individuals at rest were 
comparable 
¾ Exercise had no effect on the activation 
state of platelet in the physically active 
individuals 
¾ Exercise yielded a significant alteration 
in platelet activation demonstrated by a 
significant ↑in antibody GPIb and 
OKM5 
 
Gough et al., 
1991 
UK262 
7 healthy participants 
(25.6: 24.5 – 28)  
¾ 1 visit 
¾ 10 mins rest 
followed by 
incremental 
exercise test 
¾ Bruce Protocol ¾ ECLT 
¾ t-PA antigen 
¾ PAI-1 antigen and 
activity 
¾ ECLT, PAI antigen and activity were 
significantly ↓following exercise 
¾ t-PA significantly ↑following exercise 
¾ Small sample size 
¾ No recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
Naesh et al., 
1990 
Denmark263 
8 healthy males (25: 
22 – 29) 
¾ 1 visit 
¾ 15 mins supine 
rest, incremental 
exercise followed 
by 60 mins 
supine recovery 
¾ Cycling on 
ergometer 
↑workload by 50 
watts every 5 
mins until a HR 
of 150 bpm was 
reached and 
continued for 5 
mins 
¾ Platelet count 
¾ Platelet aggregation 
¾ β-TG 
¾ Platelet count significantly ↑ following 
exercise and returned to baseline during 
recovery period 
¾ β-TG demonstrated no change during 
exercise 
¾ ADP-induced platelet aggregation 
significantly ↑ following exercise and 
remained elevated during  recovery 
¾ Small sample size 
¾ No females included 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
 
LaCroix et al., 
1990 
USA264 
20 healthy males 
(18 – 35) 
¾ 1 visit 
¾ 5 mins rest in 
hyperbaric 
chamber 
followed by 
incremental 
exercise at 3 
atmospheric 
absolutes  
¾ 1 mins cycling on 
ergometer at 60 
rpm (unloaded) 
followed by 1 
watt ↑per min  in 
load until 
exhaustion 
¾ FVIII:C 
¾ vWF antigen 
¾ Plasminogen 
¾ Antithrombin III 
 
¾ FVIII:C and vWF significantly 
↑following exercise 
¾ No differences observed between 
change elicited at 3 atmospheric 
absolutes compared to those at 1 
atmospheric absolute 
¾ No females included 
¾ No recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
 
Vene et al., 
1990 
Yugoslavia265 
19 healthy males 
(24 + 3) 
¾ 1 visits: 
¾ Incremental 
exercise test 
¾ Bruce protocol ¾ t-PA antigen 
¾ PAI-1 antigen 
¾ t-PA significantly ↑following exercise 
¾ PAI-1 demonstrated no change 
¾ No females included 
¾ No recovery period 
¾ Failed to correct alterations in 
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 haemostatic markers for ∆ in 
plasma volume 
Chen et al., 
1989 
Taiwan266 
51 young healthy 
participants females 
(23 + 1); males (25 + 
1) 
¾ 1 visit 
¾  High intensity 
exercise 
¾ Exercised on 
bicycle ergometer 
at ¾ of maximum 
work load 
¾ Bleeding time 
¾ Platelet count 
¾ At rest females demonstrated 
significantly ↑bleeding times compared 
to males 
¾ Bleeding time significantly ↓following 
exercise in both males and females 
¾ Platelet count significantly ↑following 
exercise 
¾ No recovery period 
Ferguson et al., 
1987 
USA267 
20 male marathoners 
(37.2 + 1.9) vs. 20 
male joggers (35.3 + 
1.9) vs. 20 male 
sedentary (33.9 + 2.1) 
¾ 1 visit 
¾ 10 mins rest, 
incremental 
exercise, 
followed by 30 
mins recovery 
¾ Bruce protocol on 
treadmill 
¾ Platelet count 
¾ FDP 
¾ PT 
¾ aPTT 
¾ Antithrombin III 
¾ ECLT 
 
¾ Platelet count, PT, aPTT significantly 
↓following exercise in all three groups 
¾ FDP significantly ↑in all groups except 
sedentary individuals 
¾ Antithrombin III significantly ↑in all 
three groups 
¾ ECLT significantly ↓following exercise 
¾ No females included 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in plasma 
volume 
 
Wheeler et al., 
1986268 
19 healthy males 
(33 + 1.8) 
¾ 1 visit 
¾ 5 mins rest, 
incremental 
exercise test, 
followed by 8 
mins recovery 
¾ Branching 
multistage 
treadmill protocol 
¾ FVIII:C antigen and 
activity 
¾ FA 
¾ FA significantly ↑following exercise 
but did not ↓to resting levels in the 8 
mins recovery 
¾ FVIII:C antigen and activity 
significantly ↑following exercise and 
continued to ↑over the recovery period 
¾ No females included 
¾ Short recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
 
Mangum et al., 
1984 
USA269 
10 males participants 
(27.1 + 2.5) 
¾ 1 visits 
¾ 15 mins rest 
followed by 
incremental 
exercise  
¾ 50 watts for 5 
mins and 150 
watts  for 10 mins 
¾ ECLT 
¾ aPTT 
¾ ECLT significantly ↓ following 
exercise 
¾ aPTT demonstrated no change 
¾ Small sample size 
¾ No females included 
¾ No recovery period 
Patient Population Studies 
Yilmaz et al.,  
2004 
Turkey270 
63 male participants 
with positive exercise 
tests for CAD (52.4 + 
4.1) vs. 35 
participants with non 
significant CAD on 
angiography (52.6 + 
4.3) 
¾ 1 visit 
¾ Rest and an 
incremental 
exercise test 
¾ Modified Bruce 
Protocol 
¾ MPV ¾ MPV ↑ significantly post exercise in 
CAD group but not in control group 
¾ No recovery period 
¾ No females included 
¾ Poorly detailed methodology and 
results 
Gibbs et al., 
2001 
UK271 
20 CHF patients (64 + 
10) vs. 20 patients 
with vascular disease 
(63 + 11) vs. 20 
healthy controls (63 + 
¾ 1 visit 
¾ 20 mins rest, 
incremental 
exercise to 
exhaustion, 
¾ Modified Bruce 
Protocol 
¾ vWF antigen 
¾ sP-Sel 
¾ Fibrinogen 
¾ Significant ↑ in fibrinogen following 
exercise which remained elevated 
during recovery 
¾ No change in vWF and sP-Sel for either 
group following exercise 
¾ No comparison to healthy controls 
reported 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
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 9) followed by 30 
mins recovery 
 
 
¾ Failed to control for female 
menstrual cycle 
Li-Saw-Hee et al., 
2001 
UK272 
20 patients with 
chronic AF (65 + 11) 
20 patients with 
vascular disease (63 + 
11) vs. 20 healthy 
controls (63 + 9) 
¾ 1 visit 
¾ Incremental 
exercise to 
exhaustion 
followed by 20 
mins recovery 
¾ Bruce Protocol ¾ Fibrinogen 
¾ sP-sel 
¾ vWF antigen 
¾ PAI-1 antigen 
¾ Significant ↑ in fibrinogen in AF 
patients following exercise  
¾ PAI-1 significantly ↓following exercise 
in AF patients 
¾ No change in vWF and sP-sel 
¾ No comparison to healthy controls 
reported 
¾ Failed to correct alterations in 
coagulatory markers for ∆ in 
plasma volume 
¾ Failed to control for female 
menstrual cycle 
Lindemann et al., 
1999 
Germany273 
12 patients with CAD 
(61.7 + 1.7) vs. 11 
healthy controls (58 + 
2.5) 
¾ 1 visit 
¾ 20 mins supine 
rest followed by 
incremental 
exercise test 
¾ Cycling on 
ergometer 
commencing at 
50 watts 
and↑steadily by 
25 W every 3 
mins 
¾ P-sel expression 
¾ Fibrinogen binding to 
GP IIb/IIIa and its 
expression 
¾ Resting fibrinogen binding to GP 
IIb/IIIa and P-sel expression was 
significantly ↓in patients and ↓further 
after exercise 
¾ Failed to control for female 
menstrual cycle  
¾ No recovery period 
Wang et al., 
1999 
Taiwan274 
15 sedentary males 
(24.3 + 1.1) 
¾ 1 visit 
¾ 30 mins rest, 
followed by 
strenuous 
exercise 
¾ VO2Max test ¾ Platelet adhesion ¾ ADP-induced platelet adhesion was 
significantly ↑ following exercise 
¾ Small sample size 
Mustonen et al.,  
1998 
Finland275 
15 patients with PAD 
(59 + 8) vs. healthy 
controls (57 + 11) 
¾ 1 visit 
¾ 15 mins rest, 
incremental 
exercise test, 
followed by 30 
mins recovery 
¾ Exercise on a 
treadmill at 
constant speed of 
3.2 km/h for 2 
mins at 00 
thereafter the 
inclination angle 
was ↑by 20/ 2 
mins  
¾ vWF 
¾ TAT 
¾ D-dimer 
¾ Fibrinogen 
¾ t-PA antigen and 
activity 
¾ PAI-1 antigen 
¾ PAP 
¾ Fibrinogen, D-dimer, t-PA and PAI-1 
antigen levels were ↑ in patient group 
¾ Significant ↑ in TAT in patient group 
following exercise 
¾ D-dimer, t-PA antigen and activity and 
PAP demonstrated a significant and 
parallel ↑in both patient and control 
groups 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
¾ Failed to control for female 
menstrual cycle 
Held et al., 
1997 
Sweden276 
809 stable angina 
patients (59 + 7) vs. 
50 healthy controls 
(61 + 0.8) 
¾ 1 visit 
¾ Incremental 
exercise test 
¾ Symptom limited 
exercise test on 
bicycle 
ergometer, 
starting at 30 
watts with ↑in 10 
watts per min 
¾ t-PA antigen and 
activity 
¾ t-PA antigen was significantly ↑in 
angina patients at rest compared to 
healthy controls 
¾ t-PA antigen levels ↑following exercise 
with ∆ being greatest in healthy 
individuals 
 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
¾ No defined baseline or recovery 
period 
¾ No control for female menstrual 
cycle 
Hansen et al., 
1994 
Norway277 
14 patients with 
hypercholesterolaemia 
(49.7: 29 – 59) vs. 14 
healthy participants 
¾ 1 visit 
¾ 15 mins supine 
rest followed by 
strenuous 
¾ Cycling on 
ergometer 
starting at 75 
watts and ↑by 25 
¾ t-PA antigen and 
activity 
¾ TAT 
¾ Antithrombin III 
¾ t-PA was significantly ↑in patients at 
rest compared to health controls 
¾ Both groups exhibited a similar and 
significant ↑in t-PA and TAT during 
¾ No recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
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 (49.6 + 8.1) exercise watts every other 
mins up to 150 
watts 
activity exercise 
¾ ↑in t-PA activity was more pronounced 
in patient population 
 
Bounamaux et al., 
1992 
Switzerland278 
100 patients with 
confirmed or 
suspected CAD (55; 
31 – 80) 
¾ 1 visit 
¾ Incremental 
exercise 
¾ Diagnostic 
exercise test < 80 
APMHR 
¾ D-dimer 
¾ TAT 
¾ F 1+2 
¾ TAT and F 1+2 significantly ↑following 
exercise 
¾ D-dimer demonstrated no change 
following exercise 
¾ Blood not taken immediately after 
completion of exercise 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
¾ No control for female menstrual 
cycle 
Rydzewski et al., 
1990 
Japan279 
Group 1: 23 healthy 
controls (55.2 + 10.7) 
Group 2: 23 patients 
with CAD without 
exercise induced 
schema (58 + 10.4)  
Group 3: 22 patients 
with CAD with 
transient exercise 
induced schema (56.8 
+ 9.7) 
¾ 1 visit 
¾ Incremental 
exercise test 
¾ Symptom limited 
exercise test on 
bicycle 
ergometer, 
starting at 50 
watts ↑in 25 watts 
every 3 min 
¾ t-PA antigen 
¾ PAI-1 antigen 
¾ Plasminogen activator 
activity 
¾ t-PA-PAI-1 complex 
¾ Patients in group 3 had significantly 
↑resting levels of t-PA compared to the 
other two groups and ↑PAI-1 compared 
to group 1 
¾ Exercise induced significant ↑in levels 
of t-PA, plasminogen activator activity, 
and activator inhibitor complex and a 
significant ↓PAI-1 
¾ No recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
 
McGill et al., 
1989 
Australia280 
27 males CAD 
patients either 
asymptomatic or with 
chronic stable angina 
¾ 2 visits 
¾  30 mins supine 
rest followed by 
incremental 
exercise test 
same protocol on 
both visits 
¾ Bruce Protocol ¾ TxB2 
¾ β-TG 
¾ Platelet count 
 
¾ At rest TxB2 were comparable between 
patients with positive and negative 
exercise tests and demonstrated no 
significant ↑with exercise 
¾ Both groups of patients demonstrated a 
significant ↑in β-TG following exercise 
¾ No females included 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
 
Martos et al., 
1988 
Hungary281 
17 male post–MI (2 
months) patients 
(56.4 + 4.8) 
¾ 1 visit 
¾ Strenuous 
exercise 
¾ 85% of APMHR 
on bicycle 
ergometer 
¾ Platelet count 
¾ Platelet aggregation 
¾ Neither platelet count or ADP-induced 
platelet aggregation changed during 
exercise 
¾ Small sample size 
¾ No control group 
¾ No females included 
¾ No recovery period 
Speiser et al., 
1988 
Germany282 
Group A: 18 healthy 
athletes (23 + 3.5) 
Group B: 18 healthy 
sedentary participants 
(25.7 + 2.7)  
Group C: 17 elderly 
healthy volunteers 
(50.6 + 7.7) 
Group D: 18 patients 
with previous MI 
¾ 1 visit 
¾ Incremental 
exercise test. 
Blood taken with 
patient in 
recumbent 
position prior to 
exercise and 2 
and 60 mins post 
exercise 
¾ Group A & B 
started with a 
workload of 1 
watt per kg body 
weight for 2 
mins, ↑by 1 watt 
per kg every 2 
mins 
¾ Groups C & D 
started with a 
¾ D-dimer 
¾ Fibrinogen 
¾ t-PA antigen  
¾ PAI-1 activity 
¾ ECLT 
¾ vWF 
¾ Groups C and D had significantly 
↑resting levels of t-PA compared to 
groups A and B 
¾ Group A exhibited significantly lower 
t-PA compared to Group B 
¾ Groups B and D had significantly ↑PAI 
at rest  
¾ ELT was prolonged in groups B and D  
¾ t-PA significantly ↑in all groups during 
exercise with no differences being 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
¾ Failed to account for female 
menstrual cycle 
- 67 - 
 (54.2 + 7.9) workload of 25 
W/kg for 2 mins, 
↑by 25 W/kg 
every 2 mins 
observed between groups 
¾ ELT was significantly ↓in all groups 
following exercise, with ELT being 
shorter in groups A and C 
¾ vWF significantly ↑in all groups but D 
immediately following exercise 
¾ D-dimer and fibrinogen showed no 
significant change during exercise 
Strauss et al., 
1985 
USA283 
24 males with known 
CAD (60: 36 – 69) vs. 
9 healthy / 
hypertensive male 
participants (40: 21 – 
61) 
¾ 1 visit 
¾ Incremental 
exercise test with 
blood taken 
immediately 5 
and mins post 
exercise 
¾ Symptom-limited 
maximal exercise 
tolerance test on 
treadmill 
¾ Standard or 
Sheffield-
modified Bruce 
Protocol or 
Naughton 
protocol 
¾ PF-4 
¾ β-TG 
¾ β-TG showed significant difference 
between the two groups at rest and 
during exercise  
¾ PF-4 demonstrated a significant 
↑during exercise in the control group but 
not in the patients with CAD 
 
¾ No females included 
¾ No recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
¾ Inadequate control group; not age-
matched 
Levine et al., 
1984 
USA284 
84 males patients 
(56.9; 31 – 70) 
scheduled for 
diagnostic treadmill 
exercise 
¾ 1 visit 
¾ Exercise test 
¾ 63 patients and 10 
healthy controls 
underwent a 
modified Bruce 
protocol 
¾ 21 patients were 
studied at 2, 6, or 
12 weeks 
following an MI 
using a symptom 
limited Naughton 
Protocol 
¾ Platelet count 
¾ PF-4 
¾ PF-4 was not significantly ↑during 
exercise in healthy participants 
¾ PF-4 was significantly ↑following 
exercise in the post MI patients who 
underwent Naughton protocol 
 
¾ No females included 
¾ No recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
 
Rotmensch et al., 
1983 
USA285 
26 patients 
undergoing evaluation 
of CAD 
Group A: exercise test 
only (50 + 16 
Group B: post 
exercise thallium scan 
(49 + 10) 
¾ 1 visit 
¾ Incremental 
exercise test with 
blood taken prior, 
immediately 
after, and 30 
mins after 
completion of 
exercise  
¾ Incremental 
exercise test on 
treadmill 
¾ PF-4 
¾ TxB2 
¾ Patient’s in group A who experienced a 
positive exercise test demonstrated a 
significant ↑in PF-4, whereas patients 
whose exercise test was negative showed 
no change 
¾ Patients in group B demonstrated 
significantly ↑resting PF-4 and a 
significantly greater ↑during in PF-4 
compared to group A 
¾ TxB2 demonstrated no significant 
change with exercise 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
¾ Insufficient demographic details on 
patients 
Marcella et al., 
1983 
13 males with CAD 
(55: 36 – 69) vs. 10 
¾ 1 visit 
¾ Incremental 
¾ Incremental 
exercise test on 
¾ PF-4 
¾ β-TG 
¾ PF-4 was significantly ↑in patient 
group at rest compared to healthy 
¾ No females included 
¾ No recovery period 
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 USA286 healthy males (29:22 
– 46) 
exercise test  bicycle ergometer ¾ TxB2 
¾ Fibrinopeptide A 
¾ Fibrinopeptide B 
participants but as with TxB2, 
demonstrated no change during exercise 
¾ Fibrinopeptide A was significantly ↑in 
patient group at rest but demonstrated no 
change with exercise 
¾ Fibrinopeptide B demonstrated no 
change with exercise 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
¾ Two groups not age- matched 
Schernthaner et al., 
1983 
Austria287 
53 male post-MI (40 
days to 2 years) 
patients (52) vs. 9 
healthy males (47) 
¾ 1 visit 
¾ Incremental 
exercise followed 
by 30 mins 
recovery 
¾ Symptom limited 
bicycle ergometer 
test 
¾ PF-4 
¾ β-TG 
¾ At rest PF-4 and β-TG were 
significantly ↑in patients compared to 
controls 
¾ PF-4 and β-TG significantly ↑following 
exercise in the healthy individuals but 
not in the patient group 
¾ PF-4 and β-TG only significantly ↑in 
patients who achieved >75% of their 
predicted maximal work rate 
¾ No females included 
¾ Groups were not age-matched 
¾ Heterogeneity of MI patients 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
Kopitsky et al., 
1983 
USA288 
20 healthy males 
(35 – 59) 
¾ 1 visit 
¾ 15 mins rest 
followed by 
incremental 
exercise test 
¾ Modified Balke 
protocol on a 
treadmill 
¾ FVIII:C antigen 
¾ Thrombin induced 
FVIII:C activity 
¾ FVIII:C antigen significantly 
↑following exercise 
¾ Thrombin induced a significant ↑ in 
FVIII:C at rest and post exercise 
¾ ↑in FVIII probably due to activation of 
FVIII/vWF complex 
¾ No females included 
¾ Blood samples not taken 
immediately after exercise 
¾ No recovery period 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
Ek et al., 
1982 
Sweden289 
30 patients with MI 
(63; 50 – 78) vs. 26 
healthy participants 
(66; 50 – 80) 
¾ 1 visit 
¾ 10 mins rest 
followed by 
incremental 
exercise 
¾ Exercise on 
bicycle ergometer 
↑10 W/min until 
pulse reached 150 
bpm or until 
patient was 
unable to 
continue 
¾ PF-4 ¾ PF-4 at rest was similar between 
controls and patients 
¾ PF-4 was not significantly ↑following 
exercise in patient group 
¾ Failed to correct alterations in 
haemostatic markers for ∆ in 
plasma volume 
 
Khanna et al., 
1975 
India290 
20 males IHD (43.5; 
26 – 52) vs. 8 healthy 
males (43; 25 – 53) 
¾ 1 visit 
¾  60 mins rest 
followed by 
incremental 
exercise 
¾ Modified Bruce 
protocol 
¾ ECLT 
 
¾ Fibrinolytic response to exercise was 
significantly greater in the control group 
compared to the patient group 
 
¾ No recovery period 
¾ No females included 
 
ACS = Acute Coronary Syndromes, ADP = Adenosine Diphospate, AF = Atrial Fibrillation, APMHR = Age Predicted Maximal Heart Rate, bpm = beats per minute, 
β-TG = Beta Thromboglobulin, CAD = Coronary Artery Disease, CHF = Chronic Heart Failure, ECLT = Euglobulin Clot Lysis Time, F1+2 = Prothrombin Fragments 
1+2, FVII:C = Clotting Factor VII, FVIII:C = Clotting Factor VIII, FIX:C = Clotting Factor IX, FXII:C = Clotting Factor XII, FA = Fibrinolytic Activity, FDP = 
Fibrin Degradation Products, GPIIb/IIIa = Glycoprotein IIb/IIIa, HR = Heart Rate, IHD = Ischemic Heart Disease, MPV = Mean Platelet Volume, mins = minutes, MI 
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= Myocardial Infarction, P-sel = P-Selectin, PAD = Peripheral Artery Disease, PAP = Plasmin α2 antiplasmin complex, t-PA = tissue-type Plasminogen activator, PAI 
-1 = Plasminogen Activator inhibitor, PF-4 = Platelet Factor-4, aPTT = activated Partial Thromboplatin Time , PT = Prothrombin Time, TAT = Thrombin-
Antithrombin, TM = Thrombomodulin, TxB2 = Thromboxane B2, W = Watts, vWF = von Willebrand Factor, ↑ = increased , ↓ = decreased, ∆ = change  
 
 
 
 
 
 CHAPTER 2 
 
Methods 
 
2.1 Questionnaire Study 
  
2.1.1 Participants 
 
Between the 25th November 2003 and 28th August 2005 all patients with a diagnosis 
of AF attending the specialist AF cardiology clinic at City Hospital, Birmingham, 
West Midlands, were eligible for inclusion.  The presence of AF was defined as the 
absence of a P-wave in association with rapid oscillations or fibrillatory waves on a 
12-lead ECG, by a physician.  Patients were excluded from participation if they (1) 
were aged less than 18 years, (2) had undergone any non-pharmacological 
intervention (excluding DC cardioversion) to correct this arrhythmia, (3) had 
carcinoma/malignancy of any type, (4) had a myocardial infarction (MI) or transient 
ischemic attack (TIA)/stroke within the previous six months, (5) had coronary artery 
bypass graft (CABG) surgery or percutaneous transluminal coronary angioplasty 
(PTCA/PCI) within the previous six months, (6) could not read English, or (7) were 
cognitively impaired. 
 
AF patients were age-, and sex-matched with a hypertensive disease control group.  
Between the 3rd January 2005 and 7th October, the notes of 215 hypertensive patients 
were screened and subsequent approaches were made to the 160 patients who were 
deemed eligible.  The exclusion criteria for the hypertensive patients were identical to 
those employed for the AF patients.  
 
During the study period, 195 AF and 156 hypertensive patients were approached to 
participate.  Of these, 95 (48.7%) AF and 63 (39.4%) hypertensive patients refused to 
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 participate.  Consequently, 101 AF patients and 97 hypertensive patients provided 
written informed consent, completed the baseline questionnaires, and constitute the 
effective study population. 
 
2.1.2 Procedure 
Prior to each AF clinic, patient’s notes were screened to identify potential participants 
for the study.  Social and demographic details such as age, gender, ethnicity, and 
employment status were recorded.  Patients deemed eligible were either approached 
following their clinic appointment and given a study information sheet, or invited by 
letter in the week following their clinic appointment.  If the patient agreed to 
participate, written informed consent was obtained.  The study protocol was reviewed 
and granted ethical approval by the West Birmingham Local Research Ethics 
Committee prior to commencement of the study. 
 
Patients who participated in the study completed a battery of questionnaires on two 
separate occasions: at baseline, and at six-months.  The questionnaire pack comprised 
the following: the Beck Depression Inventory (BDI) [291], the Stait-Trait Inventory 
(STAI) [292], and the Dartmouth Care Cooperative Information Project (COOP) chart 
system [293].  All questionnaires employed had acceptable psychometric properties.  
Patients completed the questionnaires either at home or in the Cardiovascular 
Psychophysiology Unit at the University Department of Medicine at City Hospital.  If 
they expressed a preference to complete the battery of questionnaires at home, the 
questionnaire pack along with detailed instructions, consent forms (if not previously 
signed) and a stamped addressed envelope were sent to them.  If the patient expressed 
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 a preference to complete the questionnaire pack at hospital, this was done in the 
presence of an interviewer (GT).   
 
2.1.2.1 Beck Depression Inventory (BDI) 
The Beck Depression Inventory (BDI) is a 21-item self-report inventory used to 
measure depressive symptoms in adolescents and adults [291].  The original BDI was 
derived from the clinical observation of attitudes and symptoms frequently displayed 
by depressed psychiatric patients, and infrequently by non-depressed psychiatric 
patients [291].  The clinical observations were then systematically combined, and 
constitute the 21-items on the inventory, measuring an individual’s current depressive 
state.  Each item describes specific behavioural manifestations of depression in a 
series of four or five self-evaluative statements.  The statements are scored from zero 
to three, reflecting the severity of the symptom.  The patient must circle the statement 
which best describes their current feelings.  Scores range form zero to 63, with higher 
scores indicating greater levels of depressive symptoms.  Scores between zero and 
nine are classified as non-depressed, scores 10 and 15 as mildly depressed, scores 16 
to 23 as moderately depressed, and scores of 24 and over are classified as severely 
depressed [7].  A cut-off of 10 or greater was adopted in the present study to indicate 
depression; this criteria has been commonly employed previously in studies 
examining depression in patients with coronary heart disease (CHD) [295-297].  
The BDI has been shown to have acceptable internal consistency with Cronbach’s 
alpha coefficient of 0.86 for psychiatric patients and 0.81 for non-psychiatric patients.  
Variable test-retest reliability has been found with Pearson product moment 
correlations coefficients ranging from 0.48 to 0.86 for psychiatric patients and 0.60 to 
0.83 for non-psychiatric individuals [298].  However, the BDI is a measure of current 
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 depressive state and is therefore subjective to fluctuation over time, which may 
explain the occasional low test-retest reliability.   
The concurrent validity of the BDI has been determined by comparing the reported 
scores with experts’ clinical ratings of depression.  Correlations between the two have 
ranged from 0.55 to 0.96 for psychiatric patients and 0.55 to 0.73 for non-psychiatric 
individuals [298].  The BDI has been widely used to assess depressive symptoms in 
medically-ill patients [299-300], and patients with heart disease [295-297,301-302].  
Other well established instruments used to measure depression, such as the Hamilton 
Rating Scale for Depression [303] and the Zung Self-Rating Depression Scale [304] 
have been found to be strongly associated with the BDI.  
 
2.1.2.2 State-Trait Anxiety Inventory (STAI) 
The State-Trait Anxiety Inventory (STAI) is the most widely used instrument for 
measuring anxiety in adults [292].  It has been used extensively in research and 
clinical practice over the last 40 years to assess anxiety in medically-ill patients [305-
306], and patients with heart disease [295,301,307].  The STAI compromises two 
separate self-report scales, consisting of twenty statements.  The state anxiety scale 
evaluates how the respondents feel “right now”, with the trait anxiety scale assessing 
how people “generally feel”.  Each STAI score is given a weighted score of one to 
four.  A rating of four indicates the presence of a high level of anxiety for ten 
statements on the state anxiety scale and eleven statements on the trait anxiety scale.  
Conversely, a high rating indicates the absence of anxiety for the remaining ten state 
anxiety statements and nine anxiety items, and the scoring weights for these items are 
reversed.  The state anxiety scale requires examinees to circle the number which best 
describes the intensities of their current feelings: (1) not at all, (2) somewhat, (3) 
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 moderately so, and (4) very much so.  Similarly, the trait anxiety scale asks people to 
indicate how they generally feel by rating the frequency of their feelings: (1) almost 
never, (2) sometimes, (3) often, and (4) almost always.  Scores on both state and trait 
anxiety scales can range from a minimum of 20 to a maximum of 80, with higher 
scores indicating greater levels of anxiety.  A full score may still be obtained for 
respondents who omit one or two items on either scale by determining the mean 
weighted score for the completed statements; multiplying this value by 20, and then 
rounding this figure to the nearest whole number.  The STAI has been shown to have 
acceptable internal consistency across populations, with Cronbach’s alpha coefficient 
of 0.93 and 0.91 for the State and Trait Anxiety scale, respectively.   
 
2.1.2.3 Dartmouth Care Cooperative Information Project (COOP) Charts 
The Dartmouth Care Cooperative Information Project (COOP) chart system has been 
developed and refined over a decade for the purpose of making a brief, practical, and 
valid method to assess functional status of adults and adolescents [293].  Each chart 
comprises a question referring to the status of the patient over the last 4 weeks, each 
with five response choices.  Each response is illustrated by a drawing that depicts a 
level of functioning or well-being, which are scored along a 5-point ordinal scale, 
with the higher scores representing unfavourable levels of health-related quality of 
life.  The total score for the charts is 45; however, for the purposes of all subsequent 
analyses the score for the overall quality of life was not included in the total score.  
Therefore, the maximum total score was 40.  The Dartmouth COOP charts have been 
used previously to assess functional status in both medically ill [308-309], and cardiac 
patients [296,310-311]. 
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 2.1.2.4 Socio-economic status 
Townsend deprivation scores were used as a measure of socio-economic status, and 
were allocated based on an individual’s postal code [312]. Deprivation scores are 
composites of the extent of household overcrowding, unemployment, and lack of car 
and home ownership in small postal code areas across Britain.  Scores range from -7.3 
to 10.2, with higher positive scores indicating greater deprivation.  
 
2.1.2.5 Clinical variables 
Baseline clinical characteristics, such as type of AF, date of diagnosis and duration of 
AF, whether or not the patient had undergone direct current (DC) cardioversion, 
whether they received a medication regimen for rate or rhythm control, and the 
presence of any other significant cardiovascular (i.e. hypertension, diabetes, coronary 
artery disease), and non-cardiovascular co-morbidities were documented from 
patients hospital notes.   
 
2.1.2.6 Medication 
Prescriptions of anti-coagulant/anti-platelet medication (i.e. warfarin, aspirin, 
clopidogrel), digoxin, alpha- and beta-blockers, calcium channel blockers, diuretics, 
angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers, 
spirolactone, and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
(‘statins’) were recorded from patient’s records. 
 
2.1.2.10 Follow-up 
Patients enrolled in the study were followed up at six-months.  Identical questionnaire 
packs to those completed at baseline were sent to patients together with a stamped 
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 addressed envelope in which to return the second questionnaire pack.  Outcome data, 
including the number of hospitalisations for cardiovascular events and/or death from 
any cause during the six-month follow-up period were recorded from the Patient 
Information System (PiMS) at the hospital.  
 
2.2  Stress testing study 
2.2.1           Participants 
Of the 198 patients (101 AF and 97 hypertensive) who were enrolled in the 
questionnaire study (see section 2.2.1), 120 were not eligible for the stress testing 
component of the study for the following reasons: female (n=71), diabetes mellitus 
(n=41), heart failure (n=2), and anyone aged >80 years (n=96).  Of the 78 eligible 
patients, 14 (17.9%) AF patients consented to take part in the stress-testing study.  
These patients were age-matched with 10 hypertensive patients and 10 healthy 
controls.  Healthy individuals were required to undergo a thorough cardiovascular 
screening (echo-cardiography, ECG, full haemostatic profile) prior to giving informed 
consent. 
 
2.2.2 Procedure 
Patients attended the Cardiovascular Psychophysiology Unit, City Hospital NHS 
Trust, Birmingham on four separate occasions, two in a euhydrated state and two in a 
hyperhydrated state, the order of which was counterbalanced to prevent order effects.  
On arrival at the laboratory the protocol was described and patients provided written 
informed consent.  Each patient then completed the food diary describing what food 
and drink they had consumed over the previous 24-hour period.  Demographic 
characteristics, current medication, and medical co-morbidity were verified against 
details from patient’s hospital records.  Each patient was then asked to lay supine on 
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 the tilt table (Model 501, Plinth 2000, UK).  While in this position the body 
impedance analysis (BIA) was performed, the ECG and blood pressure (BP) cuff 
attached, and the cannula inserted.  Following instrumentation and instruction 
(approximately 30-minute), participants’ lay supine on the tilt table with their head 
supported for a period of 20-minutes.  During this baseline period BP measurements 
were obtained at after 13, 15, 17 and 19 minutes, with blood being drawn upon 
completion.  The patient then performed either the 12-minute mental or postural stress 
task, during which BP measurements were also obtained at minutes 5, 7, 9, and 11, 
with blood being drawn immediately upon completion.  This was followed by a 60-
minute recovery period in a supine position with BP measurements being taken at 
minutes 23, 25, 27, and 29, and minutes 53, 55, 57, and 59, with blood being drawn at 
30 and 60 minutes (see Figure 2.1).  
 
2.2.2.1 Hydration manipulation 
Patients completed testing sessions in one of two hydration states, euhydrated and 
hyperhydrated.  For the euhydration manipulation, patients were given one 500 ml 
bottle of still water and instructed to consume the fluid in the 12-hour period prior to 
arrival at the laboratory. For example, if the testing session commenced at 9:00 a.m 
the participants were instructed to consume 250 ml after 9:00 p.m on the evening 
prior to testing and the remaining 250 ml within the hour prior to the commencement 
of testing in the morning.  For the hyperhydrated manipulation, patients were given 
two 500 ml bottles contain water mixed with 50 mmol of Na+ (sodium citrate, 
Tribasic: Dihydrate, Sigma®) and one sodium saccharin tablet, and instructed to 
consume the fluid in the 12-hour period prior to arrival at the laboratory.  For both 
hydration manipulations, patients were instructed not to consume any food or other 
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 drinks in the 12-hour period prior to arrival at the laboratory, in addition to 
withholding an prescribed medication.  A dietary recall questionnaire was employed 
at the beginning each of the testing sessions to monitor food and fluid intake from the 
previous day and participants were asked to try and duplicate this as close as possible 
for each of the following testing sessions. 
 
2.2.2.2  Mental arithmetic stress task 
The participants were required to complete an eight minute version of the paced 
auditory serial addition test (PASAT) in the supine position [313]. This task involves 
adding two sequentially presented single digit (1 – 9) numbers, while retaining the 
latter of the two numbers in their memory for subsequent addition to the next number 
presented.  The task consisted of four two-minute periods with numbers being 
presented by a tape player (Sony, EFS-E14L) at rates of 4.0, 3.5, 3.0, and 2.5 seconds, 
respectively.  Prior to administration of the PASAT, the task was explained and the 
patient was given a brief practice, which consisted of the presentation of 10 numbers.  
Patients were told to call the answer out loud, and if performance broke down, to 
continue by adding the next two sequentially presented numbers.  The patients were 
also informed that their performance was being monitored and a loud noise burst 
would be delivered if they answered incorrectly or failed to respond.  The PASAT has 
been widely used as a laboratory stress task and has been shown to evoke significant 
cardiovascular, rheological, and haemostatic changes [314-317]. 
 
2.2.2.3 Postural stress task 
In the postural stress task, each participant was tilted head-up (64°), strapped to a tilt 
table for 12 minutes. This position was chosen because it elicits 90% of the 
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 cardiovascular response while avoiding the discomfort associated with standing 
upright on a tilt table [39].  A tilt of 12 minutes was chosen as it has been shown 
previously to elicit significant cardiovascular and rheological responses [315,319-
320].   
 
2.2.2.4 Cardiovascular measures 
Systemic blood pressure (systolic (SBP), diastolic (DBP), and mean arterial blood 
pressure (MAP)) and heart rate (HR) were measured from the left arm (unless 
contraindicated) using an automated auscultatory sphygmomanometer (Critikon, 
Dinamap).  The first of the series of BP measurements was initiated manually, with 
subsequent measures being initiated automatically every other minute.  Three dot 
ECG electrodes (Red Dot, 3M, Germany) were attached, two on the collar bone and 
one on a rib, to monitor the electrical activity of the heart. 
 
2.2.2.5 Body Impedance Analysis (BIA) 
Total body water (TBW), intracellular water (ICW) and extracellular water (ECW) 
were determined using a Bioelectrical Body Composition (BIA) Analyzer (Quantum 
X, RJL Systems, USA) with the participant lying supine on the tilt table [321].  Sites 
were exfoliated and cleaned (Mediswab) before tab electrodes (Q-Trace Gold 5500, 
Kendall, USA) were placed on the right side of the body.  The two signal electrodes 
were placed on the proximal phalanx of the middle finger and on the base of the 
second toe.  The two detecting electrodes were placed on imaginary lines bisecting the 
ulnar head and the mallealus.  Each participant’s fluid composition was obtained by 
inputting reactance and resistance into the Cyprus 1.2 program (RJL systems, USA). 
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 2.2.2.6 Blood measures 
2.2.2.6.1 Blood sampling  
The participant’s right arm was inspected for a suitable anticubital vein, and if 
unsuitable for cannulation, their left arm was inspected.  Venous access was obtained 
using an 18-gauge cannula (Venflon 2, Ohmeda, Sweden), attached to a 6-inch I.V. 
posiflow connector (B.D PosiFlow, Becton Dickinson, USA).  At each blood draw, 
the first 2 ml of blood was collected into a syringe and discarded.  Then, for each 
draw, 13.5 ml of blood was collected into one tube (2 ml) containing potassium 
ethylenediaminetetracetic acid (EDTA K3E 15 %, 0.054 ml, Vacuette, Greiner Bio-
one), two tubes (3 ml) containing sodium citrate (3.2% Buffered Sodium Citrate, 
Vacuette, Greiner Bio-one) and one tube (4.5 ml) containing citrate theophylline 
adenosine dipyridamole (CTAD, 3.2% Buffered Sodium Citrate, theophylline, 
adenosine, 0.3 ml dipyridamole, BD Vacutainer, Meylan Cedex).  An additional 
clotted serum tube (Vacuette, Greiner Bio-one) was also taken during the initial draw 
on each participant’s first visit.  The cannula was maintained patent throughout the 
testing session by flushing with 2 ml of saline following each draw (0.9%, NaCl).  All 
of the tubes were stored in melting ice until the end of the testing session. The clotted 
serum tube (5 ml) was sent to the biochemistry laboratory at City Hospital for liver 
and kidney function tests, blood glucose concentration, and a full lipid profile. 
   
2.2.2.6.2 Blood preparation and storage  
Citrated blood was centrifuged at 1000 rpm for 10 minutes and then the supernatant, 
platelet-rich plasma (PRP), was aspirated and placed in a clear plastic centrifugation 
tube.  A platelet count was performed using an automated haematology system (Advia 
120, Bayer Diagnostics, USA) and the PRP was spun with the remaining citrate and 
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 CTAD tubes at 3000 rpm for 20 minutes.  The platelet-poor plasma (PPP) from the 
citrate, CTAD, and centrifugation tubes was aliquoted into individual vials, and stored 
at -70°C, for later analysis.  The platelet pellet from the plastic centrifugation tube 
was re-suspended in sterile saline solution to give a platelet concentration 2 x 108/ml. 
   
The platelet adhesion assay [322] consisted of microtitre plates being coated with 
100μl of fibrinogen and incubated overnight at 4°C.  Any unbound fibrinogen was 
pipetted off and 100 μl of pooled platelet re-suspension solution was aliquoted into 
the microtitre wells and incubated for 60 minutes.  The supernatant was aspirated and 
lysed using 100 μl of 5% phosphate-buffered saline (PBS) Tween and stored as 
supernatant platelet lysate (SPL).  The wells were then carefully washed three times 
with saline, lysed with 5% PBS Tween, incubated for 30 minutes before the 
remaining solution was aspirated off and then stored as a bound plasma lysate (BPL).  
The remaining platelet re-suspension in the plastic centrifugation tube was lysed with 
0.1% PBS Tween and aliquoted into individual vials to perform the platelet lysate 
assay. 
 
2.2.2.7 Blood analysis 
2.2.2.7.1 Full Blood Count (FBC) 
Full blood count (FBC) was determined using an automated haematology system 
(Advia120, Bayer Diagnostics, USA), which provided measures of red blood cell 
(RBC) count (x 103), white blood cell (WBC) count (x 103), haemoglobin (Hb; g/dl), 
haematocrit (hct; %), total platelets (platelets; x 109/l), mean platelet volume (MPV) 
(fl), mean platelet mass (MPM) (g/dl), lymphocytes (x 109) neutrophils (x 109/l), 
monocytes (x 109/l).  
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 2.2.2.7.2 von Willebrand Factor (vWF) 
von Willebrand Factor (vWF) is a high-molecular weight procoagulant molecule 
(160kD) that has long been proposed as a marker of endothelium damage, and is of 
significant importance in haemostasis through its role in platelet-platelet and platelet-
sub-endothelium adhesion.  vWF was measured by commercially available ELISA 
(Dako, Glosrup, Denmark).  Raised levels of vWF have been demonstrated in a 
variety of cardio- and cerebrovascular disorders such as stroke [323-324], heart failure 
[325-326], coronary artery disease [327], AF [328-329], and hypertension [330-331]. 
  
2.2.2.7.3 P-Selectin (CD62P) 
P-selectin (CD62P, GMP-140, PADGEM) is a 140kD glycoprotein adhesion 
molecule which is a component of the cell-membrane within the alpha and dense 
granules [332], and Weibel-Palade bodies of the endothelial cells [333].  The 
membrane form of P-selectin has been shown to have a dual physiological role.  
Firstly, during inflammation, P-selectin is relocated onto the surface of activated 
endothelial cells where it mediates leukocyte rolling [334].  Secondly, in thrombosis, 
the expression of P-selectin in a thrombus supports the recruitment of leukocytes 
[332].  Soluble P-selectin (sP-sel) in plasma has been considered a marker of platelet 
activation [335] as P-selectin is proteolytically shed or actively cleaved from the cell 
surface (presumably by a non-specific enzyme or other mediator(s) that may arise 
from leukocytes, the endothelium, or else where) shortly after activation [335].   
 
Soluble P-selectin levels in plasma, intra-platelet P-selectin levels from the SPL 
(stored from the lysate and un-bound step of the adhesion assay), and BPL (stored 
from bound step of the adhesion assay) were all measured by ELISA.  Regents and 
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 recombinant human P-selectin (as a standard) were obtained from R&D Systems 
(UK) Ltd (Abingdon, Oxon, UK).  Levels of soluble P-selectin in plasma and the BPL 
were detected in a 1/5 dilution of phosphate-buffered saline, with the SPL being 
detected in a 1/10 dilution.   
 
2.2.2.7.4 E-Selectin (CD62E) 
E-selectin (CD62E) is a cell-surface bound leukocyte adhesion molecule specific to 
endothelial cells.  It mediates the interaction between leukocytes, platelets and the 
endothelium, and increased surface expression is thought to reflect endothelial 
activation [336].  The soluble form of E-selectin (sE-Sel) can be detected in healthy 
individuals, and although contradictory data exists, elevated levels have been found in 
patients with ischaemic heart disease [337], atherosclerosis [338], hypertension [339], 
and diabetes [340].  The only study to date to examining whether patients with AF 
had elevated levels of sE-selectin proved to be negative, demonstrating comparable 
levels compared to age- and sex-matched healthy controls in sinus rhythm [341]. 
 
Soluble E-selectin levels in plasma were measured by ELISA.  Regents and 
recombinant human E-selectin (as a standard) were obtained from R&D Systems 
(UK) Ltd (Abingdon, Oxon, UK).   
 
2.2.2.7.5 Other markers 
Total cholesterol (mmol/l) and triglycerides (mmol/l) were determined using a 
colometric system (Vitros 950, Johnson & Johnson, UK).  High density lipoprotein 
(HDL) cholesterol was determined using the direct HDL method (Sigma E2 HDL 
Cholesterol, Sigma diagnostics, UK).   
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 2.3 Data reduction and analysis 
Data was analysed using SPSS for Windows (Version 12.0.1).  All statistical tests 
were two tailed; p-values <.05 were considered statistically significant.  All 
dichotomous variables were coded zero or one, were one signified a worse outcome.  
All categorical variables were compared using the chi-square statistic.  The Yates 
continuity correction was used when there were expected frequencies of less than five 
in any cell. 
 
2.3.1 Questionnaire study 
Continuous variables were compared using independent t-tests; student’s t-test for 
parametric analysis, and Mann Whitney-U test for non-parametric analysis.  Quality-
of-life data was analyzed using correlation and multiple linear regression.  The 
demographic, clinical, and psychological variables that significantly correlated with 
quality of life at six-months were included in a multiple linear regression model.  In 
such analyses, BDI and STAI were treated as both continuous and dichotomous 
variables.  When both the continuous and dichotomous representation of a variable 
was significant, the continuous version was entered into the linear regression model. 
 
2.3.2 Stress study 
Continuous variables were compared using a one-way analysis of variance 
(ANOVA).  The cardiovascular measurements (SBP, DBP, MAP, HR) obtained 
during baseline, task, 30- and 60-minute recovery period were averaged separately to 
yield mean values.  A series of 4 time points (baseline, task, 30-minute recovery, 60-
minute recovery) X 3 participant groups (AF patients, hypertensive patients, healthy 
controls) repeated-measures multivariate analyses of variance (MANOVAs) were 
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 conducted for all cardiovascular, rheological, endothelial and platelet variables when 
participants attended in a euhydrated.   For all MANOVAs measures of effect size 
(η2) were reported.  Main effects for time and time X participant group interactions 
were explored further using Bonferroni post-hoc comparisons.  For the data presented 
in Tables and Figures 3.14 to 3.22, within-subject comparisons were undertaken using 
MANOVAs for parametric data and Friedman tests for non-parametric data, with 
between-subject comparison being undertaken using one-way ANOVAs and Kruskal-
Wallis tests, respectively.  Means (SD), standard error of the mean (SEM), and 
median (IQR) levels are reported where appropriate. 
 
For each stress task, changes in plasma volume were calculated using the following 
formula: Δplasma volume = 100 × (PVolTask − PVolBaseline) / PVolBaseline, where 
PVolBaseline is 100 minus baseline hematocrit [342].  The effect of postural-induced 
haemoconcentration on haemostatic markers was corrected for using the formula 
outlined below: 
 
 
 
 
 
 
 
Cadjusted = Cunadjusted (1+(  PVol/100) 
 
 
Cadjusted = concentration of marker when change in plasma volume have been 
accounted for  
 
Cunadjusted = concentration of marker prior to correction for changes in plasma 
volume  
To examine the effect of hydration status a series of 2 conditions (euhydrated, 
hyperhydrated) X 4 time points (baseline, task, 30-minute recovery, 60-minute 
recovery) MANOVAs were conducted on all cardiovascular, rheological, endothelial 
and platelet variables.  Main effects for condition were explored further using paired 
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 samples t-tests.  When a significant effect of condition was observed a series of 2 
condition (euhydrated, hyperhydrated) X 4 time points (baseline, task, 30-minute 
recovery, 60-minute recovery) X 3 participant groups (AF patients, hypertensive 
patients, healthy controls) MANOVAs were conducted.   
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Figure 2.1: Schematic representation of the procedure for the stress testing study 
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CHAPTER 3 
 
Results 
 
 
3.1 Questionnaire study 
 
3.1.1 Baseline characteristics of the eligible patients 
 
3.1.1.1 AF patients 
 
The demographic and clinical characteristics for the 101 participating AF patients are 
summarised in Table 3.1.  Also presented are the analogous data for the 93 patients who 
did not participate. With the exception of ethnicity, with Afro-Caribbean and South 
Asian patients more likely to refuse participation, no other significant differences in 
demographic and clinical characteristics between participants and non-participants were 
observed. 
 
The mean (SD) age of the AF participants was 66.3 (11.0) years (range; 24-84 years). 
The majority of the participants were male (61.4%), Caucasian (89.7%), and not 
currently employed (70.1%).  Further, most participants were likely to have either PAF 
(52.5%) or permanent AF (41.6%), with only a small percentage having persistent AF 
(5.9%).  The median (IQR) duration of AF was 21 months (range; 8-49 months).  
Hypertension was the most common coexisting cardiovascular co-morbidity (88.1%), 
followed by diabetes (10.9%).  With regards to medication, the majority of patients 
were receiving some form of anti-coagulant (warfarin 72.3%) or anti-platelet therapy 
(22.8%) (see Table 3.1). 
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Table 3.1: Demographic and clinical characteristics of the 194 eligible AF patients 
 
 
Participants 
(n = 101) 
Non-
participants 
(n = 93) 
Z t x2 p 
Demographic characteristics, n (%) 
Mean (SD) age, 
Years 
66.3 (11.0) 68.7 (10.6)  -1.52  .13 
Males 62 (61.4) 54 (55.7)   .10 .75 
Ethnicity 
    Caucasian 
     Afro-Caribbean 
     South-Asian 
 
96 (95.1) 
3 (3.0) 
2 (2.0) 
 
77 (82.8) 
7 (7.5) 
9 (9.7) 
   
 
7.83 
 
 
.02 
Occupational 
Status 
Employed 
 
38 (37.6) 
 
23 (24.7) 
   
3.20 
 
.08 
Mean (SD) 
deprivation score 
 
4.37 (3.80) 
 
4.78 (4.07) 
  
.88 
  
.38 
Clinical characteristics, n (%) 
Type of AF 
     Paroxysmal 
     Persistent 
     Permanent 
 
53 (52.5) 
6 (5.9) 
42 (41.6) 
 
38 (40.9) 
9 (9.7) 
46 (49.5) 
   
 
 
2.93 
 
 
 
.23 
Median (IQR) 
Duration of AF, 
Months 
 
21 (8 – 49) 
 
18 (8 – 54) 
 
.64 
 
 
  
.52 
Hypertension 89 (88.1) 79 (84.9)   .19 .66 
Diabetes 11 (10.9) 16 (17.2)   1.58 .21 
Myocardial 
Infarction 
 
6 (5.9) 
 
5 (5.4) 
   
.00 
 
.87 
Heart Failure 3 (3.0) 6 (6.4)   .66 .42 
Stroke 6 (5.9) 4  (4.3)   .04 .85 
Transient Ischemic 
Attack 
 
6 (5.9) 
 
7 (7.5) 
   
.02 
 
.88 
Current medication, n (%) 
Warfarin 75 (74.3) 63 (67.7)   .71 .40 
Antiplatelet 22 (22.8) 31 (33.3)   2.7 .10 
Digoxin 26 (25.7) 30 (32.2)   .71 .40 
Calcium Channel 
Blockers 
 
49 (48.5) 
 
37 (39.8) 
   
1.2 
 
.28 
Beta-Blocker 56 (55.4) 50 (53.8)   .00 .93 
Angiotensin-
converting-enzyme 
(ACE) inhibitor 
 
32 (31.7) 
 
36 (38.7) 
   
.76 
 
.38 
Statin 30 (29.7) 24 (25.8)   .20 .66 
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3.1.1.2 Hypertensive patients 
The demographic and clinical characteristics for the 97 participating hypertensive 
patients are summarised in Table 3.2.  Also presented are the analogous data for the 63 
hypertensive patients who were unwilling to participate. Once again, Afro-Caribbean 
and South Asian patients were more likely to refuse participation.  No other significant 
differences in demographic and clinical characteristics were observed. 
 
The mean (SD) age of the hypertensive participants was 68.0 (7.2) years (range; 50-84 
years).  The majority of the participants were male (61.4%), Caucasian (89.7%), and not 
currently employed (70.1%).  Diabetes was the most common coexisting cardiovascular 
co-morbidity (49.5%), followed by a history of MI (10.3%).  With regards to 
medication, less than half of the patients were receiving anti-platelet therapy (43.3%), in 
combination with a variety of other pharmacological agents  
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Table 3.2: Demographic and clinical characteristics of the 160 eligible hypertensive 
patients  
 
 
 
Participant 
(n = 97) 
Non-
participants 
(n = 63) 
t x2 p 
Demographic characteristics, n (%) 
Mean (SD) age, Years 68.0 (7.2) 68.9 (7.5) .80  .43 
Males 64 (66.0) 42 (66.7)  .00 1.00 
Ethnicity 
     Caucasian 
     Afro-Caribbean  
     South-Asian 
 
87 (89.7) 
9 (9.3) 
1 (1.0) 
 
48 (76.2) 
7 (11.1) 
8 (12.7) 
  
 
10.20 
 
 
<.01 
Occupational Status 
Employed 
 
29 (29.9) 
 
16 (25.4) 
  
.19 
 
.66 
Mean (SD) deprivation 
score 
 
4.74 (3.6) 
 
4.80 (3.9) 
 
.10 
 
 
 
.92 
Clinical characteristics, n (%) 
Diabetes 48 (49.5) 35 (55.6)  .35 .56 
Myocardial Infarction 10 (10.3) 6 (9.5)  .00 1.00 
Heart Failure 2 (2.1) 0 (0.0)  .18 .68 
Stroke 5 (5.2) 2 (3.2)  .04 .84 
Transient Ischemic Attack 6 (6.2) 1 (1.6)  1.00 .32 
Current medication, n (%) 
Warfarin 2 (2.1)  (3.2)  .00 1.00 
Antiplatelet 42 (43.3) 19 (30.2)  2.30 .13 
Diuretic 51 (52.6) 29 (43.0)  .42 .52 
Calcium channel blocker 39 (40.2) 30 (47.6)  .58 .45 
Beta–blocker 49 (50.5) 32 (50.8)  .00 1.00 
Alpha-blocker 53 (54.6) 35 (52.2)  .00 1.00 
Angiotensin converting 
enzyme (ACE) inhibitor 
 
42 (43.3) 
 
25 (37.3) 
  
.08 
 
.77 
Angiotensin II receptor 
blocker 
 
13 (13.4) 
 
8 (11.9) 
  
.00 
 
1.00 
Statin 57 (58.8) 28 (41.2)  2.60 .11 
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3.1.2 Demographic, clinical, and psychological characteristics of AF and 
hypertensive participants 
 
The demographic, clinical, and psychological characteristics of the 101 AF patients and 
97 hypertensive patients are summarised in Table 3.3.  No significant differences were 
observed in age, sex, ethnicity, occupational status, and deprivation score between the 
AF and hypertensive patients.  Although the hypertensive patients were more likely to 
have diabetes, the number of other cardiovascular co-morbidities was not significantly 
different between the two patient groups.  Both patient groups displayed similar levels 
of depression, state anxiety (mean score and percentage of scores > 10 on BDI and > 40 
on STAI), and QoL.  However, higher levels of trait anxiety (mean score and percentage 
of scores > 40 on STAI) were observed in the AF patients.  No significant differences in 
any of the psychological parameters were observed between PAF and permanent AF 
patients (data not shown). 
 
3.1.3 Baseline characteristics of the depressed (BDI score ≥10) and non-depressed 
(BDI score <10) AF participants 
 
The demographic and clinical characteristics of the 38 (37.6%) depressed and 63 
(62.4%) non-depressed AF patients are summarised in Table 3.4.  No significant 
differences in age, sex, ethnicity, occupational status, and deprivation score were 
observed between the depressed and non-depressed AF patients.  Depressed patients 
displayed higher levels of state and trait anxiety (mean score and percentage of scores > 
40 on STAI) and reported lower QoL. 
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Table 3.3: Demographic, clinical, and psychological characteristics of the AF and 
hypertensive patients 
 AF patients 
(n= 101) 
Hypertensive 
patients  
(n=97) 
Z t X2 p 
Demographic characteristics, n (%)  
Mean (SD) age, 
Years 
66.3 (11.0) 68.0 (7.2)  1.2  .23 
Males 62 (61.4) 64 (66.0)   .46 .50 
Ethnicity 
     White 
     Afro-Caribbean  
     South-Asian 
 
96 (95.0) 
3 (3.0) 
2 (2.0) 
 
87 (89.7) 
9 (9.3) 
1 (1.0) 
   
 
2.87 
 
 
.24 
Occupational 
Status 
 
38 (37.6) 
 
29.9 (29.9) 
   
.71 
 
.40 
Mean (SD) 
deprivation score 
 
4.37 (3.8) 
 
4.74 (3.6) 
  
.56 
 
 
 
.58 
Clinical characteristics, n (%) 
Significant co-
morbidity  
One  
Two or more 
 
 
57 (56.4) 
39 (38.6) 
 
 
50 (51.5) 
20 (20.6) 
   
 
 
2.07 
 
 
 
.15 
Hypertension, 
 
89 (88.1) 97 (100)   10.27 <.01 
Diabetes 11 (10.9) 47 (48.5)   31.92 <.01 
Myocardial 
Infarction, 
 
6 (5.9) 
 
11 (11.3) 
   
1.21 
 
.27 
Stroke 6 (5.9) 5 (5.2)   .00 1.00 
Transient Ischemic 
Attack 
 
6 (5.9) 
 
6 (6.2) 
   
.00 
 
1.00 
Psychological characteristics, n (%) 
Median (IQR) BDI 
score 
7.0 (3 – 13) 6.0 (2 – 10) -1.83   .07 
BDI score >10 38 (37.6) 29 (30.0)   1.00 .32 
Mean (SD) State 
Anxiety score 
 
35.2 (12.3) 
 
32.0 (12.0) 
  
1.85 
 
 
 
.06 
State Anxiety score 
>40, 
 
28 (27.7) 
 
22 (22.7) 
   
.23 
 
.63 
Mean (SD) Trait 
Anxiety score 
 
37.4 (12.6) 
 
33.3 (11.4) 
  
2.36 
  
.02 
Trait Anxiety score 
>40, 
 
38 (37.6) 
 
21 (21.6) 
  
.45 
  
.03 
Mean (SD) QoL 
score 
 
20.4 (5.7) 
 
19.9 (5.3) 
  
.58 
  
.57 
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Table 3.4: Demographic, clinical, and psychological characteristics of the depressed and 
non-depressed AF patients  
 Depressed 
(n=38) 
Non-
depressed 
(n=63) 
x2 T P 
Demographic characteristics, n (%) 
Mean (SD) age, Years 65.8 (10.1) 66.6 (11.5)  .34 .73 
Males 23 (60.5) 39 (61.9) .00  1.00 
Ethnicity 
     Caucasian 
     Afro-Caribbean  
     South-Asian 
 
38 (100.0) 
0 (0.0) 
0 (0.0) 
 
58 (92.1) 
3 (5.0) 
2 (3.2) 
 
 
 
3.17 
  
 
 
.21 
Occupational Status 
Employed 
 
14 (36.9) 
 
24 (38.1) 
 
.00 
  
1.00 
Mean (SD) deprivation score 4.0 (4.1) 4.5 (3.6)  .72 .48 
Clinical characteristic, n (%)  
Type of AF 
     PAF 
     Persistent 
     Permanent 
 
21 (55.3) 
1 (2.6) 
17 (44.7) 
 
33 (48.5) 
5 (7.9) 
25 (36.8) 
 
 
1.41 
  
 
.49 
Significant co-morbidity 
One  
Two or more 
 
16 (42.1) 
19 (50.0) 
 
41 (65.1) 
20 (31.7) 
 
 
3.42 
  
 
.65 
Psychological characteristics 
Mean (SD) state anxiety score 43.3 (13.5) 30.4 (8.5)  5.91 <.01 
State Anxiety score >40  
20 (52.6) 
 
8 (12.7) 
 
16.90 
  
<.01 
Mean (SD) Trait Anxiety 
Score 
 
47.3 (12.3) 
 
31.4 (8.4) 
 
 
 
7.71 
 
<.01 
State Anxiety score >40 27 (71.1) 11 (17.5) 26.77  <.01 
Mean (SD) QoL score 23.4 (5.3) 18.5 (5.1)  4.55 <.01 
 
3.1.4 Baseline characteristics of the anxious and non-anxious AF participants 
3.1.4.1 State anxiety 
The demographic and clinical characteristics of the 28 (27.7%) anxious and 68 (72.3%) 
non-anxious AF patients are summarised in Table 3.5.  No significant group differences 
were observed between the anxious and non-anxious patients.  Anxious patients 
reported higher levels of depression (mean and number of scores > 10 on BDI), trait 
anxiety (mean level and number of scores > 40 on STAI), and had a lower QoL. 
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Table 3.5: Demographic, clinical, and psychological characteristics of the anxious and 
non-anxious (state) AF patients 
 Anxious 
(n=28) 
Non-
Anxious 
(n=73) 
Z t x2 P 
Demographic characteristics, n (%) 
Mean (SD) age, 
Years 
63.5 (12.8) 67.4 (10.1)  1.60  .11 
Males 16 (57.1) 46 (63.0)   .10 .75 
Ethnicity 
     Caucasian  
     Afro-Caribbean  
     South-Asian 
 
28 (100.0) 
0 (0.0) 
0 (0.0) 
 
68 (93.2) 
3 (4.1) 
2 (2.7) 
   
 
 
2.02 
 
 
 
.37 
Occupational 
Status 
Employed 
 
12 (42.9) 
 
26 (35.6) 
   
.20 
 
.66 
Mean (SD) 
deprivation score 
 
3.9 (4.4) 
 
4.6 (3.5) 
  
.79 
 
 
 
.43 
Clinical characteristics, n (%) 
Type of AF 
     PAF 
     Persistent 
     Permanent 
 
13 (46.4) 
1 (3.6) 
14 (50.0) 
 
40 (54.8) 
5 (6.8) 
28 (38.4) 
   
 
 
1.30 
 
 
 
.52 
Significant co-
morbidity  
One  
Two or more 
 
 
13 (52.0) 
12 (48.0) 
 
 
44 (62.0) 
27 (38.0) 
   
 
 
.41 
 
 
 
.53 
Psychological characteristics, n (%) 
Median (IQR) BDI 
score 
 
15.5 (8 – 22) 
 
6.0 (3 – 10) 
 
-5.15 
   
<.01 
BDI score >10 20 (71.4) 18 (24.7)   16.92 <.01 
Mean (SD) trait 
anxiety score 
 
51.9 (8.4) 
 
31.8 (9.0) 
  
-10.20 
 
 
 
<.01 
Trait Anxiety score 
>40 
 
27 (96.4) 
 
11 (15.1) 
   
53.70 
 
<.01 
Mean (SD) QoL 
score 
 
23.7 (5.5) 
 
19.1 (5.2) 
  
-3.91 
  
<.01 
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3.1.4.2 Trait anxiety 
 
The demographic and clinical characteristics of the 29 (28.7%) anxious and 68 (67.3%) 
non-anxious AF patients are summarised in Table 3.6.  With the exception of age, with 
younger AF patients displaying greater levels of anxiety, no other significant group 
differences were observed for sex, ethnicity, occupational status, and deprivation score.  
Anxious patients reported higher levels of depression (mean and number of scores > 10 
on BDI), state anxiety (mean level and number of scores > 40 on STAI), and had a 
lower QoL. 
 
3.1.5 Baseline characteristics of the depressed (BDI score ≥ 10) and non-depressed 
(BDI score < 10) hypertensive participants 
 
The demographic and clinical characteristics of the 29 (30.0%) depressed and the 68 
(70.0%) non-depressed hypertensive patients are summarised in Table 3.7.  No 
significant group differences were observed for age, sex, ethnicity, occupational status, 
and deprivation score between the depressed and non-depressed hypertensive patients.  
As with the AF patients, depressed hypertensive patients displayed higher levels of state 
and trait anxiety (mean score and number of scores > 40 on STAI), and reported a lower 
QoL. 
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Table 3.6: Demographic, clinical, and psychological characteristics of the anxious and 
non-anxious (trait) AF patients 
 Anxious 
(n=38) 
Non-
Anxious 
(n=63) 
Z t x2 P 
Demographic characteristics, n (%) 
Mean (SD) age, 
Years 
63.0 (13.7) 68.3 (8.5)  2.42  .02 
Males 22 (58.0) 40 (63.5)   .12 .73 
Ethnicity 
     Caucasian  
     Afro-Caribbean  
     South-Asian 
 
37 (97.4) 
0 (0.)) 
1 (2.6) 
 
59 (93.7) 
3 (4.8) 
1 (1.5) 
   
 
 
1.98 
 
 
 
.37 
Occupational 
Status 
Employed 
 
14 (36.9) 
 
24 (38.1) 
   
.00 
 
1.00 
Mean (SD) 
deprivation score 
 
3.9 (4.0) 
 
4.7 (3.7) 
  
.99 
 
 
 
.32 
Clinical characteristics, n (%) 
Type of AF 
     PAF 
     Persistent 
     Permanent 
 
19 (50.0) 
1 (2.6) 
18 (47.4) 
 
34 (54.0) 
4 (7.9) 
24 (38.1) 
   
 
 
1.68 
 
 
 
.43 
Significant co-
morbidity  
One  
Two or more 
 
 
18 (47.4) 
17 (44.7) 
 
 
39 (61.9) 
22 (34.9) 
   
 
 
.97 
 
 
 
.33 
Psychological characteristics, n (%) 
Median (IQR) BDI 
score 
 
14.5 (8 – 21) 
 
5.0 (2 – 8) 
 
-6.12 
   
<.01 
BDI score >10 27 (71.1) 11 (17.5)   27.77 <.01 
Mean (SD) state 
anxiety score 
 
46.7 (11.2) 
 
28.3 (6.2) 
  
10.70 
 
 
 
<.01 
State Anxiety score 
>40 
 
27 (71.1) 
 
1 (1.6) 
   
53.70 
 
<.01 
Mean (SD) QoL 
score 
 
23.5 (5.6) 
 
18.5 (4.8) 
  
4.55 
  
<.01 
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Table 3.7: Demographic, clinical, and psychological characteristics of the depressed and 
non-depressed hypertensive patients  
 Depressed 
(n=29) 
Non-
depressed 
(n=68) 
X2 t P 
Demographic characteristics, n (%) 
Mean (SD) age, Years 66.2 (7.6) 68.6 (6.9)  1.48 .14 
Males 15 (51.7) 50 (73.5) 3.44  .06 
Ethnicity 
     Caucasian 
     Afro-Caribbean 
     South-Asian 
 
25 (86.2) 
3 (10.3) 
1 (3.4) 
 
65 (95.6) 
3 (4.4) 
0 (0.0) 
 
 
 
2.66 
  
 
 
.27 
Occupational Status 
Employed 
 
9 (31.0) 
 
21 (30.9) 
 
.00 
  
1.00 
Mean (SD) deprivation 
score 
 
4.4 (3.6) 
 
4.8 (3.5) 
 
 
 
.56 
 
.58 
Clinical characteristics, n (%) 
Significant co-morbidity 
One  
Two or more 
 
16 (55.2) 
8 (27.6) 
 
34 (50.0) 
12 (17.6) 
 
 
.13 
  
 
.72 
Diabetes 15 (51.7) 32 (47.1) .04  .84 
Psychological characteristics  
Mean (SD) state anxiety 
score 
 
43.5 (12.3) 
 
27.1 (7.8) 
 
 
 
7.80 
 
<.01 
State Anxiety score >40 16 (55.2) 6 (8.8) 22.30  <.01 
Mean (SD) Trait Anxiety 
score 
 
44.4 (11.3) 
 
28.5 (7.4) 
 
 
 
8.07 
 
<.01 
Trait Anxiety score >40 17 (58.6) 
 
4 (5.9) 30.30  
 
<.01 
Mean (SD) QoL score 23.1 (5.4) 18.4 (4.6)  4.33 <.01 
 
3.1.6 Baseline characteristics of the anxious and non-anxious hypertensive 
participants 
3.1.6.1 State anxiety 
The demographic and clinical characteristics of the 22 (22.7%) anxious and 68 (73.3%) 
non-anxious hypertensive patients are summarised in Table 3.8.  With the exception of 
age, with younger hypertensive patients displaying greater levels of anxiety, no other 
significant differences were observed in, sex, ethnicity, occupational status, and 
deprivation score between the anxious and non-anxious patients.  Anxious patients 
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reported higher levels of depression (mean and number of scores > 10 on BDI), trait 
anxiety (mean level and number of scores > 40 on STAI), and had a lower QoL. 
 
Table 3.8: Demographic, clinical, and psychological characteristics of the anxious and 
non-anxious (state) hypertensive patients 
 Anxious 
(n=22) 
Non-Anxious 
(n=71) 
Z t x2 p 
Demographic characteristics, n (%)  
Mean (SD) age, Years 64.3 (8.5) 68.6 (6.2)  2.58  <.01 
Males 11 (50.0) 53 (74.6)   3.67 .06 
Ethnicity 
     Caucasian 
     Afro-Caribbean  
     South-Asian 
 
20 (90.9) 
1 (4.5) 
1 (4.5) 
 
64 (90.1) 
7 (9.9) 
0 (0.0) 
   
 
 
3.51 
 
 
 
.15 
Occupational Status 
Employed 
 
10 (45.4) 
 
20 (28.2) 
   
2.10 
 
.21 
Mean (SD) 
deprivation score 
 
4.1 (3.8) 
 
4.8 (3.4) 
  
.83 
 
 
 
.41 
Clinical characteristics, n (%) 
Significant co-
morbidity  
One  
Two or more 
 
 
12 (63.2) 
7 (36.8) 
 
 
36 (75.0) 
12 (25.0) 
 
 
  
 
 
.45 
 
 
 
.50 
Psychological characteristics, n (%) 
Median (IQR) BDI 
score 
13.0 (9 – 17) 5.0 (2 – 8) -5.05   <.01 
BDI score >10  
16 (72.7) 
 
12 (16.9) 
   
22.29 
 
<.01 
Mean (SD) trait 
anxiety score 
 
48.0 (10.1) 
 
28.8 (7.1) 
  
-9.94 
 
 
 
<.01 
Trait Anxiety score 
>40 
 
16 (72.7) 
 
5 (7.0) 
   
37.78 
 
<.01 
Mean (SD) QoL score 24.6 (5.2) 18.2 (4.3)  -5.78  <.01 
 
 
3.1.6.2 Trait anxiety 
The demographic and clinical characteristics of the 21 (21.6%) anxious and 72 (74.2%) 
non-anxious hypertensive patients are summarised in Table 3.9.  No significant group 
differences were observed for ethnicity, occupational status, and deprivation score.  
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However, the anxious patients were more likely to be younger and female.  Anxious 
patients also displayed higher levels of depression (mean and number of scores > 10 on 
BDI), state anxiety (mean level and number of scores > 40 on STAI), and reported a 
lower QoL. 
 
 
Table 3.9: Demographic, clinical, and psychological characteristics of the anxious and 
non-anxious (trait) hypertensive patients 
 Anxious 
(n=21) 
Non-Anxious 
(n=72) 
Z T X2 P 
Demographic characteristics  
Mean (SD) age, Years 63.4 (7.9) 68.8 (6.3)  3.25  <.01 
Males 7 (33.3) 57 (79.2)   13.90 <.01 
Ethnicity 
    Caucasian 
     Afro-Caribbean  
     South-Asian 
 
18 (85.7) 
2 (9.5) 
1 (4.8) 
 
66 (91.7) 
6 (8.3) 
0 (0.0) 
   
 
 
3.52 
 
 
 
.17 
Occupational Status 
Employed; N, (%) 
 
10 (47.6) 
 
20 (27.8) 
   
2.10 
 
.15 
Mean (SD) 
deprivation score 
 
4.9 (4.0) 
 
4.6 (3.4) 
  
.29 
 
 
 
.77 
Clinical characteristics  
Significant co-
morbidity  
One  
Two or more 
 
 
11 (52.4) 
5 (23.8) 
 
 
37 (51.4) 
14 (19.4) 
 
 
  
 
 
.00 
 
 
 
1.00 
Psychological characteristics 
Median (IQR) BDI 
score 
13.0 (11 – 18) 5.0 (2 – 8) -6.00   <.01 
BDI score >10 
 
 
17 (81.0) 
 
11 (15.3) 
   
30.30 
 
<.01 
Mean (SD) state 
anxiety score 
 
48.1 (11.3) 
 
27.3 (7.2) 
  
10.13 
 
 
 
<.01 
State Anxiety score 
>40, N, 
 
16 (76.2) 
 
6 (7.2) 
   
37.80 
 
<.01 
Mean (SD) QoL score 25.1 (5.1) 18.2 (4.2)  6.21  <.01 
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3.1.7 Persistence of depression over the six-month follow-up period 
3.1.7.1 AF patients 
The persistence of depression in AF patients over the initial six-month follow-up is 
depicted in Figure 3.1.  The median (IQR) BDI score at baseline was 7.0 (3.0 – 13.0), 
with 38 (37.6%) patients reporting significant levels of depressive symptoms (BDI 
score > 10).  The BDI was returned and completed at six-months by 76 (75.2%) AF 
patients; the median (IQR) BDI score was 7.0 (3.0 – 12.8).  Of these patients, 
depression was present at follow-up in 28 (36.8%) individuals.  Of the AF patients 
depressed at baseline, 52.6% continued to report significant depressive symptoms at six-
months.  
  
Figure 3.1: Persistence of depression over the six-month follow-up period in patients 
with AF  
194 Eligible AF patients 
29
9 Not 
depressed 
9 refused 6-month 
follow-up 
Followed-up at 
6-months 
20 Depressed 
47
13 refused 6-month 
follow-up 
39 Not 
depressed 
8 Depressed 
63 Not depressed 38 Depressed 
101 Participants 
93 refused participation 
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3.1.7.2   Hypertensive patients 
 
The persistence of depression in hypertensive patients over the initial six-month follow-
up is depicted in Figure 3.2.  The median (IQR) BDI score at baseline was 6.0 (2 – 10), 
with 29 (30.0%) patients reporting significant depressive symptoms (BDI score > 10).  
The BDI was returned and completed at six-months by 68 (70.1%) patients with 
hypertension; the median (IQR) BDI score was 6.0 (2.25 – 10.75).  Of these patients, 
depression was apparent at follow-up in 20 individuals (29.4%).  Of the hypertensive 
patients depressed at baseline, 48.3% continued to report significant depressive 
symptoms at six-months.  
 
Figure 3.2: Persistence of depression over the six-month follow-up period in patients 
with hypertension  
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3.1.8 Persistence of anxiety over the six-month follow-up period 
 
3.1.8.1 State anxiety in AF patients 
 
The persistence of state anxiety in AF patients over the initial six-month follow-up is 
depicted in Figure 3.3.  The mean (SD) state anxiety score at baseline was 35.2 (12.3), 
with 28 (27.7%) patients reporting high levels of state anxiety (STAI-S scores > 40).  
The STAI-S was returned and completed at six-months by 72 (71.3%) patients; the 
mean (SD) score was 35.6 (12.3).  Of these patients, high levels of state anxiety were 
present at follow-up in 24 individuals (33.3%).  Of the AF patients reporting high levels 
of state anxiety at baseline, 57.1% continued to report elevated scores at six-months. 
 
Figure 3.3: Persistence of state anxiety over the six-month follow-up period in patients 
with AF  
194 Eligible AF patients 
23
7 Not 
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5 refused 6-month 
follow-up 
Followed-up at 
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16 Anxious 
49
24 refused 6-month 
follow-up 
41 Not 
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8 Anxious 
73 Not Anxious28 Anxious
101 Participants 
93 refused participation 
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3.1.8.2 Trait anxiety in AF patients  
 
The persistence of trait anxiety in AF patients over the initial six-month follow-up is 
depicted in Figure 3.4.  The mean (SD) trait anxiety score at baseline was 37.4 (12.6), 
with 38 (37.6%) patients reporting high levels of trait anxiety (STAI-T scores > 40).  
The STAI-T was returned and completed at six-months by 72 (71.3%) patients; the 
mean (SD) score was 36.9 (12.5).  Of these patients, high levels of trait anxiety were 
apparent at follow-up in 24 individuals (33.3%).  Of the AF patients reporting high 
levels of trait anxiety at baseline, 52.6% continued to report high levels at six-months. 
 
Figure 3.4: Persistence of trait anxiety over the six-month follow-up in patients with AF  
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3.1.8.3 State anxiety in hypertensive patients  
The persistence of state anxiety in hypertensive patients over the initial six-month 
follow-up is depicted in Figure 3.5.  The mean (SD) state anxiety score at baseline was 
32.0 (12.0), with 22 (22.7%) patients reporting high levels of state anxiety (STAI-S 
scores > 40).  The STAI-S was returned and completed at six-months by 67 (69.2%) 
patients; the mean (SD) score was 31.61 (11.9).  Of these patients, high levels of state 
anxiety were present at follow-up in 24 (33.3%) individuals.  Of the hypertensive 
patients reporting high levels of state anxiety at baseline, 57.1% continued to report 
high levels at six-months. 
 
Figure 3.5: Persistence of state anxiety over the first six-month follow-up in patients 
with hypertension  
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3.1.8.4 Trait anxiety in hypertensive patients  
The persistence of trait anxiety in hypertensive patients over the initial six-month 
follow-up is depicted in Figure 3.6.  The mean (SD) trait anxiety score at baseline was 
33.3 (11.4), with 21 (21.6%) patients reporting high levels of trait anxiety (STAI-T 
scores > 40).  The STAI-T was returned and completed at six-months by 67 (69.1%) 
patients; the mean (SD) score was 32.6 (11.2).  Of these patients, high levels of trait 
anxiety were present at follow-up in 17 (25.4%) individuals.  Of the hypertensive 
patients reporting high levels of trait anxiety at baseline, 52.6% continued to report high 
levels at six-months. 
 
Figure 3.6: Persistence of trait anxiety over the first six-month follow-up in patients 
with hypertension  
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3.1.9 Six-month outcomes measures 
3.1.9.1 Quality of life in AF patients 
The mean (SD) quality of life score at baseline was 20.4 (5.7).  The Dartmouth COOP 
charts were completed and returned at six-months by 71 (70.3%) patients; the mean 
(SD) score was 20.2 (6.2).  Table 3.10 summarises the correlation coefficients of 
baseline demographic, clinical, and psychological variables with quality of life at six-
month follow-up.  Of the variables entered, gender, ethnicity, employment status, total 
and dichotomised BDI score (< 10 and > 10), total and dichotomised state and trait 
anxiety scores (< 40 and > 40) all correlated significantly with quality life at six-
months.  Significant variables were then entered into a stepwise regression model.  
When both the continuous and dichotomous representation of a variable were 
significant, the continuous version was entered into the model.  As shown in Table 3.11, 
baseline BDI score afforded the best independent predictor of six-month QoL in 
patients with AF, with gender and current employment status also predicting.  The full 
model accounted for 34% of the variance in QoL at six-months. 
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Table 3.10: Correlation between baseline demographic, clinical and psychological 
characteristics and quality of life scores at six months in AF patients (n=70) 
 Correlation with quality of life 
scores at six months 
Significance 
 (p) 
Demographic characteristics  
Age (years) 0.12 0.17 
Gender -0.35 0.01 
Ethnicity -0.27 0.01 
Employment status 0.23 0.03 
Deprivation score (based on postcode) 0.11 0.18 
Clinical characteristics 
Type of AF -0.01 0.48 
Duration of AF -0.02 0.45 
Psychological characteristics 
Total BDI score 0.47 <0.001 
BDI scores above and below cut-off 
(dichotomised <10 or >10) 
 
0.33 
 
<0.001 
Total state anxiety score 0.42 <0.001 
State anxiety scores above and below cut-off 
(dichotomised <40 or >40) 
 
0.31 
 
0.001 
Total trait anxiety score 0.41 <0.001 
Trait anxiety scores above and below cut-off 
(dichotomised <40 or >40)  
 
0.38 
 
0.005 
 
Table 3.11: Independent baseline predictors of six month quality of life (stepwise linear 
regression model) in AF patients 
Model Contribution 
to R2 
B Beta 95% CI for B F Significance 
(p) 
1. BDI 0.20 0.41 0.46 0.22 - 0.60 18.90 <0.001 
 
2. BDI 
    Gender 
0.29 0.38 
-3.88 
 
0.43 
-0.31 
0.20 - 0.56 
-6.42- -1.34 
 
15.22 
 
<0.001 
3. BDI 
    Gender 
    Employment 
0.34 0.41 
-3.40 
3.22 
0.47 
-0.27 
0.24 
0.24 – 0.59 
-5.90 - -0.92 
0.55 – 5.90 
12.79 <0.001 
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3.1.9.2 Mortality and MACE in AF patients 
No deaths occurred during the initial six-month follow-up in patients with AF, with 
only one MACE being reported (transient ischaemic attack (TIA)). 
 
3.1.9.3 Quality of life in hypertensive patients  
The mean (SD) quality of life score at baseline was 19.9 (5.3).  The Dartmouth COOP 
charts were completed and returned at six-months by 68 (70.1%) patients, with a mean 
(SD) score of 20.5 (6.2).  Table 3.12 summarises the correlation coefficients of baseline 
demographic, clinical, and psychological variables with quality of life at six-month 
follow-up.  Of the variables entered, employment status, total and dichotomised BDI 
score (< 10 and > 10), total and dichotomised state and trait anxiety scores (< 40 and > 
40) all correlated significantly with quality life at six-months.  Significant variables 
were again entered into a stepwise regression model.  As before, when both the 
continuous and dichotomous representation of a variable were significant, the 
continuous version was entered into the model.  As shown in Table 3.13, baseline BDI 
score afforded the best independent predictor of six-month QoL in patients with 
hypertension, with current employment status also being entered into the model.  The 
total model accounted for 18% of the variance in QoL at six-months. 
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Table 3.12: Correlation between baseline demographic and psychological characteristics 
and quality of life scores at six months in hypertensive patients (n=65) 
 Correlation with quality of life 
scores at six months 
Significance 
 (p) 
Demographic characteristics  
Age (years) 0.06 0.31 
Gender -0.14 0.13 
Ethnicity -0.12 0.17 
Employment status 0.27 0.02 
Deprivation score (based on postcode) 0.10 0.22 
Psychological characteristics 
Total BDI score 0.35 <0.01 
BDI scores above and below cut-off 
(dichotomised <10 or >10) 
 
0.27 
 
0.02 
Total state anxiety score 0.30 <0.01 
State anxiety scores above and below cut-off 
(dichotomised <40 or >40) 
 
0.30 
 
<0.01 
Total trait anxiety score 0.34 <0.01 
Trait anxiety scores above and below cut-off 
(dichotomised <40 or >40)  
 
0.36 
 
<0.01 
 
Table 3.13: Independent baseline predictors of six month quality of life (stepwise linear 
regression model) in hypertensive patients 
Model Contribution 
to R2 
B Beta 95% CI for B F Significance 
(p) 
1. BDI 0.11 0.32 0.35 0.11 – 0.53 9.00 <0.01 
 
2. BDI 
    Employment 
0.18 0.34 
3.84 
0.37 
0.29 
0.13 – 0.54 
0.83 – 6.84 
8.15 0.01 
 
 
3.1.9.4 Mortality and MACE in hypertensive patients 
One death occurred during the first six-months of follow-up among the hypertensive 
patients, with two individuals being admitted for a MACE (TIA, MI/CABG). 
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3.1.10 Summary of main findings 
 
• AF and hypertensive patients displayed similar levels of depression, state 
anxiety, and QoL.  
• AF patients displayed higher levels of trait anxiety than patients with 
hypertension. 
• No significant differences in any of the psychological parameters were observed 
between PAF and permanent AF patients. 
• Depression and anxiety (state and trait) were common co-morbid conditions in 
both AF and hypertensive patients. 
• Significant symptoms of depression (BDI score > 10) persisted at six-months in 
approximately 50% of patients at six-months (52.6% vs. 48.3% for AF and 
hypertensive patients, respectively). 
• BDI score afforded the best independent predictor of six-month QoL in patients 
with AF and hypertension, with gender and current employment status also 
being entered into the model for patients with AF. 
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3.2 Stress study 
3.2.1 Baseline characteristics of participants 
The demographic and clinical characteristics of the participants, 14 AF patients, 10 
hypertensive patients, and 10 healthy individuals are summarised in Table 3.14.  All 
three groups were comparable in terms of age, ethnicity, occupational status, and body 
mass index (BMI).  Clinically, with the exception of warfarin, no significant differences 
in co-morbidity and medication usage were observed between the AF and hypertensive 
patients. 
 
3.2.2 Mental stress 
3.2.2.1 Haemodynamic reactivity 
The haemodynamic reactivity to mental stress in the euhydrated state is summarised in 
Table 3.15 and Figures 3.7 to 3.10.  Four time points X three participant group 
MANOVAs revealed temporal effects for all haemodynamic variables: systolic blood 
pressure (SBP), F (3,93) = 36.36, p<.001, η2 = .54, diastolic blood pressure (DBP), F 
(3,93) = 23.40, p<.001, η2 = .43, mean arterial pressure (MAP), F (3,93) = 31.85, 
p<.001, η2 = .51, and heart rate (HR), F (3,93) = 42.30, p<.001, η2 = .58.  Post-hoc 
analyses showed that SBP, DBP, MAP, and HR were elevated following the stress task 
(p<.05), with only SBP and HR returning to baseline levels at 30 and 60-minutes 
recovery.  Time X participant group interactions demonstrated that no significant 
differences in the temporal response to stress emerged for the three participant groups 
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Table 3.14: Baseline demographic and clinical characteristics of the AF and 
hypertensive patients and healthy individuals 
 
 
AF 
patients 
(n = 14) 
Hypertensive 
patients 
(n = 10) 
Healthy 
controls 
(n = 10) 
F x2 P 
Demographic characteristics, n (%) 
Mean (SD) age, Years 67.4 (6.1) 66.9 (5.0) 63.2 (4.3) 1.99  0.15 
Ethnicity, N, (%) 
     Caucasian 
     Afro-Caribbean 
     South-Asian 
 
14 (100.0) 
0 (0.0) 
0 (0.0) 
 
10 (100.0) 
0 (0.0) 
0 (0.0) 
 
8 (80.0) 
1 (10.0) 
1 (10.0) 
 
 
 
5.10 
 
0.27 
Mean (SD) BMI, 
Kg/M2  
 
27.1 (4.0) 
 
28.0 (3.8) 
 
24.4 (3.3) 
 
2.38 
  
0.11 
Clinical characteristics, n (%) 
Hypertension 14 (100.0) 10.0 (100.0)     
Myocardial 
Infarction 
 
2 (14.3) 
 
1 (10.0) 
  
 
 
0.00 
 
1.00 
Coronary artery 
disease  
 
3 (21.4) 
 
2 (20.0) 
   
0.00 
 
1.00 
Stroke 3 (21.4) 1 (10.0)   0.03 0.84 
Transient Ischemic 
Attack 
 
1 (7.1) 
 
0 (0.0) 
  
 
 
0.00 
 
1.00 
Current Medication, n (%) 
Warfarin 11 (78.6) 0 (0.0)   11.51 <0.01 
Antiplatelet 4 (28.6) 5 (50.0)   0.41 0.52 
Digoxin 3 (21.4) 0 (0.0)   0.88 0.35 
Diuretics 8 (57.1) 2 (20.0)   1.96 0.16 
Beta-Blocker 6 (42.9) 1 (10.0)   1.67 0.20 
Calcium Channel 
Blockers 
 
7 (50.0) 
 
6 (60.0) 
   
0.00 
 
0.95 
Angiotensin-
converting-enzyme 
(ACE) inhibitor 
 
 
4 (28.6) 
 
 
6 (60.0) 
   
 
1.25 
 
 
0.26 
Angiotensin-II-
receptor blocker 
 
5 (35.7) 
 
0 (0.0) 
   
2.61 
 
0.11 
Statin 9 (64.3) 8 (80.0)   0.14 0.70 
 
3.2.2.2 Rheological reactivity 
Table 3.16 displays the rheological reactivity to mental stress in the euhydrated state. 
MANOVA yielded a significant temporal effect for haematocrit (Hct), F (3,93) = 3.10, 
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p<0.05, η2 = .09, with levels increasing during the stress task (p<.05) and returning back 
to baseline levels at 30 and 60-minutes recovery.  Although no significant time X 
participant interaction effect was observed, F (6,93) = 1.73, p = .14, η2 = .10, further 
analysis demonstrated that the AF patients were the only group to demonstrated a 
significant rise (1.6%) during the stress task. 
 
Table 3.15: Mean (SD) haemodynamic response to mental stress in a euhydrated state 
 AF Patients 
(n = 14) 
Hypertensive Patients 
(n = 10) 
Healthy Controls 
(n = 10) 
SBP (mmHg)    
Baseline (1) 133.7 (18.2) 144.7 (8.9) 120.8 (12.5) 
Task (2) 150.0 (18.7)* 160.5 (11.3)* 141.4 (10.7)*  
30-min recovery (3) 139.8 (18.1)** 149.0 (11.3)**  124.1 (18.0)**  
60-min recovery (4) 140.4 (19.2)** 149.9 (13.8)  123.7 (19.6)**  
DBP (mmHg)    
Baseline (1) 78.6 (7.4) 80.3 (8.5) 74.9 (7.2) 
Task (2) 86.4 (9.4)* 86.9 (10.1)* 84.2 (5.6)* 
30-min recovery (3) 82.7 (9.6) 85.5 (11.7) 77.9 (7.5)** 
60-min recovery (4) 84.5 (9.9)* 84.0 (11.3) 78.0 (8.7)** 
MAP (mmHg)    
Baseline (1) 99.8 (11.4) 104.1 (9.5)§ 91.3 (10.5) 
Task (2) 108.7 (12.0)* 116.0 (10.1)* 105.3 (10.8)* 
30-min recovery (3) 104.1 (9.3) 109.9 (11.7)§ 95.8 (11.7)**  
60-min recovery (4) 106.8 (14.5) 109.7 (11.6)§ 94.4 (12.3)**  
HR (Beats/min)    
Baseline (1) 65.9 (13.1) 56.1 (5.4) 53.2 (5.5)† 
Task (2) 74.0 (15.1)* 64.7 (6.0)* 62.8 (10.5)* 
30-min recovery (3) 63.9 (13.4)**  59.3 (6.0) 53.6 (5.0)† 
60-min recovery (4) 63.8 (13.4)**  57.3 (5.6)** 52.2 (5.0) † 
* Significantly different from baseline (p<.05) 
** Significantly different from task (p<.05) 
† Significantly different from AF patients (p<.05) 
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Figure 3.7: Systolic blood pressure response to mental stress in a euhydrated state 
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Figure 3.8: Diastolic blood pressure response to mental stress in a euhydrated state 
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Figure 3.9: Mean arterial blood pressure response to mental stress in a euhydrated state 
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Figure 3.10: Heart rate response to mental stress in a euhydrated state 
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Table 3.16: Mean (SD) haematocrit response to mental stress in a euhydrated state  
 AF Patients 
(n = 14) 
Hypertensive Patients 
(n = 10) 
Healthy Controls 
(n = 10) 
Hct (%)    
Baseline (1) 39.9 (4.6) 42.2 (2.5) 38.6 (3.6) 
Task (2) 41.5 (3.9)* 42.1 (2.6) 39.4 (3.3) 
30-min recovery (3) 40.7 (4.7) 41.9 (2.3) 39.6 (3.4) 
60-min recovery (4) 40.6 (5.0) 42.3 (3.0) 39.6 (3.2) 
* Significantly different from baseline (p<.05) 
 
3.2.2.3 Endothelial reactivity 
A summary of the endothelial reactivity to mental stress in the euhydrated state is 
illustrated in Table 3.17.  Although MANOVAs showed no temporal effects for von 
Willebrand Factor (vWF), F (3,93) = 2.38, p = .09, η2 = .07, and soluble E-selectin (sE-
sel), F (3,93) = 2.85, p = .07, η2 = .08, there was a trend for vWF levels to increase 
during the task in all three participant groups.  Statistical adjustment for mental stress-
induced haemoconcentration attenuated the increase in vWF levels observed in AF 
patients and healthy controls.  Time X participant group interactions demonstrated that 
no significant differences in the temporal response to stress emerged for the three 
participant groups. 
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Table 3.17: Endothelial response to mental stress in a euhydrated state  
 AF Patients 
(n = 14) 
Hypertensive Patients 
(n = 10) 
Healthy Controls 
(n = 10) 
Mean (SD) vWF (U/l)    
Baseline (1) 132.4 (20.9) 130.9 (12.0) 125.5 (25.7) 
Task (2) 135.0 (15.4) 134.3 (19.1) 128.3 (21.4) 
30-min recovery (3) 132.9 (23.4) 125.3 (17.9) 118.6 (17.7) 
60-min recovery (4) 130.0 (17.9) 133.9 (19.9) 118.4 (15.3) 
Median (IQR) sE-sel (ng/ml)    
Baseline (1) 30.0  
(11.6 – 66.3) 
36.8  
(15.5 – 63.1) 
40.0  
(32.8 – 55.0) 
Task (2) 27.0  
(11.0 – 63.1) 
36.8  
(17.0 – 63.1) 
37.5  
(30.3 – 55.0) 
30-min recovery (3) 26.0  
(11.1 – 52.6) 
37.0  
(19.1 – 67.5) 
33.5  
(29.8 – 53.1) 
60-min recovery (4) 33.0  
(11.1 – 52.6) 
36.0  
(18.3 – 65.9) 
47.5  
(33.8 – 60.8) 
 
3.2.2.4 Platelet reactivity 
The platelet reactivity to mental stress in the euhydrated state is reported in Table 3.18.  
MANOVAs revealed no temporal effect for platelet count (Plt), F (3,90) = .05, p = .93, 
η2 = .00, mean platelet mass (MPM), F (3,90) = .60, p = .54, η2 = .02, platelet P-selectin 
(pP-sel), F (3,90) = 1.03, p = .36, η2 = .03, and platelet adhesion (% bound platelets), F 
(2,54) = 1.33, p = .26, η2 = .05.  Significant effects were observed for mean platelet 
volume (MPV), F (3,93) = 11.58, p<.001, η2 = .27, and soluble P-selectin (sP-sel), F 
(3,93) = 5.36, p<.01, η2 = .15.  Post-hoc analysis revealed a significant increase in MPV 
during the stress task (p<.05), with levels returning back to baseline levels 30 minutes 
into the recovery period.  Subsequent analysis for sP-sel found that the temporal effect 
for sP-sel was driven by elevated levels at 60-minute recovery compared to baseline 
(p<.05).  Time X participant group interactions demonstrated that no significant 
differences in the temporal response to stress emerged for the three participant groups. 
 
 - 119 - 
Table 3.18: Platelet response to mental stress in a euhydrated state  
 AF Patients 
(n = 14) 
Hypertensive 
Patients 
(n = 10) 
Healthy Controls 
(n = 10) 
Mean (SD) Plt (103/μl)    
Baseline (1) 198.2 (83.7) 201.5 (50.3) 229.9 (40.8) 
Task (2) 203.4 (82.9) 198.1 (42.1) 228.2 (47.2) 
30-min recovery (3) 201.5 (84.3) 187.4 (38.5) 236.0 (47.3) 
60-min recovery (4) 189.9 (55.0) 199.5 (39.6) 237.7 (47.2) 
Mean (SD) MPV (f/l)    
Baseline (1) 7.3 (0.5) 7.2 (0.8) 7.0 (0.5) 
Task (2) 7.8 (0.8)* 7.7 (0.8)* 7.4 (0.6)* 
30-min recovery (3) 7.3 (0.8) 7.2 (0.6) 7.1 (0.7) 
60-min recovery (4) 7.6 (0.7) 7.4 (0.7) 7.3 (0.5) 
Mean (SD) MPM (pg)    
Baseline (1) 1.83 (0.1) 1.81 (0.3) 1.78 (0.1) 
Task (2) 1.86 (0.1) 1.85 (0.3) 1.77 (0.2) 
30-min recovery (3) 1.85 (0.2) 1.85 (0.3) 1.75 (0.2) 
60-min recovery (4) 1.83 (0.1) 1.89 (0.4) 1.78 (0.2) 
Median (IQR) sP-sel (ng/ml)    
Baseline (1) 155.0  
(103.8 – 207.5) 
157.7  
(98.8 – 215.0) 
100.0  
(78.8 – 142.5) 
Task (2) 137.5  
(98.8 – 192.8) 
137.0  
(100.0 – 188.8) 
105.0  
(83.8 – 156.3) 
30-min recovery (3) 147.5  
(103.8 – 196.3) 
152.2  
(103.8 – 257.5) 
105.0  
(95.0 – 150.0) 
60-min recovery (4) 147.5  
(123.8 – 212.5) 
170.0  
(112.5 – 257.7) 
107.5  
(93.8 – 151.3) 
Median (IQR) pP-sel (ng/ml)    
Baseline (1) 1150.0  
(710.0 – 1385.0) 
1105.0  
(1000.0 – 1750.0) 
1310.0  
(1072.5 – 1587.5) 
Task (2) 1050.0  
(780.0 – 1150.0) 
1030.0  
(840.0 – 1362.5) 
1400 
 (600.0 – 1485.0) 
30-min recovery (3) 1150.0 
 (900.0 – 1385.0) 
715.0  
(530.0 –  930.0) 
1080.0 
 (727.5 – 1710.0) 
60-min recovery (4) 1300.0  
(950.0 – 1475.0) 
880.0  
(605.0 – 1285.0) 
1325.0  
(850.0 – 1837.5) 
* Significantly different from baseline (p<.05) 
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3.2.3 Postural stress 
3.2.3.1 Haemodynamic reactivity 
Table 3.19 summarises the haemodynamic perturbation to postural stress in the 
euhydrated state.  MANOVAs revealed temporal effects for DBP, F (3,84) = 4.82, 
p<.01, η2 = .14, and HR, F (3,81) = 19.41, p<.001, η2 = .42, although no significant 
effects for SBP, F (3,84) = 1.93, p = .17, η2 = .06, and MAP, F (3,84) = 1.96, p = .13, η2 
= 0.7 were evident.  Post-hoc analysis revealed a significant increase in HR from 
baseline to task (p<.05) which returned to baseline levels at 30 and 60-minutes 
recovery.  Subsequent analysis for DBP indicated that the temporal effect was driven by 
the elevated levels at 30 and 60-minute recovery compared to baseline (p<.05).  Time X 
participant group interactions demonstrated a significant effect for DBP, F (6,84) = 
3.46, p<.01, η2 = .20, with only the hypertensive and healthy participants demonstrating 
a significant increase from baseline to task.  No significant time X participant group 
interactions emerged for SBP, MAP, and HR. 
 
3.2.3.2 Rheological reactivity 
Table 3.20 and Figure 3.11 present the analogous rheological data.  MANOVA revealed 
a significant temporal effect for haematocrit (Hct), F (3,93) = 46.6, p<.001, η2 = 0.60.  
Post-hoc analysis indicated that there was a significant increase in Hct from baseline to 
task (p<.05) of approximately 2.5%, which returned to baseline levels at 30 and 60-
minutes recovery. Time X participant group interactions demonstrated no significant 
differences in the temporal response to stress for the three participant groups. 
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Table 3.19: Mean (SD) haemodynamic response to postural stress in a euhydrated state  
 AF Patients 
(n = 14) 
Hypertensive Patients 
(n = 10) 
Healthy Controls 
(n = 10) 
SBP (mmHg)    
Baseline (1) 132.0 (18.4) 139.6 (12.0)§ 121.7 (13.8)‡ 
Task (2) 129.6 (21.2) 139.3 (18.8)§ 120.9 (14.5)‡ 
30-min recovery (3) 132.9 (15.2) 144.7 (15.1)§ 123.5 (17.2)‡ 
60-min recovery (4) 134.9 (13.8) 143.3 (14.2)§ 122.9 (16.4)‡ 
DBP (mmHg)    
Baseline (1) 78.6 (8.8) 78.2 (9.5) 75.9 (7.4) 
Task (2) 77.2 (10.9) 82.2 (12.8) 80.6 (8.0)* 
30-min recovery (3) 80.6 (9.3) 83.7 (10.2)* 77.1 (8.8) 
60-min recovery (4) 81.6 (8.6) 83.3 (10.1) 77.1 (8.9) 
MAP (mmHg)    
Baseline (1) 99.4 (12.5) 101.3 (9.5) 92.1 (10.1) 
Task (2) 96.6 (13.2) 103.7 (13.3) 94.6 (10.9) 
30-min recovery (3) 100.1 (11.1) 107.0 (10.2) 90.8 (15.9) 
60-min recovery (4) 103.1 (11.2) 105.2 (8.1) 93.3 (11.7) 
HR (Beats/min)    
Baseline (1) 65.7 (15.0) 56.7 (6.5) † 57.7 (6.7)† 
Task (2) 69.1 (17.2) 63.2 (6.9)* 64.9 (9.7)* 
30-min recovery (3) 66.8 (15.5) 57.1 (6.7)** 56.2 (5.5)† 
60-min recovery (4) 64.8 (14.1) 55.0 (5.6)** 55.8 (6.3) 
* Significantly different from baseline (p<.05) 
** Significantly different from task (p<.05) 
† Significantly different from AF patients (p<.05) 
 
Table 3.20: Mean (SD) haematocrit response to postural stress in a euhydrated state  
 AF Patients 
(n = 14) 
Hypertensive Patients 
(n = 10) 
Healthy Controls 
(n = 10) 
Hct (%)    
Baseline (1) 40.5 (4.6) 40.7 (2.6) 39.6 (2.8) 
Task (2) 43.1 (3.9)* 43.1 (2.8)* 42.1 (2.6)* 
30-min recovery (3) 40.5 (4.5)** 41.1 (3.3) 39.7 (3.3) 
60-min recovery (4) 40.4 (4.4)** 41.0 (2.6)** 39.6 (3.2)** 
* Significantly different from baseline (p<.05) 
** Significantly different from task (p<.05) 
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Figure 3.11: Mean haematocrit response to postural stress in a euhydrated state 
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3.2.3.3 Endothelial reactivity 
The endothelial reactivity to postural stress in the euhydrated state is summarised in 
Table 3.21.  MANOVAs revealed temporal effects for von Willebrand Factor (vWF), F 
(3,93) = 3.92, p <.05, η2 = .11, and soluble E-selectin (sE-sel), F (3,93) = 9.16, p <.001, 
η2 = .22.  Although post-hoc analysis failed to demonstrate a significant increase in 
vWF during the task, there was a tendency toward an increase in patients with AF and 
hypertension.  Post-hoc analysis indicated that levels of sE-sel increased during the task 
(p<.05), returning back to baseline levels at 30 and 60-minutes recovery.  Interestingly, 
this increase appeared to be greater in patients with hypertension and healthy controls.  
The temporal effect for vWF remained when the raw data was adjusted for postural 
induced haemoconcentration, F (3,93) = 6.87, p<.01, η2 = .18, however, the effect for 
sE-sel, F (3,93) = 2.31, p = .11, η2 = .07, was no longer statistically significant.  Time X 
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participant group interactions demonstrated no significant differences in the temporal 
response to stress for the three participant groups. 
 
Table 3.21: Endothelial response to postural stress in a euhydrated state  
 AF Patients 
(n = 14) 
Hypertensive Patients 
(n = 10) 
Healthy Controls 
(n = 10) 
Mean (SD) vWF (U/l)    
Baseline (1) 127.4 (16.8) 131.4 (25.0) 123.6 (16.8) 
Task (2) 133.6 (13.6) 144.8 (41.4) 122.3 (15.6) 
30-min recovery (3) 125.2 (15.7) 131.1 (22.9) 119.3 (21.1) 
60-min recovery (4) 130.1 (15.4) 133.9 (22.6) 116.9 (21.3) 
Median (IQR) sE-sel (ng/ml)    
Baseline (1) 44.0  
(15.0 – 67.8) 
37.0  
(16.2 – 63.1) 
48.9  
(36.3 – 115.0) 
Task (2) 50.8 * 
(18.8 – 67.8) 
48.0 * 
(15.4 – 67.8) 
56.0  
(39.8 – 115.0) 
30-min recovery (3) 42.0  
(14.8 – 67.8) 
29.0  
(13.8 – 61.3) 
46.0  
(33.5 – 68.8 ) 
60-min recovery (4) 45.5 
 (15.1 – 67.8) 
39.0  
(20.4 – 67.0) 
46.5  
(34.8 – 100.0) 
* Significantly different from baseline (p<.05) 
 
3.2.3.4 Platelet reactivity 
Table 3.22 presents the platelet reactivity to postural stress in the euhydrated state.  
MANOVAs yielded temporal effects for Plt, F (3,93) = 4.36, p<.05, η2 = .12, MPV, F 
(3,90) = 7.75, p<.001, η2 = .21, MPM, F (3,81) = 4.27, p<.05, η2 = .14, sP-sel, F (3,93) 
= 4.98, p<.05, η2 = .14, pP-sel, F (3,93) = 3.19, p<.05, η2 = .09, although no effect was 
observed for platelet adhesion (% bound platelets), F (2,60) = .17, p = .85, η2 = .01.  
Post-hoc analyses revealed significant increases in Plt, MPV, sP-sel during the stress 
task (p<.05), all of which returned back to baseline levels at 30 and 60-minutes 
recovery.  pP-sel demonstrated a temporal decrease, which gained significance at 30 and 
60-minutes recovery (p<.05).   Time X participant group interactions demonstrated no 
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significant temporal differences between the three participant groups for any of the 
platelet variables.  However, there was a trend, F (2,31) = 1.73, p=.19, for hypertensive 
patients to display a greater increase in sP-sel from baseline to task (32.5ng/ml) 
compared to AF patients (11.4 ng/ml) and healthy controls (7.5 ng/ml).  Statistical 
adjustment for postural induced haemoconcentration attenuated the increase in sP-sel 
(p>.05), and transformed the significant increase in platelet count to a decrease (<.05).   
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Table 3.22: Platelet response to postural stress in a euhydrated state   
 AF Patient 
(n = 14) 
Hypertensive 
Patients 
(n = 10) 
Healthy Controls 
(n = 10) 
Mean (SD) Plt (103/μl)    
Baseline (1) 207.9 (80.9) 195.5 (26.5) 223.5 (33.8) 
Task (2) 228.2 (89.4)* 204.3 (29.3) 234.5 (50.7) 
30-min recovery (3) 213.5 (83.0)** 194.0 (28.8) 213.0 (55.0) 
60-min recovery (4) 217.2 (85.9) 188.0 (21.6) 214.2 (55.6) 
Mean (SD) MPV (f/l)    
Baseline (1) 7.6 (0.8) 7.3 (1.0) 6.9 (0.6) 
Task (2) 7.9 (1.0) 7.7 (1.1) 7.2 (0.5) 
30-min recovery (3) 7.5 (0.6) 7.2 (1.0) 6.6 (0.5)† 
60-min recovery (4) 7.5 (0.7) 7.3 (0.9) 6.8 (0.6) 
Mean (SD) MPM (pg)    
Baseline (1) 1.92 (0.2) 1.84 (0.3) 1.77 (0.2) 
Task (2) 1.91 (0.2) 1.87 (0.3) 1.80 (0.2) 
30-min recovery (3) 1.89 (0.2) 1.78 (0.3) 1.71 (0.1) 
60-min recovery (4) 1.91 (0.2) 1.81 (0.3) 1.66 (0.2) 
Median (IQR) sP-sel (ng/ml)    
Baseline (1) 147.5  
(116.3 – 222.5) 
160.0  
(118.8 – 280.0) 
107.5  
(93.8 – 167.3) 
Task (2) 170.0 * 
(113.8 – 232.5) 
170.0 * 
(135.0 – 355.0) 
107.5  
(93.8 – 186.3) 
30-min recovery (3) 140.0  
(116.3 – 215.0) 
175.0  
(117.5 – 230.0)** 
100.0  
(90.0 – 173.8) 
60-min recovery (4) 140.0 ** 
(117.5 - 215.0) 
160.0 ** 
(108.8 – 251.3) 
107.5  
(98.8 – 177.5) 
Median (IQR) pP-sel (ng/ml)    
Baseline (1) 1070.0  
(430.0 – 1425.0) 
1010.0  
(460.0 – 1105.0) 
1200.0  
(985.0 - 1545.0) 
Task (2) 1020.0  
(345.0 – 1450.0) 
1000.0  
(460.0 – 1185.0) 
1140.0  
(575.0 – 1767.0) 
30-min recovery (3) 950.0  
(430.0 – 1157.0) 
860.0  
(400.0 – 1080.0) 
930.0 ** 
(627.0 – 1362.5) 
60-min recovery (4) 770.0  
(437.5 – 1132.5) 
620.0  
(582.5 – 1080.0) 
1010.0 ** 
(632.5 – 1240.0) 
* Significantly different from baseline (p<.05) 
** Significantly different from task (p<.05) 
† Significantly different from AF patients (p<.05) 
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3.2.4 Effect of hydration status on the cardiovascular, rheological, and 
haemostatsic response to mental stress 
Table 3.23 reports baseline haematocrit, total body water (TBW), intracellular water 
(ICW), and extracellular water (ECW) during the euhydrated and hyperhydrated 
sessions.  Paired-samples t-tests revealed significantly elevated levels of TBW, t (33) = 
2.13, p <.05, and ICW, t (33) = 2.45, p <.05 when participants attended in a 
hyperhydrated state, although ECW, t (33) = 0.88, p = .38, and haematocrit, t (33) = 
0.12, p = .90 were not affected. 
 
Table 3.23: Mean (SD) haematocrit and body impedance measures in the euhydrated 
and hyperhydrated conditions: mental stress sessions 
Variable Euhydration Hyperhydration 
Haematocrit (%) 40.2 (4.0) 40.1 (4.2) 
Total body water (L) 48.7 (6.5) 49.4 (6.6)* 
Intracellular water (L) 28.7 (3.8) 29.1 (3.8)* 
Extracellular water (L) 20.0 (3.1) 20.2 (3.2) 
* Significantly different from euhydration condition 
3.2.4.1 Haemodynamic reactivity 
Condition X time point MANOVAs revealed a hydration condition effect for SBP, F 
(1,31) = 5.48, p <.05, η2 = .15, DBP, F (1,31) = 9.74, p <.01, η2 = .24, and MAP, 
F(1,31) = 4.88, p < .05, η2 = .14 with levels being significantly lower during the stress 
task when participants were in a hyperhydrated state (Figures 3.12 and 3.13).   A 
significant condition X participant group interaction effect emerged for SBP, F (2,31) = 
4.05, p<.05, η2 = .21 and MAP, F(2,31) = 3.33, p < .05, η2 = .18,  with hypertensive 
patients displaying the greatest reduction in arterial blood pressure (SBP and MAP) 
compared to patients with AF and healthy individuals (Figure 3.12a). 
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Figure 3.12: Mean (SEM) systolic blood pressure response to mental stress in a 
euhydrated and hyperhydrated state 
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Figure 3.12a: Mean (SEM) systolic blood pressure in a euhydrated and hyperhydrated 
state: effect of participant group 
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Figure 3.13: Mean (SEM) diastolic blood pressure response to mental stress in a 
euhydrated and hyperhydrated state 
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* Significantly different from hyperhydrated condition for given time point (p<.05)  
† Significant difference in percentage change from baseline (1) to task (2) for two conditions 
 
3.2.4.2 Rheological reactivity 
No main effect for hydration was evident for haematocrit, F (1,33) = .22, p = .65,  η2 = 
.01. 
 
3.2.4.3 Endothelial reactivity 
 
MANOVA revealed a condition effect for vWF, F (1,31) = 11.04, p <.01, η2 = .25, with 
levels being reduced at all measurement points when participants were hyperhydrated 
(Figure 3.14).  There was a trend for differing effects of hydration between the three 
participant groups. Condition X participant groups interactions, F (2,31) = 2.82, p=.08, 
η2 = .15 (Figure 3.14a) demonstrated that patients with AF and hypertension displayed a 
reduction in vWF levels, with no significant change in healthy controls (Figure 3.14a).  
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Figure 3.14: Mean (SEM) von Willebrand Factor response to mental stress in a 
euhydrated and hyperhydrated state 
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Figure 3.14a: Mean (SEM) von Willebrand Factor in a euhydrated and hyperhydrated 
state: effect of participant group *   *
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3.2.4.4 Platelet reactivity 
 
A summary of the platelet reactivity to mental stress in the two hydration conditions is 
depicted in Figures 3.15 to 3.17.  MANOVA revealed condition effects for MPM, F 
(1,27) = 7.91, p<.01, η2 = .23, sP-sel (1,31) = 6.56, p<.05, η2 = .18, and a trend for 
MPV, F (1,28) = 3.16, p = .09, η2 = .10.  Post-hoc analyses revealed a significant 
reduction in baseline and task levels of MPM and MPV (p<.05), as well as an 
attenuation in the MPV response to the stress when participants were hyperhydrated 
(Figure 3.15).  In addition, sPs-sel levels were significantly elevated at all measurement 
points when participants were hyperhydrated.  No condition X participant group 
interaction effects emerged for any of the platelet variables. 
 
Figure 3.15: Mean (SEM) platelet volume response to mental stress in a euhydrated and 
hyperhydrated state 
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† Significant different in percentage change from baseline (1) to task (2) for two conditions 
 
0
7.9 Euhydrated
* Hyperhydrated
7.7
† 
M
ea
n 
pl
at
el
et
 v
ol
um
e 
(fl
)
7.5
7.3
7.1
6.9
6.7
1 2 3 4
               Baseline                   Task          30-min Recovery     60-min Recovery 
 - 131 - 
Figure 3.16: Mean (SEM) platelet mass response to mental stress in a euhydrated and 
hyperhydrated state 
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Figure 3.17: Mean (SEM) soluble P-selectin mass response to mental stress in a 
euhydrated and hyperhydrated state 
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3.2.5 Effect of hydration status on the cardiovascular, rheological, and 
haemostatsic response to postural stress 
Baseline haematocrit, TBW, ICW, and ECW for the euhydrated and hyperhydrated 
sessions are shown in Table 3.24.  Paired-samples t-tests revealed no significantly 
differences in TBW, t (33) = 0.48, p = .64, ICW, t (33) = 0.70, p .49, ECW, t (33) = 
0.79, p = .44, and haematocrit, t (33) = 1.56, p = .13. 
 
Table 3.24: Mean (SD) haematocrit and body impedance measures in the euhydrated 
and hyperhydrated conditions: postural stress sessions 
Variable Euhydration Hyperhydration 
Haematocrit (%) 40.3 (3.6) 39.6 (3.8) 
Total body water (L) 49.0 (6.8) 49.4 (7.6) 
Intracellular water (L) 29.0 (4.1) 29.6 (6.1) 
Extracellular water (L) 20.1 (3.1) 19.9 (3.6) 
 
 
3.2.5.1 Cardiovascular reactivity 
There were no significant condition effects for any of the cardiovascular parameters: 
SBP, F (1,29) = .23, p = .63, η2 = .01, DBP, F (1,29) = .02, p = .89, η2 = .00, MAP, F 
(1,29) = .06, p = .80, η2 = .00, and HR, F (1,27) = .50, p = .49, η2 = .02. 
 
3.2.5.2 Rheological reactivity  
The rheological reactivity to postural stress in the two hydration conditions is depicted 
in Figures 3.18.  MANOVA revealed no significant effect condition for haematocrit, 
although there was a trend towards a lower level in a hyperhydrated state, F (1,27) = 
3.27, p = .08, η2 = .11. 
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Figure 3.18: Mean (SEM) haematocrit response to postural stress in a euhydrated and 
hyperhydrated state 
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3.2.5.3 Endothelial reactivity 
A summary of the endothelial reactivity to postural stress in the two hydration 
conditions is presented in Figures 3.19 and 3.20.  MANOVAs revealed a significant 
condition effect for vWF, F (1,31) = 5.25, p <.05, η2 = .15, and sE-sel, F (1,31) = 5.42, 
p <.05, η2 = .15.  Post-hoc analyses indicated that hyperhydration not only reduced vWF 
and sEs-sel levels, but attenuated their reactivity to postural stress.  Condition X 
participant group analysis revealed that healthy individuals displayed a significant 
decrease in sE-sel levels when hyperhydrated, with AF and hypertensive patients 
displaying no significant change, F (2,31) = 4.89, p<.05, η2 = .24 (Figure 3.20a). 
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Figure 3.19: Mean (SEM) von Willebrand Factor response to postural stress in a 
euhydrated and hyperhydrated state 
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Figure 3.20: Mean (SEM) soluble E-selectin response to postural stress in a euhydrated 
and hyperhydrated state 
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Figure 3.20a: Mean (SEM) soluble E-selectin levels in a euhydrated and hyperhydrated 
state: effect of participant group 
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3.2.5.4 Platelet reactivity 
 
Platelet reactivity to postural stress in the two hydration conditions is depicted in 
Figures 3.21 to 3.23.  MANOVA revealed significant condition effects for MPM, F 
(1,26) = 4.36, p<.05, η2 = .11, sP-sel (1,31) = 16.95, p<.001, η2 = .35, and pP-sel, F 
(1,31) = 25.91, p<.001, η2 = .46.  Post-hoc analyses revealed that baseline and task 
MPM levels were lower when participants were hyperhydrated, with levels of sP-sel 
and pP-sel being higher during hyperhydartion (p<.05).  No condition X participant 
group interaction effects emerged for any of the platelet variables. 
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Figure 3.21: Mean (SEM) platelet mass response to postural stress in a euhydrated and 
hyperhydrated state 
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Figure 3.22: Mean (SEM) soluble P-selectin response to postural stress in a euhydrated 
and hyperhydrated state 
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Figure 3.23: Mean (SEM) platelet P-selectin response to postural stress in a euhydrated 
and hyperhydrated state 
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3.2.6 Summary of main findings 
3.2.6.1 Mental stress 
• Mental stress elicited significant increases in all haemodynamic variables (SBP, 
DBP, MAP, HR).  The SBP response to the stress task was more pronounced in 
healthy controls compared to patients with AF and hypertension.  
Hyperhydration significantly lowered baseline and task SBP and DBP levels, as 
well as attenuating the DBP response to the stress task.   Interestingly, the 
reduction in SBP with hyperhydration was only apparent in patients with 
hypertension. 
• A significant haemoconcentration was observed following the stress task, 
although this response was only significant in patients with AF (1.6% increase in 
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Hct).  No significant effect of hydration was evident for stress-induced 
haemoconcentration. 
• Although non-significant, there was a trend for vWF to increase following the 
stress task.  Hyperhydration significantly lowered vWF levels at all 
measurement points, although this was only evident in the patients with AF and 
hypertension. 
• Mental stress yielded a significant increase in MPV from baseline to task.  
Hyperhydration significantly lowered baseline and task MPM and MPV levels, 
in addition to abolishing the MPV response to the stress task.  sP-sel and pP-sel 
levels were significantly elevated at all measurement points when participants 
were hyperhydrated. 
 
 
3.2.6.2       Postural stress 
• Postural stress yielded a significant increase in HR in all three participant 
groups, whereas the increase in DBP was only evident in hypertensive patients 
and healthy controls.   
• Postural stress elicited a significant haemoconcentration, with Hct increasing by 
approximately 2.5%.  There was a tendency for hyperhydration to lower Hct 
levels across all measurement points. 
• Perturbation of the endothelium was apparent following postural stress.  sE-sel 
increased from baseline to task across all participant groups, with a trend 
towards an increase in vWF levels being observed in patients with AF and 
hypertension.  Hyperhydration reduced vWF and sE-sel levels as well as 
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attenuating the sE-sel response to postural stress in patients with hypertension 
and healthy controls. 
• Significant increases in platelet count, MPV, MPM, sP-sel were observed 
following the postural stress task.  pP-sel demonstrated a temporal decrease, 
which was significant at 30 and 60-minute recovery.  Platelet count response 
was exaggerated in AF patients, whereas hypertensive patients demonstrated the 
greatest increase in sP-sel from baseline to task.  Hyperhydration significantly 
reduced MPM levels at baseline and task, as well as elevating levels of sP-sel 
and pP-sel. 
 
CHAPTER 4 
 
Discussion 
 
 
4.1 Questionnaire study 
 
The prevalence and prognostic significance of depression has received a large amount 
of attention in patients with coronary heart disease (CHD).  Such exploration in AF 
patients has not been forthcoming, and the current study is the first to examine the 
persistence of depression and anxiety, and their implications for disease progression and 
future QoL. 
 
The current study revealed that significant symptoms of depression (BDI scores >10) 
were evident in 38% of patients with AF at baseline, with elevated state and trait 
anxiety (STAI score >40) being reported in 28% and 38% of patients, respectively.  
Depression and anxiety (trait) were found to be highly common co-morbid conditions in 
AF patients, with 71% of patients reporting BDI scores >10 also exhibiting high levels 
of anxiety.  Rates of depression in patients following a MI range from 20 to 37% 
[47,48,50,51,58,67,68], with two meta-analyses demonstrating that depressive 
symptoms yield a two-fold elevation in all-cause mortality, cardiac mortality, and future 
cardiovascular events [76,77].  Anxiety is an additional negative emotion implicated in 
the progression of CHD.  Similar prevalence rates of anxiety (24 – 31%) have been 
reported following a MI [67,79,80], although findings on its prognostic significance 
have been inconsistent [65-66,74,78-81].  Such findings imply that our cohort of AF 
patients present a comparable levels of psychological morbidity to post-MI patients.  
However, in contrast to previous research [50-51,67-68], elevated symptoms of 
depression were not more likely to be reported in females.   
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Hypertensive patients reported similar rates of depression (30%) and state anxiety 
(23%) to patients with AF, although hypertensive patients exhibited lower levels of trait 
anxiety (22%).  Although no previously published data in AF patients exists, the 
prevalence of depression in hypertensive patients has received some attention [343 – 
345].  Rabkin and colleagues are one of the few groups to explore this relationship, 
demonstrating that a diagnosis of major depression was three times more common 
among hypertensive patients even when known cardiac risk factors (age, sex, chronic 
co-morbidity, and current anti-hypertensive medication) were taken into account [344].  
Bonnet and colleagues reported that the prevalence of mild depressive symptoms, 
measured by the Hospital Anxiety Depression scale were approximately 20% in 
hypertensive patients, with females displaying significantly higher levels than males 
(26% vs. 14%, respectively) [345].   
 
In comparison to depression and anxiety, health-related quality of life (QoL) has been 
extensively studied in AF patients, with the current study revealing no significant 
differences in QoL between patients with AF and hypertension.  Only five observational 
studies [107-111] have previously examined QoL in what could be termed a ‘general’ 
AF population, demonstrating that AF patients suffer a poorer QoL (SF-36) when 
compared to CHD patients [107], the general population [111], and healthy controls 
[107,109-110].  The largest (n = 152) observation study to date demonstrated that 
patients with PAF displayed QoL scores similar to cardiac disease patients (PTCA, MI, 
and heart failure) and significantly worse than healthy controls [107].  Nilsson and 
colleagues are the only authors to report differences in QoL between AF patients and a 
hypertensive control group [131].  In contrast to the current study, the authors 
demonstrated a lower QoL on six of the eight scales of the SF-36 in AF patients when 
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compared to hypertensive controls.  However, it highly plausible that the differences 
between the two studies may be explained by the exaggerated baseline scores in the 
previous study, due to their highly symptomatic nature of their condition or 
experiencing the uncertainty of having to undergoing an invasive medical procedure 
(pulmonary vein isolation).  
 
Differences in QoL between patients with PAF and permanent AF have not been subject 
to investigation.  The current study, although not powered to detect differences between 
the sub-groups of AF patients, demonstrated that patients with PAF showed comparable 
levels of QoL when compared to patients with permanent AF (t (93) = -1.28; p>.05).  
Only one of the five observational studies examined QoL inclusively in a cohort of 
permanent AF patients.  This study found that males with permanent AF displayed 
similar levels of QoL (SF-36) in comparison to an aged-matched control group in sinus 
rhythm [109].  The authors argued that having a predictable clinical course of rate 
control and anti-coagulation, in addition to relatively well-controlled heart rates, might 
explain the equivocal findings.  However, a recent study demonstrated that there was no 
significant association between achieved heart rate either at rest or during exercise and 
QoL [346].  Conversely, the significant impairment in QoL reported in PAF patients 
[107-108,110] may be a consequence of rapid heart rates that are potentially more 
symptom-producing than permanent (rate-controlled) AF, or individuals perceiving 
their illness to be more intrusive on their everyday lives [347].    
 
The current study reports that females AF patients have a poorer QoL than male AF 
patients (t (99) = 3.43; p <.05).  Paquette and colleagues previously explored the 
potential gender differences in QoL in patients with PAF/persistent AF, demonstrating 
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that female patients display poorer physical component summary scores on the SF-36 
than their male counterparts [108].    Although this result was confounded by the fact 
that female patients were significantly older than males, it was speculated that such 
discrepancies could not fully account for sex differences in QoL [108].  The authors 
argued that the greater impact of AF on QoL in women may be attributed to their 
heightened sensitivity to the disease and its associated symptoms, sex differences in the 
perception of illness, or a lower threshold for reporting illness burden.  However, 
previous research has found that increased sensitivity to symptoms is unlikely to be a 
major factor driving these differences, as the impairment of QoL experienced by women 
persisted even after controlling for somatization scores [108]. 
 
No study to date has explored the course of depression and anxiety in patients with AF.  
Findings from the current study demonstrate that significant symptoms of depression 
(BDI scores >10) and trait anxiety (STAI scores >40), persisted over the first six-
months of follow-up in 52.6% of patients.  Such results add further support to our 
baseline data; AF patients experience a significant degree of psychological morbidity, 
which is protracted and not limited to a single point of observation.   
 
The prognostic significance of depression and anxiety in predicting future QoL, MACE 
and mortality has not been studied in patients with AF.  The current study demonstrates 
that female gender, ethnicity, employment status and baseline BDI, state and trait 
anxiety scores were significantly correlated with QoL at six-months.  Stepwise 
regression analysis revealed that baseline BDI score provided the best independent 
predictor of QoL at follow-up.  A study by Lane and colleagues examined the predictors 
of four and 12-month QoL in patients following MI [67,348].  At both time points, 
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baseline BDI, state and trait anxiety, male gender, and employment status were 
significantly correlated with QoL.  Stepwise linear regression analysis demonstrated 
that baseline BDI score provided the best independent predictor of QoL, although 
living/partner status, Peel Index score, and state anxiety were also found to be of 
significance.  The total model accounted for 23% and 28% of the variation in QoL 
scores at four and 12-months, respectively.   Such findings are in line with previous 
research relating depressive symptomatology to future QoL in post-MI patients [64].   
 
4.2 Stress study 
The hypothesis that behavioural exposures such as physical activity, mental stress, and 
postural change can trigger the onset of acute coronary syndromes (ACS) is intuitively 
appealing.  Although anecdotal [158-160] and epidemiological evidence [169] supports 
such a hypothesis, research examining the underlying mechanisms is far from 
conclusive.  Controlled laboratory experiments have provided us with a useful model 
for examining the pathways through which such activities may precipitate ACS.  The 
current study aimed to determine the effects of mental and postural stress on 
haemorheology, endothelial function, and markers of platelet reactivity in patients with 
AF.  In addition, we examined whether an enhanced hydration status could attenuate the 
development of a prothrombotic state in response to such stressors. 
 
4.2.1 Effect of stress and hydration status on haemodynamic reactivity 
Mental stress elicited increases in SBP, DBP, MAP, and HR, whereas the postural stress 
only increased HR.  The haemodynamic response to mental stress was not uniform 
across the three participant groups; healthy individuals demonstrated a trend toward 
exaggerated blood pressure reactivity (MAP) compared to patients with AF and 
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hypertension, F (6,96) = 1.72, p = .13,η = .10.  Overall, the magnitude of the 
haemodynamic reactions to mental stress [175-177,314,349-351] and the postural 
challenge [206,207,209,210,352-253] were broadly similar to those reported in previous 
studies.  Previous research employing the PASAT as a laboratory stress task has been 
limited to healthy individuals [175-177,349-351], or on cardiac patients without a 
control group [314].  Although the current study was the first to use the PASAT to 
examine differences in reactivity between cardiac patients and healthy individuals, other 
studies, employing different stress tasks, have produced inconsistent findings [198-
202,354].   
 
Earlier studies have found that hypertensive patients display elevated haemodynamic 
reactivity in comparison to normotensive controls during acute behavioural stresses 
[355].  A recent study reiterated such findings, demonstrating an exaggerated blood 
pressure and heart rate response during mental stress in a hypertensive cohort [200].  
Abstinence from medical therapy prior to the testing session may have accounted for the 
inconsistencies, with medication discontinued for only 12-hours prior to stress testing 
session in the current study in comparison to the four-week employed by Tomoda et al. 
[200].  Given that the wash out period for any given drug should exceed five times its 
half-life, it is clear that a 12-hour period of withdrawal would be insufficient for 
complete clearance, and may have lead to an attenuation of the haemodynamic 
response.   
 
The current study demonstrates that hyperhydration reduced arterial blood pressure at 
rest, in addition to attenuating its responsiveness to the mental stress task.  Interestingly, 
further analysis revealed that this reduction in blood pressure occurred mainly in 
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patients with hypertension.  Studies examining the effect of acute water injection (~500 
ml) have demonstrated a pressor response, characterised by an increase in total 
peripheral resistance and subsequently arterial blood pressure [356-360], which 
appeared to be maintained up to 50-minutes following fluid consumption [360-361].  
Participants in the present study consumed their second bolus (500 ml) of fluid >90-
minutes before baseline haemodynamic measures were obtained.  This procedural 
nuance may explain the null effects observed in our healthy controls and AF patients.  
To our knowledge, the current study is the first to demonstrate a beneficial effect of 
fluid loading in a hypertensive cohort.  Unfortunately, with a lack of objective measures 
of sympathetic activation, vascular compliance, naturetic peptide release, and 
renin/angiotensin II turnover it is difficult to speculate over potential mechanisms 
contributing to this improved blood pressure profile. 
 
4.2.2 Effects of stress and hydration on haemorheological reactivity 
A degree of haemoconcentration was observed following acute mental and postural 
stress, as revealed by a significant increase in haematocrit (Hct).  The majority of 
previous research examining the haemorheological response to mental stress has been 
conducted on healthy individuals [175-183].  The magnitude of the increase seen in the 
healthy cohort, although not statistically significant, is of the same order as previously 
published research [175-183].  Data from patient populations are scarce, although 
Bacon and colleagues demonstrated that patients with coronary artery disease (CAD) 
displayed no significant changes in haematocrit or plasma viscosity following the 
PASAT [314].   
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The extent of haemoconcentration observed during mental stress was not uniform across 
the three participant groups; AF patients displayed an exaggerated response compared 
to healthy individuals, with hypertensive patients demonstrating no haemorheological 
change.  Although the underlying mechanisms of mental stress-induced 
hemoconcentration remain to be fully elucidated, it is currently believed that increases 
in capillary pressure are the driving force behind this phenomenon [175-177,179,351].  
If changes in hydrostatic pressure were the major determinant of transcapillary 
exchange one would expect relatively similar increases in Hct across all three 
participant groups, with healthy individuals potentially displaying a greater response 
due to their exaggerated haemodynamic reactivity.  The lack of a haemorheological 
response observed in patients with hypertension could be attributed to elevated levels of 
arterial stiffness.  It has been demonstrated that the chronic elevation of luminal 
pressure in hypertension can lead to increased collagen production, subsequently 
increasing intima-medial thickness and decreasing vessel compliance [362].  The 
progressive decrease in vascular compliance, which occurs predominately in central and 
conduit arteries, causes significant alterations in flow dynamics, decreasing 
microvascular perfusion [362] and potentially reducing transvascular exchange.  The 
underlying hypertension observed in all our AF patients makes it unlikely that 
transferral of hydrostatic forces to the microcirculation is the sole explanation for 
differences between the three groups.  It would appear plausible that AF patients exhibit 
greater capillary exchange as a result of increased vascular permeability.  Small 
increases in permeability are considered to occur in a number of disease states, with 
inflammation being one of the main candidates for such changes [363].  Numerous 
studies have demonstrated that patients with AF display greater levels of inflammation 
in comparison to healthy controls measured through changes in plasma levels of IL-6 
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and CRP [364-365].  In light of such findings, it would appear reasonable to speculate 
that excessive capillary exchange in response to increases in hydrostatic pressure may 
be mediated by levels of microvascular inflammation. 
 
Assumption of an upright posture leads to a rapid pooling of blood in the lower 
extremities, subsequently increasing gravitational hydrostatic pressure and causing 
shifts of plasma into the surrounding tissues [366-367].   The 2.5% increase in 
haematocrit or 13% decrease in plasma volume we observed following head-up-tilt 
(HUT) is consistent with previous research [205-213,215,217-225,368-369], and based 
on dye-dilution techniques translates to an approximately 350 – 400 ml loss of fluid into 
the interstitium [205-206,215,219,221].   This net movement of fluid is eventually 
halted when equilibrium is resumed due to increased interstial hydrostatic pressure and 
increased intravascular oncotic pressure [205].  The current study, in line with previous 
research [368-369], demonstrates that the restoration of plasma volume on resumption 
of supine position is complete within 30-minutes.  In contrast to mental stress-induced 
haemoconcentration, no significant differences in the haemorheological response to 
posture were observed.  We previously speculated that differences in the transferral of 
hydrostatic forces to the microcirculation, and inflammatory reductions in vascular 
permeability might influence transvascular shifts of plasma in response to such a 
stressor.  During postural change, with capillary pressure in the lower limbs rising to 
approximately 100 mmHg [370], it would appear unlikely that the aforementioned 
variables would significantly influence this hydrostatically driven response.   
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4.2.2 Effects of stress and hydration on markers of endothelial dysfunction and 
platelet reactivity 
Mental stress elicited a significant increase in MPV and a trend towards an increase in 
vWF levels, with postural change causing alterations in all indices of platelet reactivity 
and endothelial function.  The increase in platelet count observed during postural stress 
was broadly similar to a previously reported result [211].  When examining the 
concentration of non-diffusible blood constituents’ such as platelets, it is important to 
account for the volume in which they are measured.  With the correction for plasma 
volume abolishing the changes we observed, it would appear that haemoconcentration is 
the mechanism underlying increases in platelet count in response to postural change. 
Other investigators have speculated that changes in platelet count and volume during 
postural stress may be due to increased splenic expulsion of platelets of increased size 
[213].  Although support for this hypothesis has been derived from catecholamine 
infusion studies [371-373], Cohn (1966) demonstrated that epinephrine not only 
produced arteriolar dilatation and venoconstriction but also elicited a loss of plasma 
volume [374].    
 
Platelet size has been shown to reflect platelet activity [375], with changes in MPV 
thought to reflect the level of platelet stimulation (physiology) and/or the rate of platelet 
production (biology) [376].  Larger platelets have been shown to be denser [377], 
aggregate more rapidly, have a higher capacity for thromboxane B2 production [378], 
release more serotonin and β-TG [379-380], and express more GP Ib and GP IIb-IIIa 
receptors [382-383].  As a consequence, larger platelets are considered to have a greater 
thrombotic potential [270].   Although the increase in MPV in response to mental stress 
was in contrast to previous research [203], the current study was the first to report an 
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increase in platelet size during postural change.  Since such changes in platelet volume 
(MPV) cannot be accounted for by haemoconcentration or by alterations in spleen 
discharge, other physiological mechanisms need to be invoked.  In vitro experiments by 
Jagroop and colleagues suggest MPV can be transiently increased by certain agonists 
[383].  These authors demonstrated that although epinephrine was unable to alter 
platelet volume on its own, when combined with stress related neurotransmitters (e.g. 
serotonin) it could be significantly increased.  Such findings suggest that the change in 
MPV observed during the stress tasks may be due to an increase in size of existing 
platelets in the circulation rather than the expulsion of fresh platelets from the spleen. 
 
Increased plasma levels and decreased intra-platelet levels of P-selectin further suggest 
that postural stress can cause an increase in platelet reactivity.  Although previous 
research examining platelet activation in this respect is mainly limited to the assessment 
of platelet aggregation [211,213-214,216], Andrew and colleagues found no change in 
the platelet membrane expression of P-selectin using flow cytometry during standing 
[213].  The mechanisms responsible for increased P-selectin expression are initiated 
through an activation of the hypothalamic-pituitary-adrenocortical (HPA) axis and 
sympathetic-adrenal-medullary (SAM) system.  The secreted catecholamines [209,210] 
are thought to bind to alpha-2 adrenoreceptors on the platelet membrane [211] causing a 
translocation of intra-platelet α-granules [384].  When α-granules fuse with the platelet 
membrane there is a brief expression of P-selectin before it is proteolytically shed or 
actively cleaved from the cell surface.  Although the current observations would appear 
to demonstrate this process, with haemoconcentration attenuating the increase in plasma 
levels of P-selectin other physiological mechanism cannot be discounted.  
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Although von Willebrand Factor (vWF) has consistently been shown to increase 
following acute mental stress [185-186,189,196], no study has assessed whether 
postural change can elicit changes in plasma indices of endothelial damage/dysfunction.  
Although there was a trend for vWF to increase during both stress tasks, with a 
significant increase in sE-sel during postural change, stress-induced 
haemoconcentration again appeared to account for such findings.  With the hypertensive 
patients displaying no haemorheological change during mental stress it would appear 
plausible that any increase in vWF observed may be the result of shear stress [385] or 
catecholamine induced release from vascular endothelial cells [386].   
 
With the exact mechanism responsible for transient increases in vWF yet to be fully 
determined [387], it is difficult to account for the reduction in vWF levels in patients 
with AF and hypertension.  Although the most plausible explanation might be that an 
elevation in plasma volume would produce a subsequent dilution of the haemostatic 
molecule, no decrease in haematocrit levels was observed when participants were 
hyperhydrated.  With increases in shear stress being implicated in the release of vWF, it 
may be expected that individuals displaying the greatest reduction in blood pressure 
when hyperhydrated would also display the greatest reduction in vWF levels.  Although 
this appears to hold true for healthy individuals and patients with hypertension, such an 
explanation cannot account for the reduction in vWF levels in AF patients. 
 
4.2.4 Clinical implications 
Given the prognostic significance of depression and anxiety for CHD patients, it would 
appear that such variables could now be considered as novel risk factors for the 
development and progression of ACS.  With the prevalence rates of depression and 
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anxiety observed in our AF cohort comparable to post-MI patients, it would appear they 
experience a significant degree psychological morbidity, which may be predictive future 
cardiovascular morbidity and mortality.  Although the current study failed to 
demonstrate any predictive significance for depression and anxiety over a six-month 
follow-up period, it should be conceded that there were few events and power was 
insufficient to detect associations.  It remains plausible that such relationships could 
emerge over more protracted follow-up periods with larger numbers of events.  If this 
were the case, it may be beneficial to screen AF patients for psychological morbidities, 
providing effective and safe treatment strategies were appropriate. 
 
The significant alteration in haemorheology, endothelial perturbation, and platelet 
reactivity observed during mental and postural stress provides further 
pathophysiological evidence for the behavioural triggering of ACS.  It would be 
reasonable to assume that the haemoconcentration and increases in haemodynamic and 
mechanical shear stress could trigger plaque disruption.  In addition, the increases in 
platelet morphology and reactivity would provide a prothrombotic milieu, which may 
transfer a disrupted plaque into a ‘clinically active’ plaque through partial or complete 
vessel occlusion.  The exaggerated haemorheological reactivity observed during mental 
stress in AF patients may also predispose such individuals to a greater risk of plaque 
rupture and ACS during periods of emotional distress. 
 
Although it has been previously demonstrated that increased fluid consumption is 
associated with a decreased risk of CHD [388], only speculative hypotheses have been 
provided to explain such findings.  In an attempt to test the possibility that this is a 
causal association, the current study examined the effects of fluid loading on blood 
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rheology and haemostasis at rest and in response to commonly encountered behavioural 
activities.  We demonstrated that a short term increase in hydration status has the 
potential to lower blood pressure in patients with hypertension, in addition to 
attenuating the haemodynamic reactivity to mental stress in all participant groups.  
Enhanced hydration was also shown to have significant benefits on endothelial function 
in patients with AF and hypertension.  Although further prospective data are required to 
confirm such findings, our results would suggest that increased water consumption 
should be implemented into the ‘package of care’ for individuals with ‘classical’ risk 
factors for CHD. 
 
4.2.5 Study limitations 
A number of potential limitations need to be considered.  Firstly, it could be argued that 
the lack of a control session reduces the strength of our study protocol.  Although this 
may have merit, it has been consistently demonstrated that haematocrit does not change 
during a prolonged period of unstimulated rest [179-180,192].  Patterson and colleagues 
echoed these findings for the platelet proteins β-TG and PF-4 [192]; however, a recent 
study demonstrated a decrease in plasma P-selectin levels during 45 minute supine rest 
[389].  The likely decrease in P-selectin during sleep or prolonged supine rest only 
further replicates the physiological changes occurring during awakening.  Secondly, it 
has been proposed that the blood sampling procedure employed during the HUT 
protocol leads to a significant underestimation of haemorheological change.  It has been 
speculated that postural-induced haemoconcentration established in the dependent 
regions may be poorly reflected in the overall circulation due to uneven or slow 
intravascular mixing of blood.  Lundvall and colleagues found that such an 
underestimation of plasma volume loss could be avoided if blood was sampled shortly 
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(<90 seconds) after an individual is returned to a supine position [218].  If this 
methodological discrepancy has lead to an underestimation of our haemorheological 
changes, this only adds strengths to the findings that the change in blood viscosity 
during orthostasis may be clinically significant.  Thirdly, a lack of objective measures of 
hormonal/neurotransmitter activity, capillary pressure, arterial stiffness, and 
renin/angiotensin II turnover make it difficult to draw definitive conclusions regarding 
the mechanisms underlying the observed changes during the stress tasks and the 
hydration manipulation.  However, with ethical limitation on blood donation it would 
have been unfeasible to obtain measures requiring further sampling.  
 
4.2.6 Future studies 
Although there has been a plethora of research examining the QoL in patients with AF 
[390], the current study is the first to examine the prevalence of depression and anxiety 
in patients with AF.  Further studies are required to confirm or refute our findings. 
Future research should also examine the effect of rate and rhythm controlling treatment 
strategies, as well as the effects of anti-coagulation regimes on psychological and social 
characteristic.  With the follow-up period employed in this study limited to six-months, 
it would also be of interest to determine whether depression and anxiety have a 
prognostic value in predicting future cardiovascular morbidity and mortality over a 
protracted follow-up period. 
 
The current study was also the first to examine the effect of behavioural stress on 
markers of haemorheology and haemostasis in an AF population.  Although future 
studies examining differences in stress reactivity between different sub-populations of 
AF patients (e.g. PAF vs. persistent AF vs. permanent AF) may be of interest, insight 
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may be better served by further investigation of the mechanisms underlying the 
development of a prothrombotic state during behavioural activities.   
 
The novel finding that enhanced hydration status can significantly lower blood pressure 
in a hypertensive cohort, in addition to improving endothelial function in patients with 
AF and hypertension may have considerable clinical implications and should be 
explored further.  Again, investigators would be advised to focus on the mechanisms 
underlying this response, before determining what type and volume of fluid would 
provide the optimal improvement in blood pressure and endothelial profile.  In addition, 
it would be of interest to know if the benefits of hyperhydration are confined to patients 
with hypertension and AF, or whether such a manipulation could be implemented into 
the care of other patients with established cardiovascular disease. 
 
4.2.7 Conclusion 
This thesis has demonstrated that (1) AF patients experience a significant degree of 
psychological morbidity, and (2) mental and postural stress can elicit changes resonant 
with the development of a prothrombotic state which, in turn, can be attenuated when an 
individual is hyperhydrated.  Such findings provide further insight into level of 
psychological impairment experienced in this patient population, in addition to further 
elucidating the potential mechanisms through which behavioural activities can trigger 
the onset and progression of ACS.  The reduction in blood pressure and improvement in 
endothelial function when hyperhydrated may have potential clinical implications.  If 
these findings are substantiated in future studies, alterations in fluid balance may 
provide a cheap, side-effect free method for altering an individual’s cardiovascular risk 
profile.   
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